[{"id":"a1cf","symbol":"A1CF","href":"/targets/a1cf/","tldr":"A1CF (APOBEC1 complementation factor) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"abcb1","symbol":"ABCB1","href":"/targets/abcb1/","tldr":"ABCB1 (ATP-dependent translocase ABCB1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer, Non-small-cell lung cancer and 1 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"abcc1","symbol":"ABCC1","href":"/targets/abcc1/","tldr":"ABCC1 (ATP-binding cassette sub-family C member 1) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"abcc10","symbol":"ABCC10","href":"/targets/abcc10/","tldr":"ABCC10 (ATP-binding cassette sub-family C member 10) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"abcc3","symbol":"ABCC3","href":"/targets/abcc3/","tldr":"ABCC3 (ATP-binding cassette sub-family C member 3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"abcc4","symbol":"ABCC4","href":"/targets/abcc4/","tldr":"ABCC4 (ATP-binding cassette sub-family C member 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Angiosarcoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"abcg2","symbol":"ABCG2","href":"/targets/abcg2/","tldr":"ABCG2 (Broad substrate specificity ATP-binding cassette transporter ABCG2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"abi1","symbol":"ABI1","href":"/targets/abi1/","tldr":"ABI1 (Abl interactor 1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"abl2","symbol":"ABL2","href":"/targets/abl2/","tldr":"ABL2 (Tyrosine-protein kinase ABL2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Endometrial cancer, Lung cancer and 2 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"abo","symbol":"ABO","href":"/targets/abo/","tldr":"ABO (Histo-blood group ABO system transferase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ackr3","symbol":"ACKR3","href":"/targets/ackr3/","tldr":"ACKR3 (Atypical chemokine receptor 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer, Colorectal cancer, Skin cancer and 1 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"acoxl","symbol":"ACOXL","href":"/targets/acoxl/","tldr":"ACOXL (Acyl-coenzyme A oxidase-like protein) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.","roles":[],"tier":"association-only"},{"id":"acsl3","symbol":"ACSL3","href":"/targets/acsl3/","tldr":"ACSL3 (Fatty acid CoA ligase Acsl3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"acsl6","symbol":"ACSL6","href":"/targets/acsl6/","tldr":"ACSL6 (Long-chain-fatty-acid--CoA ligase 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas and Liposarcoma.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"acsm3","symbol":"ACSM3","href":"/targets/acsm3/","tldr":"ACSM3 (Acyl-coenzyme A synthetase ACSM3, mitochondrial) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"acta1","symbol":"ACTA1","href":"/targets/acta1/","tldr":"ACTA1 (Actin, alpha skeletal muscle) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"acta2","symbol":"ACTA2","href":"/targets/acta2/","tldr":"ACTA2 (Actin, aortic smooth muscle) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.","roles":[],"tier":"association-only"},{"id":"actb","symbol":"ACTB","href":"/targets/actb/","tldr":"ACTB (Actin, cytoplasmic 1) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"actg1","symbol":"ACTG1","href":"/targets/actg1/","tldr":"ACTG1 (Actin, cytoplasmic 2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"actl6a","symbol":"ACTL6A","href":"/targets/actl6a/","tldr":"ACTL6A (Actin-like protein 6A) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"acvr1b","symbol":"ACVR1B","href":"/targets/acvr1b/","tldr":"ACVR1B (Activin receptor type-1B) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Colorectal cancer, Breast cancer and 4 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"acvr2a","symbol":"ACVR2A","href":"/targets/acvr2a/","tldr":"ACVR2A (Activin receptor type-2A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"adam29","symbol":"ADAM29","href":"/targets/adam29/","tldr":"ADAM29 (Disintegrin and metalloproteinase domain-containing protein 29) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"adamts9","symbol":"ADAMTS9","href":"/targets/adamts9/","tldr":"ADAMTS9 (A disintegrin and metalloproteinase with thrombospondin motifs 9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"adh1b","symbol":"ADH1B","href":"/targets/adh1b/","tldr":"ADH1B (All-trans-retinol dehydrogenase [NAD(+)] ADH1B) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Oesophageal cancer.","roles":[],"tier":"association-only"},{"id":"adra1a","symbol":"ADRA1A","href":"/targets/adra1a/","tldr":"ADRA1A (Alpha-1A adrenergic receptor) is a receptor that reads hormone signals inside the cell nucleus. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours and Prostate cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"adra1b","symbol":"ADRA1B","href":"/targets/adra1b/","tldr":"ADRA1B (Alpha-1B adrenergic receptor) is a receptor that reads hormone signals inside the cell nucleus. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"adra1d","symbol":"ADRA1D","href":"/targets/adra1d/","tldr":"ADRA1D (Alpha-1D adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"adra2a","symbol":"ADRA2A","href":"/targets/adra2a/","tldr":"ADRA2A (Alpha-2A adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"adra2b","symbol":"ADRA2B","href":"/targets/adra2b/","tldr":"ADRA2B (Alpha-2B adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"adra2c","symbol":"ADRA2C","href":"/targets/adra2c/","tldr":"ADRA2C (Alpha-2C adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"adrm1","symbol":"ADRM1","href":"/targets/adrm1/","tldr":"ADRM1 (Proteasomal ubiquitin receptor ADRM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"aebp1","symbol":"AEBP1","href":"/targets/aebp1/","tldr":"AEBP1 (Adipocyte enhancer-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"afdn","symbol":"AFDN","href":"/targets/afdn/","tldr":"AFDN (Afadin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"aff1","symbol":"AFF1","href":"/targets/aff1/","tldr":"AFF1 (AF4/FMR2 family member 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Melanoma and 1 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"aff3","symbol":"AFF3","href":"/targets/aff3/","tldr":"AFF3 (AF4/FMR2 family member 3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Thyroid cancer, Skin cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"aff4","symbol":"AFF4","href":"/targets/aff4/","tldr":"AFF4 (AF4/FMR2 family member 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Skin cancer, Colorectal cancer and 3 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"aggf1","symbol":"AGGF1","href":"/targets/aggf1/","tldr":"AGGF1 (Angiogenic factor with G patch and FHA domains 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"agk","symbol":"AGK","href":"/targets/agk/","tldr":"AGK (Acylglycerol kinase, mitochondrial) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"agr2","symbol":"AGR2","href":"/targets/agr2/","tldr":"AGR2 (Anterior gradient protein 2 homolog) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"agtrap","symbol":"AGTRAP","href":"/targets/agtrap/","tldr":"AGTRAP (Type-1 angiotensin II receptor-associated protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"aimp2","symbol":"AIMP2","href":"/targets/aimp2/","tldr":"AIMP2 (Aminoacyl tRNA synthase complex-interacting multifunctional protein 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"ajuba","symbol":"AJUBA","href":"/targets/ajuba/","tldr":"AJUBA (LIM domain-containing protein ajuba) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"akap9","symbol":"AKAP9","href":"/targets/akap9/","tldr":"AKAP9 (A-kinase anchor protein 9) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"alcam","symbol":"ALCAM","href":"/targets/alcam/","tldr":"ALCAM (CD166 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"aldh1a2","symbol":"ALDH1A2","href":"/targets/aldh1a2/","tldr":"ALDH1A2 (Retinal dehydrogenase 2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"aldh2","symbol":"ALDH2","href":"/targets/aldh2/","tldr":"ALDH2 (Aldehyde dehydrogenase, mitochondrial) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Osteosarcoma.","roles":["drug-target","oncogene-driver"],"tier":"clinical-evidence"},{"id":"alpk1","symbol":"ALPK1","href":"/targets/alpk1/","tldr":"ALPK1 (Alpha-protein kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"amer1","symbol":"AMER1","href":"/targets/amer1/","tldr":"AMER1 (APC membrane recruitment protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Skin cancer, Leukaemia and 3 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"angpt1","symbol":"ANGPT1","href":"/targets/angpt1/","tldr":"ANGPT1 (Angiopoietin-1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"ank1","symbol":"ANK1","href":"/targets/ank1/","tldr":"ANK1 (Ankyrin-1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Prostate cancer, Angiosarcoma and 2 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ankrd11","symbol":"ANKRD11","href":"/targets/ankrd11/","tldr":"ANKRD11 (Ankyrin repeat domain-containing protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-Hodgkin lymphoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"ano7","symbol":"ANO7","href":"/targets/ano7/","tldr":"ANO7 (Anoctamin-7) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"ap3b1","symbol":"AP3B1","href":"/targets/ap3b1/","tldr":"AP3B1 (AP-3 complex subunit beta-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"apbb1ip","symbol":"APBB1IP","href":"/targets/apbb1ip/","tldr":"APBB1IP (Amyloid beta A4 precursor protein-binding family B member 1-interacting protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"apc","symbol":"APC","href":"/targets/apc/","tldr":"APC (Adenomatous polyposis coli protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Hepatocellular carcinoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"approved-drug"},{"id":"aph1a","symbol":"APH1A","href":"/targets/aph1a/","tldr":"APH1A (Gamma-secretase subunit APH-1A) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.","roles":["drug-target"],"tier":"approved-drug"},{"id":"aph1b","symbol":"APH1B","href":"/targets/aph1b/","tldr":"APH1B (Gamma-secretase subunit APH-1B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.","roles":["drug-target"],"tier":"approved-drug"},{"id":"apobec3b","symbol":"APOBEC3B","href":"/targets/apobec3b/","tldr":"APOBEC3B (DNA dC->dU-editing enzyme APOBEC-3B) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.","roles":[],"tier":"association-only"},{"id":"apoe","symbol":"APOE","href":"/targets/apoe/","tldr":"APOE (Apolipoprotein E) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"araf","symbol":"ARAF","href":"/targets/araf/","tldr":"ARAF (Serine/threonine-protein kinase A-Raf) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Colorectal cancer, Langerhans cell histiocytosis and 4 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"areg","symbol":"AREG","href":"/targets/areg/","tldr":"AREG (Amphiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Head and neck squamous cell carcinoma and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"arhgap26","symbol":"ARHGAP26","href":"/targets/arhgap26/","tldr":"ARHGAP26 (Rho GTPase-activating protein 26) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Leukaemia and 2 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"arhgap35","symbol":"ARHGAP35","href":"/targets/arhgap35/","tldr":"ARHGAP35 (Rho GTPase-activating protein 35) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Bladder & urothelial cancer, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"arhgap5","symbol":"ARHGAP5","href":"/targets/arhgap5/","tldr":"ARHGAP5 (Rho GTPase-activating protein 5) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Multiple myeloma, Pancreatic ductal adenocarcinoma and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"arhgef10","symbol":"ARHGEF10","href":"/targets/arhgef10/","tldr":"ARHGEF10 (Rho guanine nucleotide exchange factor 10) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Cutaneous squamous cell carcinoma, Non-small-cell lung cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"arhgef10l","symbol":"ARHGEF10L","href":"/targets/arhgef10l/","tldr":"ARHGEF10L (Rho guanine nucleotide exchange factor 10-like protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Renal cell carcinoma, Basal cell carcinoma and Clear cell renal cell carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"arhgef12","symbol":"ARHGEF12","href":"/targets/arhgef12/","tldr":"ARHGEF12 (Rho guanine nucleotide exchange factor 12) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Renal cell carcinoma, Skin cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"arhgef5","symbol":"ARHGEF5","href":"/targets/arhgef5/","tldr":"ARHGEF5 (Rho guanine nucleotide exchange factor 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"arid1a","symbol":"ARID1A","href":"/targets/arid1a/","tldr":"ARID1A (AT-rich interactive domain-containing protein 1A) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Colorectal cancer, Endometrial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"arid1b","symbol":"ARID1B","href":"/targets/arid1b/","tldr":"ARID1B (AT-rich interactive domain-containing protein 1B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Colorectal cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"arid2","symbol":"ARID2","href":"/targets/arid2/","tldr":"ARID2 (AT-rich interactive domain-containing protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Oesophageal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"arid5b","symbol":"ARID5B","href":"/targets/arid5b/","tldr":"ARID5B (AT-rich interactive domain-containing protein 5B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.","roles":[],"tier":"association-only"},{"id":"arnt","symbol":"ARNT","href":"/targets/arnt/","tldr":"ARNT (Aryl hydrocarbon receptor nuclear translocator) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Breast cancer, Small-cell lung cancer and 1 more.","roles":["drug-target","tumour-suppressor"],"tier":"approved-drug"},{"id":"arrb1","symbol":"ARRB1","href":"/targets/arrb1/","tldr":"ARRB1 (Beta-arrestin-1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"arrb2","symbol":"ARRB2","href":"/targets/arrb2/","tldr":"ARRB2 (Beta-arrestin-2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ascl1","symbol":"ASCL1","href":"/targets/ascl1/","tldr":"ASCL1 (Achaete-scute homolog 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Atypical teratoid/rhabdoid tumour.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"asns","symbol":"ASNS","href":"/targets/asns/","tldr":"ASNS (Asparagine synthetase [glutamine-hydrolysing]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"aspscr1","symbol":"ASPSCR1","href":"/targets/aspscr1/","tldr":"ASPSCR1 (Tether containing UBX domain for GLUT4) is a gene. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas.","roles":["drug-target","fusion-partner"],"tier":"association-only"},{"id":"ass1","symbol":"ASS1","href":"/targets/ass1/","tldr":"ASS1 (Argininosuccinate synthase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Sarcomas.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"asxl1","symbol":"ASXL1","href":"/targets/asxl1/","tldr":"ASXL1 (Polycomb group protein ASXL1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Myelodysplastic syndromes / neoplasms and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"asxl2","symbol":"ASXL2","href":"/targets/asxl2/","tldr":"ASXL2 (Putative Polycomb group protein ASXL2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer and Acute myeloid leukaemia.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"atf1","symbol":"ATF1","href":"/targets/atf1/","tldr":"ATF1 (Cyclic AMP-dependent transcription factor ATF-1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas, Colorectal cancer and Melanoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"atf7ip","symbol":"ATF7IP","href":"/targets/atf7ip/","tldr":"ATF7IP (Activating transcription factor 7-interacting protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer and Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"atg12","symbol":"ATG12","href":"/targets/atg12/","tldr":"ATG12 (Ubiquitin-like protein ATG12) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"atg7","symbol":"ATG7","href":"/targets/atg7/","tldr":"ATG7 (Ubiquitin-like modifier-activating enzyme ATG7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma and Clear cell renal cell carcinoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"atic","symbol":"ATIC","href":"/targets/atic/","tldr":"ATIC (Bifunctional purine biosynthesis protein ATIC) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Lung cancer.","roles":[],"tier":"association-only"},{"id":"atm","symbol":"ATM","href":"/targets/atm/","tldr":"ATM is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"atp1a1","symbol":"ATP1A1","href":"/targets/atp1a1/","tldr":"ATP1A1 (Sodium/potassium-transporting ATPase subunit alpha-1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Gastric & gastro-oesophageal junction cancer and Colorectal cancer.","roles":["drug-target","oncogene-driver"],"tier":"clinical-evidence"},{"id":"atp2b3","symbol":"ATP2B3","href":"/targets/atp2b3/","tldr":"ATP2B3 (Plasma membrane calcium-transporting ATPase 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Lung cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"atp4a","symbol":"ATP4A","href":"/targets/atp4a/","tldr":"ATP4A (Potassium-transporting ATPase alpha chain 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Gastric & gastro-oesophageal junction cancer and Non-Hodgkin lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"atp4b","symbol":"ATP4B","href":"/targets/atp4b/","tldr":"ATP4B (Potassium-transporting ATPase subunit beta) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Gastric & gastro-oesophageal junction cancer and Non-Hodgkin lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"atp7b","symbol":"ATP7B","href":"/targets/atp7b/","tldr":"ATP7B (Copper-transporting ATPase 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"atrx","symbol":"ATRX","href":"/targets/atrx/","tldr":"ATRX (Chromatin remodeler ATRX) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Neuroendocrine tumours, Adrenocortical carcinoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"atxn1l","symbol":"ATXN1L","href":"/targets/atxn1l/","tldr":"ATXN1L (Ataxin-1-like) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma and Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"atxn7","symbol":"ATXN7","href":"/targets/atxn7/","tldr":"ATXN7 (Ataxin-7) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"aurka","symbol":"AURKA","href":"/targets/aurka/","tldr":"AURKA (Aurora kinase A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer, Ovarian cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"aurkb","symbol":"AURKB","href":"/targets/aurkb/","tldr":"AURKB (Aurora kinase B) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"axin1","symbol":"AXIN1","href":"/targets/axin1/","tldr":"AXIN1 (Axin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Oesophageal cancer, Skin cancer and 5 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"axin2","symbol":"AXIN2","href":"/targets/axin2/","tldr":"AXIN2 (Axin-2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Skin cancer, Lung cancer and 2 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"b2m","symbol":"B2M","href":"/targets/b2m/","tldr":"B2M (Beta-2-microglobulin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Colorectal cancer, Lung cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"b4galt1","symbol":"B4GALT1","href":"/targets/b4galt1/","tldr":"B4GALT1 (Beta-1,4-galactosyltransferase 1) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"bach2","symbol":"BACH2","href":"/targets/bach2/","tldr":"BACH2 (Transcription regulator protein BACH2) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer and Basal cell carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"bag4","symbol":"BAG4","href":"/targets/bag4/","tldr":"BAG4 (BAG family molecular chaperone regulator 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"bak1","symbol":"BAK1","href":"/targets/bak1/","tldr":"BAK1 (Bcl-2 homologous antagonist/killer) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.","roles":[],"tier":"association-only"},{"id":"bap1","symbol":"BAP1","href":"/targets/bap1/","tldr":"BAP1 (Ubiquitin carboxyl-terminal hydrolase BAP1) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Mesothelioma, Biliary tract cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"bard1","symbol":"BARD1","href":"/targets/bard1/","tldr":"BARD1 (BRCA1-associated RING domain protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer, Gastric & gastro-oesophageal junction cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"baz1a","symbol":"BAZ1A","href":"/targets/baz1a/","tldr":"BAZ1A (Bromodomain adjacent to zinc finger domain protein 1A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"bcl10","symbol":"BCL10","href":"/targets/bcl10/","tldr":"BCL10 (B-cell lymphoma/leukaemia 10) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Diffuse large B-cell lymphoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"bcl11a","symbol":"BCL11A","href":"/targets/bcl11a/","tldr":"BCL11A (BCL11 transcription factor A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Skin cancer, Breast cancer and 2 more.","roles":["oncogene-driver","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"bcl11b","symbol":"BCL11B","href":"/targets/bcl11b/","tldr":"BCL11B (B-cell lymphoma/leukaemia 11B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Vulvar cancer, Non-Hodgkin lymphoma, Skin cancer and 5 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"bcl3","symbol":"BCL3","href":"/targets/bcl3/","tldr":"BCL3 (B-cell lymphoma 3 protein) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"bcl6","symbol":"BCL6","href":"/targets/bcl6/","tldr":"BCL6 (B-cell lymphoma 6 protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Myeloproliferative neoplasms and 3 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"bcl7a","symbol":"BCL7A","href":"/targets/bcl7a/","tldr":"BCL7A (B-cell CLL/lymphoma 7 protein family member A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and 1 more.","roles":["oncogene-driver","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"bcl9","symbol":"BCL9","href":"/targets/bcl9/","tldr":"BCL9 (B-cell CLL/lymphoma 9 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"bcl9l","symbol":"BCL9L","href":"/targets/bcl9l/","tldr":"BCL9L (B-cell CLL/lymphoma 9-like protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 1 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"bclaf1","symbol":"BCLAF1","href":"/targets/bclaf1/","tldr":"BCLAF1 (Bcl-2-associated transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Gastric & gastro-oesophageal junction cancer, Acute myeloid leukaemia and 2 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"bcor","symbol":"BCOR","href":"/targets/bcor/","tldr":"BCOR (BCL-6 corepressor) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Endometrial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"bcorl1","symbol":"BCORL1","href":"/targets/bcorl1/","tldr":"BCORL1 (BCL-6 corepressor-like protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Pancreatic ductal adenocarcinoma, Skin cancer and 4 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"bik","symbol":"BIK","href":"/targets/bik/","tldr":"BIK (Bcl-2-interacting killer) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"birc3","symbol":"BIRC3","href":"/targets/birc3/","tldr":"BIRC3 (Baculoviral IAP repeat-containing protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 4 more.","roles":["drug-target","oncogene-driver","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"birc5","symbol":"BIRC5","href":"/targets/birc5/","tldr":"BIRC5 (Baculoviral IAP repeat-containing protein 5) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer and HER2-positive breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"birc6","symbol":"BIRC6","href":"/targets/birc6/","tldr":"BIRC6 (Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"birc7","symbol":"BIRC7","href":"/targets/birc7/","tldr":"BIRC7 (Baculoviral IAP repeat-containing protein 7) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"blk","symbol":"BLK","href":"/targets/blk/","tldr":"BLK (Tyrosine-protein kinase Blk) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"blm","symbol":"BLM","href":"/targets/blm/","tldr":"BLM (RecQ-like DNA helicase BLM) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Colorectal cancer, Breast cancer and 4 more.","roles":["dna-repair"],"tier":"association-only"},{"id":"bmp2","symbol":"BMP2","href":"/targets/bmp2/","tldr":"BMP2 (Bone morphogenetic protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"bmp4","symbol":"BMP4","href":"/targets/bmp4/","tldr":"BMP4 (Bone morphogenetic protein 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"bmp5","symbol":"BMP5","href":"/targets/bmp5/","tldr":"BMP5 (Bone morphogenetic protein 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"bmp6","symbol":"BMP6","href":"/targets/bmp6/","tldr":"BMP6 (Bone morphogenetic protein 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"bmp7","symbol":"BMP7","href":"/targets/bmp7/","tldr":"BMP7 (Bone morphogenetic protein 7) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"bmpr1a","symbol":"BMPR1A","href":"/targets/bmpr1a/","tldr":"BMPR1A (Bone morphogenetic protein receptor type-1A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Breast cancer and 1 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"bnc2","symbol":"BNC2","href":"/targets/bnc2/","tldr":"BNC2 (Zinc finger protein basonuclin-2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"brd7","symbol":"BRD7","href":"/targets/brd7/","tldr":"BRD7 (Bromodomain-containing protein 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma and Melanoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"brip1","symbol":"BRIP1","href":"/targets/brip1/","tldr":"BRIP1 (Fanconi anaemia group J protein) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer, Gastric & gastro-oesophageal junction cancer and 3 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"btc","symbol":"BTC","href":"/targets/btc/","tldr":"BTC (Probetacellulin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"btg1","symbol":"BTG1","href":"/targets/btg1/","tldr":"BTG1 (BTG anti-proliferation factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"btg2","symbol":"BTG2","href":"/targets/btg2/","tldr":"BTG2 (BTG anti-proliferation factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Chronic lymphocytic leukaemia.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"bub1b","symbol":"BUB1B","href":"/targets/bub1b/","tldr":"BUB1B (Mitotic checkpoint serine/threonine-protein kinase BUB1 beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Skin cancer, Breast cancer and 3 more.","roles":[],"tier":"association-only"},{"id":"c11orf65","symbol":"C11orf65","href":"/targets/c11orf65/","tldr":"C11orf65 (chromosome 11 open reading frame 65) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer, Colorectal cancer, Ovarian cancer and 4 more.","roles":[],"tier":"association-only"},{"id":"cacna1d","symbol":"CACNA1D","href":"/targets/cacna1d/","tldr":"CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor"],"tier":"clinical-evidence"},{"id":"cacna1g","symbol":"CACNA1G","href":"/targets/cacna1g/","tldr":"CACNA1G (Voltage-dependent T-type calcium channel subunit alpha-1G) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cacna1h","symbol":"CACNA1H","href":"/targets/cacna1h/","tldr":"CACNA1H (Voltage-dependent T-type calcium channel subunit alpha-1H) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cacna1i","symbol":"CACNA1I","href":"/targets/cacna1i/","tldr":"CACNA1I (Voltage-dependent T-type calcium channel subunit alpha-1I) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cadm2","symbol":"CADM2","href":"/targets/cadm2/","tldr":"CADM2 (Cell adhesion molecule 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"calr","symbol":"CALR","href":"/targets/calr/","tldr":"CALR (Calreticulin) is a gene. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Essential thrombocythaemia and Primary myelofibrosis.","roles":["drug-target","biomarker","fusion-partner"],"tier":"approved-drug"},{"id":"camta1","symbol":"CAMTA1","href":"/targets/camta1/","tldr":"CAMTA1 (Calmodulin-binding transcription activator 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Prostate cancer, Breast cancer and 3 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cant1","symbol":"CANT1","href":"/targets/cant1/","tldr":"CANT1 (Soluble calcium-activated nucleotidase 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer and Oesophageal and junctional adenocarcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"card11","symbol":"CARD11","href":"/targets/card11/","tldr":"CARD11 (Caspase recruitment domain-containing protein 11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Hepatocellular carcinoma, Skin cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"cars1","symbol":"CARS1","href":"/targets/cars1/","tldr":"CARS1 (Cysteine--tRNA ligase, cytoplasmic) is an enzyme. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Skin cancer, Lung cancer and Melanoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"casp10","symbol":"CASP10","href":"/targets/casp10/","tldr":"CASP10 (Caspase-10) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Gastric & gastro-oesophageal junction cancer and Non-Hodgkin lymphoma.","roles":[],"tier":"association-only"},{"id":"casp8","symbol":"CASP8","href":"/targets/casp8/","tldr":"CASP8 (Caspase-8) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Skin cancer, Cervical cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"casr","symbol":"CASR","href":"/targets/casr/","tldr":"CASR (Extracellular calcium-sensing receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"casz1","symbol":"CASZ1","href":"/targets/casz1/","tldr":"CASZ1 (Zinc finger protein castor homolog 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"cbfa2t3","symbol":"CBFA2T3","href":"/targets/cbfa2t3/","tldr":"CBFA2T3 (Transcriptional corepressor CBFA2T3) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Breast cancer, Lung cancer and 2 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"cbfb","symbol":"CBFB","href":"/targets/cbfb/","tldr":"CBFB (Core-binding factor subunit beta) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"cbl","symbol":"CBL","href":"/targets/cbl/","tldr":"CBL (E3 ubiquitin-protein ligase CBL) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"cblb","symbol":"CBLB","href":"/targets/cblb/","tldr":"CBLB (E3 ubiquitin-protein ligase CBL-B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Skin cancer, Breast cancer and 2 more.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"cblc","symbol":"CBLC","href":"/targets/cblc/","tldr":"CBLC (E3 ubiquitin-protein ligase CBL-C) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ccar1","symbol":"CCAR1","href":"/targets/ccar1/","tldr":"CCAR1 (Cell division cycle and apoptosis regulator protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"ccdc170","symbol":"CCDC170","href":"/targets/ccdc170/","tldr":"CCDC170 (Coiled-coil domain-containing protein 170) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"ccdc6","symbol":"CCDC6","href":"/targets/ccdc6/","tldr":"CCDC6 (Coiled-coil domain-containing protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.","roles":["drug-target","tumour-suppressor"],"tier":"approved-drug"},{"id":"ccdc88c","symbol":"CCDC88C","href":"/targets/ccdc88c/","tldr":"CCDC88C (coiled-coil and HOOK domain protein 88C) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ccn2","symbol":"CCN2","href":"/targets/ccn2/","tldr":"CCN2 (CCN family member 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"ccnb1ip1","symbol":"CCNB1IP1","href":"/targets/ccnb1ip1/","tldr":"CCNB1IP1 (E3 ubiquitin-protein ligase CCNB1IP1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.","roles":[],"tier":"association-only"},{"id":"ccnd1","symbol":"CCND1","href":"/targets/ccnd1/","tldr":"CCND1 (G1/S-specific cyclin-D1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker, a fusion partner and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Skin cancer, Multiple myeloma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner","dna-repair"],"tier":"approved-drug"},{"id":"ccnd2","symbol":"CCND2","href":"/targets/ccnd2/","tldr":"CCND2 (G1/S-specific cyclin-D2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Skin cancer and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ccnd3","symbol":"CCND3","href":"/targets/ccnd3/","tldr":"CCND3 (G1/S-specific cyclin-D3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ccne1","symbol":"CCNE1","href":"/targets/ccne1/","tldr":"CCNE1 (G1/S-specific cyclin-E1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ccne2","symbol":"CCNE2","href":"/targets/ccne2/","tldr":"CCNE2 (G1/S-specific cyclin-E2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ccnh","symbol":"CCNH","href":"/targets/ccnh/","tldr":"CCNH (Cyclin-H) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ccnt1","symbol":"CCNT1","href":"/targets/ccnt1/","tldr":"CCNT1 (Cyclin-T1) is a protein that switches other genes on and off. In the public catalogues it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":[],"tier":"cohort-driver"},{"id":"ccr7","symbol":"CCR7","href":"/targets/ccr7/","tldr":"CCR7 (C-C chemokine receptor type 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Diffuse large B-cell lymphoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"cd200","symbol":"CD200","href":"/targets/cd200/","tldr":"CD200 (OX-2 membrane glycoprotein) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"cd209","symbol":"CD209","href":"/targets/cd209/","tldr":"CD209 (CD209 antigen) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Gastric & gastro-oesophageal junction cancer and Non-small-cell lung cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"cd3d","symbol":"CD3D","href":"/targets/cd3d/","tldr":"CD3D (T-cell surface glycoprotein CD3 delta chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cd3g","symbol":"CD3G","href":"/targets/cd3g/","tldr":"CD3G (T-cell surface glycoprotein CD3 gamma chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cd44","symbol":"CD44","href":"/targets/cd44/","tldr":"CD44 (CD44 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal cancer and 5 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"cd58","symbol":"CD58","href":"/targets/cd58/","tldr":"CD58 (Lymphocyte function-associated antigen 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"cd74","symbol":"CD74","href":"/targets/cd74/","tldr":"CD74 (HLA class II histocompatibility antigen gamma chain) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Lung cancer and Non-small-cell lung cancer.","roles":["drug-target","fusion-partner"],"tier":"approved-drug"},{"id":"cd79a","symbol":"CD79A","href":"/targets/cd79a/","tldr":"CD79A (B-cell antigen receptor complex-associated protein alpha chain) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Non-Hodgkin lymphoma and Skin cancer.","roles":[],"tier":"association-only"},{"id":"cd83","symbol":"CD83","href":"/targets/cd83/","tldr":"CD83 (CD83 antigen) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"cda","symbol":"CDA","href":"/targets/cda/","tldr":"CDA (Cytidine deaminase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms and Myelodysplastic syndromes / neoplasms.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cdc37","symbol":"CDC37","href":"/targets/cdc37/","tldr":"CDC37 (Hsp90 co-chaperone Cdc37) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cdc50a","symbol":"CDC50A","href":"/targets/cdc50a/","tldr":"CDC50A (Cell cycle control protein 50A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"cdc73","symbol":"CDC73","href":"/targets/cdc73/","tldr":"CDC73 (Parafibromin) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Endometrial cancer, Colorectal cancer and 1 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cdca7","symbol":"CDCA7","href":"/targets/cdca7/","tldr":"CDCA7 (Cell division cycle-associated protein 7) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"cdh1","symbol":"CDH1","href":"/targets/cdh1/","tldr":"CDH1 (Cadherin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"cdh10","symbol":"CDH10","href":"/targets/cdh10/","tldr":"CDH10 (Cadherin-10) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Endometrial cancer and Non-small-cell lung cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"cdh11","symbol":"CDH11","href":"/targets/cdh11/","tldr":"CDH11 (Cadherin-11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"cdk12","symbol":"CDK12","href":"/targets/cdk12/","tldr":"CDK12 (Cyclin-dependent kinase 12) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Ovarian cancer, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"cdk2","symbol":"CDK2","href":"/targets/cdk2/","tldr":"CDK2 (Cyclin-dependent kinase 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"cdk5","symbol":"CDK5","href":"/targets/cdk5/","tldr":"CDK5 (Cyclin-dependent kinase 5) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"cdk9","symbol":"CDK9","href":"/targets/cdk9/","tldr":"CDK9 (Cyclin-dependent kinase 9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Oesophageal cancer and Neuroblastoma.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"cdkal1","symbol":"CDKAL1","href":"/targets/cdkal1/","tldr":"CDKAL1 (Threonylcarbamoyladenosine tRNA methylthiotransferase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cdkn1a","symbol":"CDKN1A","href":"/targets/cdkn1a/","tldr":"CDKN1A (Cyclin-dependent kinase inhibitor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Hepatocellular carcinoma, Colorectal cancer and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"cdkn1b","symbol":"CDKN1B","href":"/targets/cdkn1b/","tldr":"CDKN1B (Cyclin-dependent kinase inhibitor 1B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer, Prostate cancer, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"cdkn2a","symbol":"CDKN2A","href":"/targets/cdkn2a/","tldr":"CDKN2A (Cyclin-dependent kinase inhibitor 2A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Bladder & urothelial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"cdkn2b","symbol":"CDKN2B","href":"/targets/cdkn2b/","tldr":"CDKN2B (Cyclin-dependent kinase 4 inhibitor B) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer and 5 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"cdkn2c","symbol":"CDKN2C","href":"/targets/cdkn2c/","tldr":"CDKN2C (Cyclin-dependent kinase 4 inhibitor C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Brain and spinal cord tumours and Burkitt lymphoma.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"cdx2","symbol":"CDX2","href":"/targets/cdx2/","tldr":"CDX2 (Homeobox protein CDX-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Skin cancer and 3 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ceacam1","symbol":"CEACAM1","href":"/targets/ceacam1/","tldr":"CEACAM1 (Cell adhesion molecule CEACAM1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Hepatocellular carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"cebpa","symbol":"CEBPA","href":"/targets/cebpa/","tldr":"CEBPA (CCAAT/enhancer-binding protein alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"celf2","symbol":"CELF2","href":"/targets/celf2/","tldr":"CELF2 (CUGBP Elav-like family member 2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cep43","symbol":"CEP43","href":"/targets/cep43/","tldr":"CEP43 (Centrosomal protein 43) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.","roles":["fusion-partner"],"tier":"association-only"},{"id":"cep89","symbol":"CEP89","href":"/targets/cep89/","tldr":"CEP89 (Centrosomal protein of 89 kDa) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cflar","symbol":"CFLAR","href":"/targets/cflar/","tldr":"CFLAR (CASP8 and FADD-like apoptosis regulator) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"chchd7","symbol":"CHCHD7","href":"/targets/chchd7/","tldr":"CHCHD7 (Coiled-coil-helix-coiled-coil-helix domain-containing protein 7) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Oral cavity cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"chd2","symbol":"CHD2","href":"/targets/chd2/","tldr":"CHD2 (ATP-dependent chromatin remodeler CHD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Bladder & urothelial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"chd4","symbol":"CHD4","href":"/targets/chd4/","tldr":"CHD4 (ATP-dependent chromatin remodeler CHD4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer, Colorectal cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"chd7","symbol":"CHD7","href":"/targets/chd7/","tldr":"CHD7 (ATP-dependent chromatin remodeler CHD7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"chd8","symbol":"CHD8","href":"/targets/chd8/","tldr":"CHD8 (ATP-dependent chromatin remodeler CHD8) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"chek1","symbol":"CHEK1","href":"/targets/chek1/","tldr":"CHEK1 (Serine/threonine-protein kinase Chk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer and Small-cell lung cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"chek2","symbol":"CHEK2","href":"/targets/chek2/","tldr":"CHEK2 (Serine/threonine-protein kinase Chk2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Sarcomas and 5 more.","roles":["drug-target","oncogene-driver","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"chmp4c","symbol":"CHMP4C","href":"/targets/chmp4c/","tldr":"CHMP4C (Charged multivesicular body protein 4c) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"chrdl1","symbol":"CHRDL1","href":"/targets/chrdl1/","tldr":"CHRDL1 (Chordin-like protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"chrna3","symbol":"CHRNA3","href":"/targets/chrna3/","tldr":"CHRNA3 (Neuronal acetylcholine receptor subunit alpha-3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"chrna4","symbol":"CHRNA4","href":"/targets/chrna4/","tldr":"CHRNA4 (Neuronal acetylcholine receptor subunit alpha-4) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"chrna5","symbol":"CHRNA5","href":"/targets/chrna5/","tldr":"CHRNA5 (Neuronal acetylcholine receptor subunit alpha-5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Lung cancer.","roles":[],"tier":"association-only"},{"id":"cic","symbol":"CIC","href":"/targets/cic/","tldr":"CIC (Protein capicua homolog) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ciita","symbol":"CIITA","href":"/targets/ciita/","tldr":"CIITA (MHC class II transactivator) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Skin cancer, Colorectal cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"cip2a","symbol":"CIP2A","href":"/targets/cip2a/","tldr":"CIP2A (cellular inhibitor of PP2A) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"clcn6","symbol":"CLCN6","href":"/targets/clcn6/","tldr":"CLCN6 (H(+)/Cl(-) exchange transporter 6) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"clip1","symbol":"CLIP1","href":"/targets/clip1/","tldr":"CLIP1 (CAP-Gly domain-containing linker protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Cervical cancer, Oesophageal cancer and 2 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"clptm1l","symbol":"CLPTM1L","href":"/targets/clptm1l/","tldr":"CLPTM1L (Lipid scramblase CLPTM1L) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cltc","symbol":"CLTC","href":"/targets/cltc/","tldr":"CLTC (Clathrin heavy chain 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"cltcl1","symbol":"CLTCL1","href":"/targets/cltcl1/","tldr":"CLTCL1 (Clathrin heavy chain 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Prostate cancer, Skin cancer and 2 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"cmtr2","symbol":"CMTR2","href":"/targets/cmtr2/","tldr":"CMTR2 (Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"cnbp","symbol":"CNBP","href":"/targets/cnbp/","tldr":"CNBP (CCHC-type zinc finger nucleic acid binding protein) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cnksr1","symbol":"CNKSR1","href":"/targets/cnksr1/","tldr":"CNKSR1 (Connector enhancer of kinase suppressor of ras 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cnksr2","symbol":"CNKSR2","href":"/targets/cnksr2/","tldr":"CNKSR2 (Connector enhancer of kinase suppressor of ras 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cnot3","symbol":"CNOT3","href":"/targets/cnot3/","tldr":"CNOT3 (CCR4-NOT transcription complex subunit 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Leukaemia, Non-Hodgkin lymphoma and 4 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cnot9","symbol":"CNOT9","href":"/targets/cnot9/","tldr":"CNOT9 (CCR4-NOT transcription complex subunit 9) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cntrl","symbol":"CNTRL","href":"/targets/cntrl/","tldr":"CNTRL (Centriolin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Nasopharyngeal carcinoma, Cutaneous squamous cell carcinoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"col1a1","symbol":"COL1A1","href":"/targets/col1a1/","tldr":"COL1A1 (Collagen alpha-1(I) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Anal cancer, Pancreatic ductal adenocarcinoma and 3 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"col2a1","symbol":"COL2A1","href":"/targets/col2a1/","tldr":"COL2A1 (Collagen alpha-1(II) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer and Papillary thyroid cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"col6a3","symbol":"COL6A3","href":"/targets/col6a3/","tldr":"COL6A3 (Collagen alpha-3(VI) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Melanoma.","roles":["drug-target","tumour-suppressor"],"tier":"approved-drug"},{"id":"col6a6","symbol":"COL6A6","href":"/targets/col6a6/","tldr":"COL6A6 (Collagen alpha-6(VI) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"cpeb3","symbol":"CPEB3","href":"/targets/cpeb3/","tldr":"CPEB3 (Cytoplasmic polyadenylation element-binding protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Basal cell carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cpsf6","symbol":"CPSF6","href":"/targets/cpsf6/","tldr":"CPSF6 (Cleavage and polyadenylation specificity factor subunit 6) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.","roles":[],"tier":"association-only"},{"id":"cpvl","symbol":"CPVL","href":"/targets/cpvl/","tldr":"CPVL (Probable serine carboxypeptidase CPVL) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"creb1","symbol":"CREB1","href":"/targets/creb1/","tldr":"CREB1 (Cyclic AMP-responsive element-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer, Sarcomas, Skin cancer and 1 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"creb3l1","symbol":"CREB3L1","href":"/targets/creb3l1/","tldr":"CREB3L1 (Cyclic AMP-responsive element-binding protein 3-like protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas, Lung cancer and Breast cancer.","roles":[],"tier":"association-only"},{"id":"creb3l2","symbol":"CREB3L2","href":"/targets/creb3l2/","tldr":"CREB3L2 (Cyclic AMP-responsive element-binding protein 3-like protein 2) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas, Breast cancer and Lung cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"crebbp","symbol":"CREBBP","href":"/targets/crebbp/","tldr":"CREBBP (CREB-binding protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Bladder & urothelial cancer, Leukaemia and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"crkl","symbol":"CRKL","href":"/targets/crkl/","tldr":"CRKL (Crk-like protein) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"crlf2","symbol":"CRLF2","href":"/targets/crlf2/","tldr":"CRLF2 (Cytokine receptor-like factor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Acute lymphoblastic leukaemia and 2 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"crtc1","symbol":"CRTC1","href":"/targets/crtc1/","tldr":"CRTC1 (CREB-regulated transcription coactivator 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers, Lung cancer, Skin cancer and 5 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"crtc3","symbol":"CRTC3","href":"/targets/crtc3/","tldr":"CRTC3 (CREB-regulated transcription coactivator 3) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Oral cavity cancer.","roles":[],"tier":"association-only"},{"id":"csf1","symbol":"CSF1","href":"/targets/csf1/","tldr":"CSF1 (Macrophage colony-stimulating factor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Tenosynovial giant cell tumour.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"csf2rb","symbol":"CSF2RB","href":"/targets/csf2rb/","tldr":"CSF2RB (Cytokine receptor common subunit beta) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Sarcomas, Leukaemia, Myeloproliferative neoplasms and 1 more.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"csk","symbol":"CSK","href":"/targets/csk/","tldr":"CSK (Tyrosine-protein kinase CSK) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"csmd3","symbol":"CSMD3","href":"/targets/csmd3/","tldr":"CSMD3 (CUB and sushi domain-containing protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"csnk1a1","symbol":"CSNK1A1","href":"/targets/csnk1a1/","tldr":"CSNK1A1 (Casein kinase I isoform alpha) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"csnk1e","symbol":"CSNK1E","href":"/targets/csnk1e/","tldr":"CSNK1E (Casein kinase I isoform epsilon) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Follicular lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cspg4","symbol":"CSPG4","href":"/targets/cspg4/","tldr":"CSPG4 (Chondroitin sulfate proteoglycan 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"ctag1b","symbol":"CTAG1B","href":"/targets/ctag1b/","tldr":"CTAG1B (Cancer/testis antigen 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ctag2","symbol":"CTAG2","href":"/targets/ctag2/","tldr":"CTAG2 (Cancer/testis antigen 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ctcf","symbol":"CTCF","href":"/targets/ctcf/","tldr":"CTCF (Transcriptional repressor CTCF) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Breast cancer, Head and neck squamous cell carcinoma and 4 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ctnna1","symbol":"CTNNA1","href":"/targets/ctnna1/","tldr":"CTNNA1 (Catenin alpha-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer and Cervical cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ctnna2","symbol":"CTNNA2","href":"/targets/ctnna2/","tldr":"CTNNA2 (Catenin alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ctnnb1","symbol":"CTNNB1","href":"/targets/ctnnb1/","tldr":"CTNNB1 (Catenin beta-1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Hepatocellular carcinoma, Colorectal cancer, Ovarian cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"approved-drug"},{"id":"ctnnd2","symbol":"CTNND2","href":"/targets/ctnnd2/","tldr":"CTNND2 (Catenin delta-2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ctr9","symbol":"CTR9","href":"/targets/ctr9/","tldr":"CTR9 (RNA polymerase-associated protein CTR9 homolog) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Wilms tumour.","roles":[],"tier":"association-only"},{"id":"ctsh","symbol":"CTSH","href":"/targets/ctsh/","tldr":"CTSH (Pro-cathepsin H) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ctss","symbol":"CTSS","href":"/targets/ctss/","tldr":"CTSS (Cathepsin S) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"cul1","symbol":"CUL1","href":"/targets/cul1/","tldr":"CUL1 (Cullin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cul3","symbol":"CUL3","href":"/targets/cul3/","tldr":"CUL3 (Cullin-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Non-small-cell lung cancer and Papillary renal cell carcinoma.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"cul4a","symbol":"CUL4A","href":"/targets/cul4a/","tldr":"CUL4A (Cullin-4A) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"cul7","symbol":"CUL7","href":"/targets/cul7/","tldr":"CUL7 (Cullin-7) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"cux1","symbol":"CUX1","href":"/targets/cux1/","tldr":"CUX1 (Homeobox protein cut-like 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Leukaemia, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"cx3cl1","symbol":"CX3CL1","href":"/targets/cx3cl1/","tldr":"CX3CL1 (Fractalkine) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"cxcl10","symbol":"CXCL10","href":"/targets/cxcl10/","tldr":"CXCL10 (C-X-C motif chemokine 10) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Osteosarcoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"cyld","symbol":"CYLD","href":"/targets/cyld/","tldr":"CYLD (Ubiquitin carboxyl-terminal hydrolase CYLD) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Colorectal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"cyp11b1","symbol":"CYP11B1","href":"/targets/cyp11b1/","tldr":"CYP11B1 (Cytochrome P450 11B1, mitochondrial) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Renal cell carcinoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cyp1b1","symbol":"CYP1B1","href":"/targets/cyp1b1/","tldr":"CYP1B1 (Cytochrome P450 1B1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"cyp2c8","symbol":"CYP2C8","href":"/targets/cyp2c8/","tldr":"CYP2C8 (Cytochrome P450 2C8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Melanoma and Pleural mesothelioma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cyp2d6","symbol":"CYP2D6","href":"/targets/cyp2d6/","tldr":"CYP2D6 (Cytochrome P450 2D6) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"cysltr2","symbol":"CYSLTR2","href":"/targets/cysltr2/","tldr":"CYSLTR2 (Cysteinyl leukotriene receptor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer and Uveal melanoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"daxx","symbol":"DAXX","href":"/targets/daxx/","tldr":"DAXX (Death domain-associated protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroendocrine tumours, Adrenocortical carcinoma, Pancreatic ductal adenocarcinoma and 2 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"dazap1","symbol":"DAZAP1","href":"/targets/dazap1/","tldr":"DAZAP1 (DAZ-associated protein 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mantle cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"dcaf12l2","symbol":"DCAF12L2","href":"/targets/dcaf12l2/","tldr":"DCAF12L2 (DDB1- and CUL4-associated factor 12-like protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Prostate cancer, Glioma & glioblastoma and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"dcc","symbol":"DCC","href":"/targets/dcc/","tldr":"DCC (Netrin receptor DCC) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Hepatocellular carcinoma and 3 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"dclre1b","symbol":"DCLRE1B","href":"/targets/dclre1b/","tldr":"DCLRE1B (5' exonuclease Apollo) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"dctn1","symbol":"DCTN1","href":"/targets/dctn1/","tldr":"DCTN1 (Dynactin subunit 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ddb1","symbol":"DDB1","href":"/targets/ddb1/","tldr":"DDB1 (DNA damage-binding protein 1) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"ddb2","symbol":"DDB2","href":"/targets/ddb2/","tldr":"DDB2 (DNA damage-binding protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Skin cancer and Acute myeloid leukaemia.","roles":["oncogene-driver","tumour-suppressor","dna-repair"],"tier":"cohort-driver"},{"id":"ddit3","symbol":"DDIT3","href":"/targets/ddit3/","tldr":"DDIT3 (DDIT3 upstream open reading frame protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas and Liposarcoma.","roles":[],"tier":"association-only"},{"id":"ddx10","symbol":"DDX10","href":"/targets/ddx10/","tldr":"DDX10 (Probable ATP-dependent RNA helicase DDX10) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer and Skin cancer.","roles":[],"tier":"association-only"},{"id":"ddx3x","symbol":"DDX3X","href":"/targets/ddx3x/","tldr":"DDX3X (ATP-dependent RNA helicase DDX3X) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ddx41","symbol":"DDX41","href":"/targets/ddx41/","tldr":"DDX41 (Probable ATP-dependent RNA helicase DDX41) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Myelodysplastic syndromes / neoplasms and 1 more.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"ddx43","symbol":"DDX43","href":"/targets/ddx43/","tldr":"DDX43 (Probable ATP-dependent RNA helicase DDX43) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Uveal melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ddx5","symbol":"DDX5","href":"/targets/ddx5/","tldr":"DDX5 (Probable ATP-dependent RNA helicase DDX5) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer and Skin cancer.","roles":[],"tier":"association-only"},{"id":"ddx6","symbol":"DDX6","href":"/targets/ddx6/","tldr":"DDX6 (Probable ATP-dependent RNA helicase DDX6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Lung cancer, Leiomyosarcoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"defa1","symbol":"DEFA1","href":"/targets/defa1/","tldr":"DEFA1 (Neutrophil defensin 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"dek","symbol":"DEK","href":"/targets/dek/","tldr":"DEK (DEK proto-oncogene) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer and Gastric & gastro-oesophageal junction cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"dgcr8","symbol":"DGCR8","href":"/targets/dgcr8/","tldr":"DGCR8 (Microprocessor complex subunit DGCR8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Thyroid cancer, Diffuse large B-cell lymphoma and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"dhx9","symbol":"DHX9","href":"/targets/dhx9/","tldr":"DHX9 (ATP-dependent RNA helicase A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"dicer1","symbol":"DICER1","href":"/targets/dicer1/","tldr":"DICER1 (Endoribonuclease Dicer) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Sarcomas, Brain and spinal cord tumours and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"dis3","symbol":"DIS3","href":"/targets/dis3/","tldr":"DIS3 (Exosome complex exonuclease RRP44) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"dkk1","symbol":"DKK1","href":"/targets/dkk1/","tldr":"DKK1 (Dickkopf-related protein 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"dlc1","symbol":"DLC1","href":"/targets/dlc1/","tldr":"DLC1 (Rho GTPase-activating protein 7) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dll1","symbol":"DLL1","href":"/targets/dll1/","tldr":"DLL1 (Delta-like protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dll4","symbol":"DLL4","href":"/targets/dll4/","tldr":"DLL4 (Delta-like protein 4) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","antigen"],"tier":"clinical-evidence"},{"id":"dlst","symbol":"DLST","href":"/targets/dlst/","tldr":"DLST (Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours.","roles":[],"tier":"association-only"},{"id":"dna2","symbol":"DNA2","href":"/targets/dna2/","tldr":"DNA2 (DNA replication ATP-dependent helicase/nuclease DNA2) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"dnah11","symbol":"DNAH11","href":"/targets/dnah11/","tldr":"DNAH11 (Dynein axonemal heavy chain 11) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dnajb1","symbol":"DNAJB1","href":"/targets/dnajb1/","tldr":"DNAJB1 (DnaJ homolog subfamily B member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dnajc1","symbol":"DNAJC1","href":"/targets/dnajc1/","tldr":"DNAJC1 (DnaJ homolog subfamily C member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dnm2","symbol":"DNM2","href":"/targets/dnm2/","tldr":"DNM2 (Dynamin-2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma, Colorectal cancer and 3 more.","roles":[],"tier":"association-only"},{"id":"dnmt3b","symbol":"DNMT3B","href":"/targets/dnmt3b/","tldr":"DNMT3B (DNA (cytosine-5)-methyltransferase 3B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dock8","symbol":"DOCK8","href":"/targets/dock8/","tldr":"DOCK8 (Dedicator of cytokinesis protein 8) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dot1l","symbol":"DOT1L","href":"/targets/dot1l/","tldr":"DOT1L (Histone-lysine N-methyltransferase, H3 lysine-79 specific) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Diffuse large B-cell lymphoma and Neuroblastoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"dpyd","symbol":"DPYD","href":"/targets/dpyd/","tldr":"DPYD (Dihydropyrimidine dehydrogenase [NADP(+)]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma and Gastric & gastro-oesophageal junction cancer.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"drd5","symbol":"DRD5","href":"/targets/drd5/","tldr":"DRD5 (Dopamine receptor D5) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"drosha","symbol":"DROSHA","href":"/targets/drosha/","tldr":"DROSHA (Ribonuclease 3) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Brain and spinal cord tumours, Pancreatic ductal adenocarcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"dsp","symbol":"DSP","href":"/targets/dsp/","tldr":"DSP (Desmoplakin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"dtx1","symbol":"DTX1","href":"/targets/dtx1/","tldr":"DTX1 (E3 ubiquitin-protein ligase DTX1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma and Chronic lymphocytic leukaemia.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"dusp16","symbol":"DUSP16","href":"/targets/dusp16/","tldr":"DUSP16 (Dual specificity protein phosphatase 16) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"dusp2","symbol":"DUSP2","href":"/targets/dusp2/","tldr":"DUSP2 (Dual specificity protein phosphatase 2) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"dusp6","symbol":"DUSP6","href":"/targets/dusp6/","tldr":"DUSP6 (Dual specificity protein phosphatase 6) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ebf1","symbol":"EBF1","href":"/targets/ebf1/","tldr":"EBF1 (Transcription factor COE1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Neuroendocrine tumours and 4 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ebf2","symbol":"EBF2","href":"/targets/ebf2/","tldr":"EBF2 (Transcription factor COE2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ecscr","symbol":"ECSCR","href":"/targets/ecscr/","tldr":"ECSCR (Endothelial cell-specific chemotaxis regulator) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ednra","symbol":"EDNRA","href":"/targets/ednra/","tldr":"EDNRA (Endothelin-1 receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"eed","symbol":"EED","href":"/targets/eed/","tldr":"EED (Polycomb protein EED) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and the evidence so far is association rather than a proven role.","roles":["drug-target"],"tier":"association-only"},{"id":"eftud2","symbol":"EFTUD2","href":"/targets/eftud2/","tldr":"EFTUD2 (116 kDa U5 small nuclear ribonucleoprotein component) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"egf","symbol":"EGF","href":"/targets/egf/","tldr":"EGF (Pro-epidermal growth factor) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"egr2","symbol":"EGR2","href":"/targets/egr2/","tldr":"EGR2 (E3 SUMO-protein ligase EGR2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Chronic lymphocytic leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"ehbp1","symbol":"EHBP1","href":"/targets/ehbp1/","tldr":"EHBP1 (EH domain-binding protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"eif1ax","symbol":"EIF1AX","href":"/targets/eif1ax/","tldr":"EIF1AX (Eukaryotic translation initiation factor 1A, X-chromosomal) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Lung cancer, Prostate cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"eif2ak3","symbol":"EIF2AK3","href":"/targets/eif2ak3/","tldr":"EIF2AK3 (Eukaryotic translation initiation factor 2-alpha kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"eif3e","symbol":"EIF3E","href":"/targets/eif3e/","tldr":"EIF3E (Eukaryotic translation initiation factor 3 subunit E) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Breast cancer and Lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"eif4a1","symbol":"EIF4A1","href":"/targets/eif4a1/","tldr":"EIF4A1 (Eukaryotic initiation factor 4A-I) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"eif4a2","symbol":"EIF4A2","href":"/targets/eif4a2/","tldr":"EIF4A2 (Eukaryotic initiation factor 4A-II) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"eif4ebp1","symbol":"EIF4EBP1","href":"/targets/eif4ebp1/","tldr":"EIF4EBP1 (Eukaryotic translation initiation factor 4E-binding protein 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Gastric & gastro-oesophageal junction cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"elac2","symbol":"ELAC2","href":"/targets/elac2/","tldr":"ELAC2 (Zinc phosphodiesterase ELAC protein 2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"elf3","symbol":"ELF3","href":"/targets/elf3/","tldr":"ELF3 (ETS-related transcription factor Elf-3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Colorectal cancer and Biliary tract cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"elf4","symbol":"ELF4","href":"/targets/elf4/","tldr":"ELF4 (ETS-related transcription factor Elf-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer and Acute myeloid leukaemia.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"elk4","symbol":"ELK4","href":"/targets/elk4/","tldr":"ELK4 (ETS domain-containing protein Elk-4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma and Skin cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"ell","symbol":"ELL","href":"/targets/ell/","tldr":"ELL (RNA polymerase II elongation factor ELL) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer, Breast cancer, Skin cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"eln","symbol":"ELN","href":"/targets/eln/","tldr":"ELN (Elastin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer and Cutaneous squamous cell carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"elp1","symbol":"ELP1","href":"/targets/elp1/","tldr":"ELP1 (Elongator complex protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Medulloblastoma.","roles":[],"tier":"association-only"},{"id":"elp4","symbol":"ELP4","href":"/targets/elp4/","tldr":"ELP4 (Elongator complex protein 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"eml4","symbol":"EML4","href":"/targets/eml4/","tldr":"EML4 (Echinoderm microtubule-associated protein-like 4) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer and Non-small-cell lung cancer.","roles":["drug-target","fusion-partner"],"tier":"approved-drug"},{"id":"emsy","symbol":"EMSY","href":"/targets/emsy/","tldr":"EMSY (BRCA2-interacting transcriptional repressor EMSY) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"eomes","symbol":"EOMES","href":"/targets/eomes/","tldr":"EOMES (Eomesodermin homolog) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"ep300","symbol":"EP300","href":"/targets/ep300/","tldr":"EP300 (Histone acetyltransferase p300) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Bladder & urothelial cancer, Head and neck squamous cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"epha1","symbol":"EPHA1","href":"/targets/epha1/","tldr":"EPHA1 (Ephrin type-A receptor 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"epha10","symbol":"EPHA10","href":"/targets/epha10/","tldr":"EPHA10 (Ephrin type-A receptor 10) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"epha3","symbol":"EPHA3","href":"/targets/epha3/","tldr":"EPHA3 (Ephrin type-A receptor 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours, Thyroid cancer, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor"],"tier":"approved-drug"},{"id":"epha4","symbol":"EPHA4","href":"/targets/epha4/","tldr":"EPHA4 (Ephrin type-A receptor 4) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"epha5","symbol":"EPHA5","href":"/targets/epha5/","tldr":"EPHA5 (Ephrin type-A receptor 5) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"epha6","symbol":"EPHA6","href":"/targets/epha6/","tldr":"EPHA6 (Ephrin type-A receptor 6) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"epha7","symbol":"EPHA7","href":"/targets/epha7/","tldr":"EPHA7 (Ephrin type-A receptor 7) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer, Neuroendocrine tumours, Colorectal cancer and 2 more.","roles":["drug-target","oncogene-driver","tumour-suppressor"],"tier":"approved-drug"},{"id":"epha8","symbol":"EPHA8","href":"/targets/epha8/","tldr":"EPHA8 (Ephrin type-A receptor 8) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours and Thyroid cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ephb1","symbol":"EPHB1","href":"/targets/ephb1/","tldr":"EPHB1 (Ephrin type-B receptor 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ephb2","symbol":"EPHB2","href":"/targets/ephb2/","tldr":"EPHB2 (Ephrin type-B receptor 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"ephb3","symbol":"EPHB3","href":"/targets/ephb3/","tldr":"EPHB3 (Ephrin type-B receptor 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ephb4","symbol":"EPHB4","href":"/targets/ephb4/","tldr":"EPHB4 (Ephrin type-B receptor 4) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"eps15","symbol":"EPS15","href":"/targets/eps15/","tldr":"EPS15 (Epidermal growth factor receptor substrate 15) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer, Non-Hodgkin lymphoma and 2 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"erbin","symbol":"ERBIN","href":"/targets/erbin/","tldr":"ERBIN (Erbin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"erc1","symbol":"ERC1","href":"/targets/erc1/","tldr":"ERC1 (ELKS/Rab6-interacting/CAST family member 1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"ercc1","symbol":"ERCC1","href":"/targets/ercc1/","tldr":"ERCC1 (DNA excision repair protein ERCC-1) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Mesothelioma, Ovarian cancer and 1 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"ercc2","symbol":"ERCC2","href":"/targets/ercc2/","tldr":"ERCC2 (General transcription and DNA repair factor IIH helicase subunit XPD) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Skin cancer, Colorectal cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"ercc3","symbol":"ERCC3","href":"/targets/ercc3/","tldr":"ERCC3 (General transcription and DNA repair factor IIH helicase/translocase subunit XPB) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Skin cancer, Ovarian cancer and 3 more.","roles":["drug-target","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"ercc4","symbol":"ERCC4","href":"/targets/ercc4/","tldr":"ERCC4 (DNA repair endonuclease XPF) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Skin cancer, Myeloproliferative neoplasms and 4 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"ercc5","symbol":"ERCC5","href":"/targets/ercc5/","tldr":"ERCC5 (DNA excision repair protein ERCC-5) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Skin cancer, Neuroendocrine tumours and 3 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"ercc6","symbol":"ERCC6","href":"/targets/ercc6/","tldr":"ERCC6 (Chimeric ERCC6-PGBD3 protein) is a gene. The public catalogues list it as a drug target, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Lung cancer.","roles":["drug-target","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"ereg","symbol":"EREG","href":"/targets/ereg/","tldr":"EREG (Proepiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"erg","symbol":"ERG","href":"/targets/erg/","tldr":"ERG (Transcriptional regulator ERG) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Prostate cancer, Non-Hodgkin lymphoma and 4 more.","roles":["oncogene-driver","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"erlin2","symbol":"ERLIN2","href":"/targets/erlin2/","tldr":"ERLIN2 (Erlin-2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"errfi1","symbol":"ERRFI1","href":"/targets/errfi1/","tldr":"ERRFI1 (ERBB receptor feedback inhibitor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Biliary tract cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"esr2","symbol":"ESR2","href":"/targets/esr2/","tldr":"ESR2 (Oestrogen receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer and Prostate cancer.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"esrp1","symbol":"ESRP1","href":"/targets/esrp1/","tldr":"ESRP1 (Epithelial splicing regulatory protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"esrra","symbol":"ESRRA","href":"/targets/esrra/","tldr":"ESRRA (Steroid hormone receptor ERR1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers and Adenoid cystic carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"etnk1","symbol":"ETNK1","href":"/targets/etnk1/","tldr":"ETNK1 (Ethanolamine kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Breast cancer and Myeloproliferative neoplasms.","roles":[],"tier":"association-only"},{"id":"ets1","symbol":"ETS1","href":"/targets/ets1/","tldr":"ETS1 (ETS proto-oncogene 1, transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"ets2","symbol":"ETS2","href":"/targets/ets2/","tldr":"ETS2 (ETS proto-oncogene 2, transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"etv1","symbol":"ETV1","href":"/targets/etv1/","tldr":"ETV1 (ETS translocation variant 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Breast cancer and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"etv4","symbol":"ETV4","href":"/targets/etv4/","tldr":"ETV4 (ETS translocation variant 4) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 1 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"etv5","symbol":"ETV5","href":"/targets/etv5/","tldr":"ETV5 (ETS translocation variant 5) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Neuroendocrine tumours and 4 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"etv6","symbol":"ETV6","href":"/targets/etv6/","tldr":"ETV6 (Transcription factor ETV6) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"exo1","symbol":"EXO1","href":"/targets/exo1/","tldr":"EXO1 (Exonuclease 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"ext1","symbol":"EXT1","href":"/targets/ext1/","tldr":"EXT1 (Exostosin-1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas, Breast cancer, Ovarian cancer and 2 more.","roles":[],"tier":"association-only"},{"id":"ext2","symbol":"EXT2","href":"/targets/ext2/","tldr":"EXT2 (Exostosin-2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Ovarian cancer, Skin cancer and Breast cancer.","roles":[],"tier":"association-only"},{"id":"ezr","symbol":"EZR","href":"/targets/ezr/","tldr":"EZR (Ezrin) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Lung cancer.","roles":[],"tier":"association-only"},{"id":"faap20","symbol":"FAAP20","href":"/targets/faap20/","tldr":"FAAP20 (Fanconi anaemia core complex-associated protein 20) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"fam114a2","symbol":"FAM114A2","href":"/targets/fam114a2/","tldr":"FAM114A2 (family with sequence similarity 114 member A2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fam131b","symbol":"FAM131B","href":"/targets/fam131b/","tldr":"FAM131B (family with sequence similarity 131 member B) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fam135b","symbol":"FAM135B","href":"/targets/fam135b/","tldr":"FAM135B (family with sequence similarity 135 member B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Endometrial cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"fam174b","symbol":"FAM174B","href":"/targets/fam174b/","tldr":"FAM174B (Membrane protein FAM174B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Medulloblastoma and Paediatric low-grade glioma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"fanca","symbol":"FANCA","href":"/targets/fanca/","tldr":"FANCA (Fanconi anaemia group A protein) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Skin cancer, Ovarian cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"fancb","symbol":"FANCB","href":"/targets/fancb/","tldr":"FANCB (Fanconi anaemia group B protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"fancc","symbol":"FANCC","href":"/targets/fancc/","tldr":"FANCC (Fanconi anaemia group C protein) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Leukaemia, Pancreatic ductal adenocarcinoma and 5 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"fancd2","symbol":"FANCD2","href":"/targets/fancd2/","tldr":"FANCD2 (Fanconi anaemia group D2 protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms, Breast cancer and 5 more.","roles":["dna-repair"],"tier":"association-only"},{"id":"fance","symbol":"FANCE","href":"/targets/fance/","tldr":"FANCE (Fanconi anaemia group E protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Colorectal cancer, Myeloproliferative neoplasms and 2 more.","roles":["dna-repair"],"tier":"association-only"},{"id":"fancf","symbol":"FANCF","href":"/targets/fancf/","tldr":"FANCF (Fanconi anaemia group F protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Skin cancer and Melanoma.","roles":["dna-repair"],"tier":"association-only"},{"id":"fancg","symbol":"FANCG","href":"/targets/fancg/","tldr":"FANCG (Fanconi anaemia group G protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms, Colorectal cancer and 2 more.","roles":["dna-repair"],"tier":"association-only"},{"id":"fanci","symbol":"FANCI","href":"/targets/fanci/","tldr":"FANCI (Fanconi anaemia group I protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"fancl","symbol":"FANCL","href":"/targets/fancl/","tldr":"FANCL (E3 ubiquitin-protein ligase FANCL) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"fancm","symbol":"FANCM","href":"/targets/fancm/","tldr":"FANCM (Fanconi anaemia group M protein) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Breast cancer and Ovarian cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"fas","symbol":"FAS","href":"/targets/fas/","tldr":"FAS (Tumour necrosis factor receptor superfamily member 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Cervical cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"fat1","symbol":"FAT1","href":"/targets/fat1/","tldr":"FAT1 (Protocadherin Fat 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Lung cancer, Bladder & urothelial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"fat2","symbol":"FAT2","href":"/targets/fat2/","tldr":"FAT2 (Protocadherin Fat 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Vulvar cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"fat3","symbol":"FAT3","href":"/targets/fat3/","tldr":"FAT3 (Protocadherin Fat 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Pancreatic ductal adenocarcinoma, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"fat4","symbol":"FAT4","href":"/targets/fat4/","tldr":"FAT4 (Protocadherin Fat 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Colorectal cancer, Hepatocellular carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"fbln2","symbol":"FBLN2","href":"/targets/fbln2/","tldr":"FBLN2 (Fibulin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Bladder & urothelial cancer, Hepatocellular carcinoma and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"fbn2","symbol":"FBN2","href":"/targets/fbn2/","tldr":"FBN2 (Fibrillin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroblastoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"fbxo11","symbol":"FBXO11","href":"/targets/fbxo11/","tldr":"FBXO11 (F-box only protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"fbxw11","symbol":"FBXW11","href":"/targets/fbxw11/","tldr":"FBXW11 (F-box/WD repeat-containing protein 11) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"fbxw7","symbol":"FBXW7","href":"/targets/fbxw7/","tldr":"FBXW7 (F-box/WD repeat-containing protein 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Non-Hodgkin lymphoma, Endometrial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"fcgr2a","symbol":"FCGR2A","href":"/targets/fcgr2a/","tldr":"FCGR2A (Low affinity immunoglobulin gamma Fc region receptor II-a) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fcgr2b","symbol":"FCGR2B","href":"/targets/fcgr2b/","tldr":"FCGR2B (Low affinity immunoglobulin gamma Fc region receptor II-b) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Non-Hodgkin lymphoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"fcgr3a","symbol":"FCGR3A","href":"/targets/fcgr3a/","tldr":"FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fcrl4","symbol":"FCRL4","href":"/targets/fcrl4/","tldr":"FCRL4 (Fc receptor-like protein 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Skin cancer, Lung cancer and 2 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"fdps","symbol":"FDPS","href":"/targets/fdps/","tldr":"FDPS (Farnesyl pyrophosphate synthase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Multiple myeloma and Breast cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"fermt2","symbol":"FERMT2","href":"/targets/fermt2/","tldr":"FERMT2 (Fermitin family homolog 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fes","symbol":"FES","href":"/targets/fes/","tldr":"FES (Tyrosine-protein kinase Fes/Fps) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Leukaemia and Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"fev","symbol":"FEV","href":"/targets/fev/","tldr":"FEV (FEV transcription factor, ETS family member) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"fga","symbol":"FGA","href":"/targets/fga/","tldr":"FGA (Fibrinogen alpha chain) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"fgb","symbol":"FGB","href":"/targets/fgb/","tldr":"FGB (Fibrinogen beta chain) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"fgd1","symbol":"FGD1","href":"/targets/fgd1/","tldr":"FGD1 (FYVE, RhoGEF and PH domain-containing protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"fgd5","symbol":"FGD5","href":"/targets/fgd5/","tldr":"FGD5 (FYVE, RhoGEF and PH domain-containing protein 5) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"fgf1","symbol":"FGF1","href":"/targets/fgf1/","tldr":"FGF1 (Fibroblast growth factor 1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"fgf10","symbol":"FGF10","href":"/targets/fgf10/","tldr":"FGF10 (Fibroblast growth factor 10) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf13","symbol":"FGF13","href":"/targets/fgf13/","tldr":"FGF13 (Fibroblast growth factor 13) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"fgf16","symbol":"FGF16","href":"/targets/fgf16/","tldr":"FGF16 (Fibroblast growth factor 16) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf17","symbol":"FGF17","href":"/targets/fgf17/","tldr":"FGF17 (Fibroblast growth factor 17) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf18","symbol":"FGF18","href":"/targets/fgf18/","tldr":"FGF18 (Fibroblast growth factor 18) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf19","symbol":"FGF19","href":"/targets/fgf19/","tldr":"FGF19 (Fibroblast growth factor 19) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma and Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fgf2","symbol":"FGF2","href":"/targets/fgf2/","tldr":"FGF2 (Fibroblast growth factor 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fgf20","symbol":"FGF20","href":"/targets/fgf20/","tldr":"FGF20 (Fibroblast growth factor 20) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf22","symbol":"FGF22","href":"/targets/fgf22/","tldr":"FGF22 (Fibroblast growth factor 22) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf23","symbol":"FGF23","href":"/targets/fgf23/","tldr":"FGF23 (Fibroblast growth factor 23) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and an approved or late-stage drug is recorded against it.","roles":["drug-target","antigen"],"tier":"approved-drug"},{"id":"fgf3","symbol":"FGF3","href":"/targets/fgf3/","tldr":"FGF3 (Fibroblast growth factor 3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Hepatocellular carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fgf4","symbol":"FGF4","href":"/targets/fgf4/","tldr":"FGF4 (Fibroblast growth factor 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fgf5","symbol":"FGF5","href":"/targets/fgf5/","tldr":"FGF5 (Fibroblast growth factor 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf6","symbol":"FGF6","href":"/targets/fgf6/","tldr":"FGF6 (Fibroblast growth factor 6) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf7","symbol":"FGF7","href":"/targets/fgf7/","tldr":"FGF7 (Fibroblast growth factor 7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"fgf8","symbol":"FGF8","href":"/targets/fgf8/","tldr":"FGF8 (Fibroblast growth factor 8) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf9","symbol":"FGF9","href":"/targets/fgf9/","tldr":"FGF9 (Fibroblast growth factor 9) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgfr1op2","symbol":"FGFR1OP2","href":"/targets/fgfr1op2/","tldr":"FGFR1OP2 (FGFR1 oncogene partner 2) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia.","roles":["fusion-partner"],"tier":"association-only"},{"id":"fgfr4","symbol":"FGFR4","href":"/targets/fgfr4/","tldr":"FGFR4 (Fibroblast growth factor receptor 4) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Sarcomas, Biliary tract cancer, Colorectal cancer and 5 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"approved-drug"},{"id":"fgg","symbol":"FGG","href":"/targets/fgg/","tldr":"FGG (Fibrinogen gamma chain) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"fgr","symbol":"FGR","href":"/targets/fgr/","tldr":"FGR (Tyrosine-protein kinase Fgr) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"fh","symbol":"FH","href":"/targets/fh/","tldr":"FH (Fumarate hydratase, mitochondrial) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Skin cancer, Papillary renal cell carcinoma and 1 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"fhit","symbol":"FHIT","href":"/targets/fhit/","tldr":"FHIT (Bis(5'-adenosyl)-triphosphatase) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer, Skin cancer and 1 more.","roles":["oncogene-driver","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"fip1l1","symbol":"FIP1L1","href":"/targets/fip1l1/","tldr":"FIP1L1 (Pre-mRNA 3'-end-processing factor FIP1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"flcn","symbol":"FLCN","href":"/targets/flcn/","tldr":"FLCN (Folliculin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Colorectal cancer, Gastric & gastro-oesophageal junction cancer and 3 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"flg","symbol":"FLG","href":"/targets/flg/","tldr":"FLG (Filaggrin) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Mesothelioma, Acute myeloid leukaemia and 2 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"flt3lg","symbol":"FLT3LG","href":"/targets/flt3lg/","tldr":"FLT3LG (Fms-related tyrosine kinase 3 ligand) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fmn1","symbol":"FMN1","href":"/targets/fmn1/","tldr":"FMN1 (Formin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fmn2","symbol":"FMN2","href":"/targets/fmn2/","tldr":"FMN2 (Formin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor","dna-repair"],"tier":"cohort-driver"},{"id":"fn1","symbol":"FN1","href":"/targets/fn1/","tldr":"FN1 (Fibronectin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fndc3b","symbol":"FNDC3B","href":"/targets/fndc3b/","tldr":"FNDC3B (Fibronectin type III domain-containing protein 3B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-Hodgkin lymphoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"fntb","symbol":"FNTB","href":"/targets/fntb/","tldr":"FNTB (Protein farnesyltransferase subunit beta) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fos","symbol":"FOS","href":"/targets/fos/","tldr":"FOS (Fos proto-oncogene, AP-1 transcription factor subunit) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fosb","symbol":"FOSB","href":"/targets/fosb/","tldr":"FOSB (FosB proto-oncogene, AP-1 transcription factor subunit) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"foxa1","symbol":"FOXA1","href":"/targets/foxa1/","tldr":"FOXA1 (Hepatocyte nuclear factor 3-alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Breast cancer, Neuroendocrine tumours and 1 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"foxa2","symbol":"FOXA2","href":"/targets/foxa2/","tldr":"FOXA2 (Hepatocyte nuclear factor 3-beta) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"foxc2","symbol":"FOXC2","href":"/targets/foxc2/","tldr":"FOXC2 (Forkhead box protein C2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"foxe1","symbol":"FOXE1","href":"/targets/foxe1/","tldr":"FOXE1 (Forkhead box protein E1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"foxf1","symbol":"FOXF1","href":"/targets/foxf1/","tldr":"FOXF1 (Forkhead box protein F1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"foxl2","symbol":"FOXL2","href":"/targets/foxl2/","tldr":"FOXL2 (Forkhead box protein L2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"foxo1","symbol":"FOXO1","href":"/targets/foxo1/","tldr":"FOXO1 (Forkhead box protein O1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Non-Hodgkin lymphoma, Ovarian cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"foxo3","symbol":"FOXO3","href":"/targets/foxo3/","tldr":"FOXO3 (Forkhead box protein O3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Acute myeloid leukaemia and 1 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"foxo4","symbol":"FOXO4","href":"/targets/foxo4/","tldr":"FOXO4 (Forkhead box protein O4) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"foxp1","symbol":"FOXP1","href":"/targets/foxp1/","tldr":"FOXP1 (Forkhead box protein P1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 5 more.","roles":["tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"foxp3","symbol":"FOXP3","href":"/targets/foxp3/","tldr":"FOXP3 (Forkhead box protein P3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"foxp4","symbol":"FOXP4","href":"/targets/foxp4/","tldr":"FOXP4 (Forkhead box protein P4) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"foxr2","symbol":"FOXR2","href":"/targets/foxr2/","tldr":"FOXR2 (Forkhead box protein R2) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"frs2","symbol":"FRS2","href":"/targets/frs2/","tldr":"FRS2 (Fibroblast growth factor receptor substrate 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"frs3","symbol":"FRS3","href":"/targets/frs3/","tldr":"FRS3 (Fibroblast growth factor receptor substrate 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fto","symbol":"FTO","href":"/targets/fto/","tldr":"FTO (Alpha-ketoglutarate-dependent dioxygenase FTO) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"fubp1","symbol":"FUBP1","href":"/targets/fubp1/","tldr":"FUBP1 (Far upstream element-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Colorectal cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"fus","symbol":"FUS","href":"/targets/fus/","tldr":"FUS (RNA-binding protein FUS) is a gene. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Hepatocellular carcinoma and Liposarcoma.","roles":["fusion-partner"],"tier":"cohort-driver"},{"id":"fxr1","symbol":"FXR1","href":"/targets/fxr1/","tldr":"FXR1 (RNA-binding protein FXR1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fyn","symbol":"FYN","href":"/targets/fyn/","tldr":"FYN (Tyrosine-protein kinase Fyn) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Myeloproliferative neoplasms and 2 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"gab1","symbol":"GAB1","href":"/targets/gab1/","tldr":"GAB1 (GRB2-associated-binding protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"gab2","symbol":"GAB2","href":"/targets/gab2/","tldr":"GAB2 (GRB2-associated-binding protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms and Chronic myeloid leukaemia.","roles":[],"tier":"association-only"},{"id":"gabrg3","symbol":"GABRG3","href":"/targets/gabrg3/","tldr":"GABRG3 (Gamma-aminobutyric acid receptor subunit gamma-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"gadd45a","symbol":"GADD45A","href":"/targets/gadd45a/","tldr":"GADD45A (Growth arrest and DNA damage-inducible protein GADD45 alpha) is a gene. The public catalogues list it as a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"galnt14","symbol":"GALNT14","href":"/targets/galnt14/","tldr":"GALNT14 (Polypeptide N-acetylgalactosaminyltransferase 14) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"gas6","symbol":"GAS6","href":"/targets/gas6/","tldr":"GAS6 (Growth arrest-specific protein 6) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"gata1","symbol":"GATA1","href":"/targets/gata1/","tldr":"GATA1 (Erythroid transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 1 more.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"gata2","symbol":"GATA2","href":"/targets/gata2/","tldr":"GATA2 (Endothelial transcription factor GATA-2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Myelodysplastic syndromes / neoplasms and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"gata3","symbol":"GATA3","href":"/targets/gata3/","tldr":"GATA3 (Trans-acting T-cell-specific transcription factor GATA-3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Leukaemia and 2 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"gdf7","symbol":"GDF7","href":"/targets/gdf7/","tldr":"GDF7 (Growth/differentiation factor 7) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ghsr","symbol":"GHSR","href":"/targets/ghsr/","tldr":"GHSR (Growth hormone secretagogue receptor type 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"gli1","symbol":"GLI1","href":"/targets/gli1/","tldr":"GLI1 (Transcription activator GLI1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas and Leiomyosarcoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"gmps","symbol":"GMPS","href":"/targets/gmps/","tldr":"GMPS (GMP synthase [glutamine-hydrolysing]) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"gna11","symbol":"GNA11","href":"/targets/gna11/","tldr":"GNA11 (Guanine nucleotide-binding protein subunit alpha-11) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Melanoma and 1 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"gna13","symbol":"GNA13","href":"/targets/gna13/","tldr":"GNA13 (Guanine nucleotide-binding protein subunit alpha-13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"gnai2","symbol":"GNAI2","href":"/targets/gnai2/","tldr":"GNAI2 (Guanine nucleotide-binding protein G(i) subunit alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Burkitt lymphoma.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"gnaq","symbol":"GNAQ","href":"/targets/gnaq/","tldr":"GNAQ (Guanine nucleotide-binding protein G(q) subunit alpha) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Breast cancer and 3 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"gnas","symbol":"GNAS","href":"/targets/gnas/","tldr":"GNAS (Neuroendocrine secretory protein 55) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Pancreatic ductal adenocarcinoma, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"gnb1","symbol":"GNB1","href":"/targets/gnb1/","tldr":"GNB1 (Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.","roles":[],"tier":"association-only"},{"id":"golga4","symbol":"GOLGA4","href":"/targets/golga4/","tldr":"GOLGA4 (Golgin subfamily A member 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"golga5","symbol":"GOLGA5","href":"/targets/golga5/","tldr":"GOLGA5 (Golgin subfamily A member 5) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"golgb1","symbol":"GOLGB1","href":"/targets/golgb1/","tldr":"GOLGB1 (Golgin subfamily B member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"gopc","symbol":"GOPC","href":"/targets/gopc/","tldr":"GOPC (Golgi-associated PDZ and coiled-coil motif-containing protein) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"gpaa1","symbol":"GPAA1","href":"/targets/gpaa1/","tldr":"GPAA1 (GPI-anchor transamidase component GPAA1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"gpc5","symbol":"GPC5","href":"/targets/gpc5/","tldr":"GPC5 (Glypican-5) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer and Biliary tract cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"gpr161","symbol":"GPR161","href":"/targets/gpr161/","tldr":"GPR161 (G protein-coupled receptor 161) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Medulloblastoma.","roles":[],"tier":"association-only"},{"id":"grb2","symbol":"GRB2","href":"/targets/grb2/","tldr":"GRB2 (Growth factor receptor-bound protein 2) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Chronic myeloid leukaemia.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"grem1","symbol":"GREM1","href":"/targets/grem1/","tldr":"GREM1 (Gremlin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"grhl2","symbol":"GRHL2","href":"/targets/grhl2/","tldr":"GRHL2 (Grainyhead-like protein 2 homolog) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"grhpr","symbol":"GRHPR","href":"/targets/grhpr/","tldr":"GRHPR (Glyoxylate reductase/hydroxypyruvate reductase) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"grin2a","symbol":"GRIN2A","href":"/targets/grin2a/","tldr":"GRIN2A (Glutamate receptor ionotropic, NMDA 2A) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Lung cancer, Skin cancer and 5 more.","roles":["drug-target","oncogene-driver","fusion-partner"],"tier":"clinical-evidence"},{"id":"grm3","symbol":"GRM3","href":"/targets/grm3/","tldr":"GRM3 (Metabotropic glutamate receptor 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Renal cell carcinoma, Oesophageal cancer, Chromophobe renal cell carcinoma and 2 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"gsk3b","symbol":"GSK3B","href":"/targets/gsk3b/","tldr":"GSK3B (Glycogen synthase kinase-3 beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["drug-target","tumour-suppressor"],"tier":"clinical-evidence"},{"id":"gstp1","symbol":"GSTP1","href":"/targets/gstp1/","tldr":"GSTP1 (Glutathione S-transferase P) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"gtf2i","symbol":"GTF2I","href":"/targets/gtf2i/","tldr":"GTF2I (General transcription factor II-I) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thymoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"h1-2","symbol":"H1-2","href":"/targets/h1-2/","tldr":"H1-2 (Histone H1.2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h1-3","symbol":"H1-3","href":"/targets/h1-3/","tldr":"H1-3 (Histone H1.3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h1-5","symbol":"H1-5","href":"/targets/h1-5/","tldr":"H1-5 (Histone H1.5) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h2ac17","symbol":"H2AC17","href":"/targets/h2ac17/","tldr":"H2AC17 (Histone H2A type 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h2ac6","symbol":"H2AC6","href":"/targets/h2ac6/","tldr":"H2AC6 (Histone H2A type 1-C) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h2bc12","symbol":"H2BC12","href":"/targets/h2bc12/","tldr":"H2BC12 (Histone H2B type 1-K) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h2bc5","symbol":"H2BC5","href":"/targets/h2bc5/","tldr":"H2BC5 (Histone H2B type 1-D) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h3-3a","symbol":"H3-3A","href":"/targets/h3-3a/","tldr":"H3.3 is one of the histone proteins DNA wraps around; a single change at position 27 (K27M) locks brain-stem and midline gliomas in an immature state and defines the diagnosis.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"h3-3b","symbol":"H3-3B","href":"/targets/h3-3b/","tldr":"H3-3B (Histone H3.3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Melanoma and Diffuse midline glioma, H3 K27-altered.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h3c14","symbol":"H3C14","href":"/targets/h3c14/","tldr":"H3C14 (Histone H3.2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse midline glioma, H3 K27-altered.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h3c2","symbol":"H3C2","href":"/targets/h3c2/","tldr":"H3C2 (Histone H3.1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Bladder & urothelial cancer, Oesophageal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"h3c4","symbol":"H3C4","href":"/targets/h3c4/","tldr":"H3C4 (Histone H3.1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h4c9","symbol":"H4C9","href":"/targets/h4c9/","tldr":"H4C9 (Histone H4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Chronic lymphocytic leukaemia.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"habp2","symbol":"HABP2","href":"/targets/habp2/","tldr":"HABP2 (Factor VII-activating protease) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"hbb","symbol":"HBB","href":"/targets/hbb/","tldr":"HBB (Haemoglobin subunit beta) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"hbegf","symbol":"HBEGF","href":"/targets/hbegf/","tldr":"HBEGF (Proheparin-binding EGF-like growth factor) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"hcar3","symbol":"HCAR3","href":"/targets/hcar3/","tldr":"HCAR3 (Hydroxycarboxylic acid receptor 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"hdac10","symbol":"HDAC10","href":"/targets/hdac10/","tldr":"HDAC10 (Polyamine deacetylase HDAC10) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Multiple myeloma.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"hdac11","symbol":"HDAC11","href":"/targets/hdac11/","tldr":"HDAC11 (Histone deacetylase 11) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Skin cancer and Multiple myeloma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"hdac4","symbol":"HDAC4","href":"/targets/hdac4/","tldr":"HDAC4 (Histone deacetylase 4) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Non-Hodgkin lymphoma, Multiple myeloma and 1 more.","roles":["drug-target","oncogene-driver"],"tier":"approved-drug"},{"id":"hdac5","symbol":"HDAC5","href":"/targets/hdac5/","tldr":"HDAC5 (Histone deacetylase 5) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Multiple myeloma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"hdac7","symbol":"HDAC7","href":"/targets/hdac7/","tldr":"HDAC7 (Histone deacetylase 7) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Multiple myeloma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"hdac8","symbol":"HDAC8","href":"/targets/hdac8/","tldr":"HDAC8 (Histone deacetylase 8) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Multiple myeloma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"hdac9","symbol":"HDAC9","href":"/targets/hdac9/","tldr":"HDAC9 (Histone deacetylase 9) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 4 more.","roles":["drug-target","biomarker","fusion-partner"],"tier":"approved-drug"},{"id":"herpud1","symbol":"HERPUD1","href":"/targets/herpud1/","tldr":"HERPUD1 (Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"hey1","symbol":"HEY1","href":"/targets/hey1/","tldr":"HEY1 (Hairy/enhancer-of-split related with YRPW motif protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas and Chondrosarcoma.","roles":[],"tier":"association-only"},{"id":"hgf","symbol":"HGF","href":"/targets/hgf/","tldr":"HGF (Hepatocyte growth factor) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"hhip","symbol":"HHIP","href":"/targets/hhip/","tldr":"HHIP (Hedgehog-interacting protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"hip1","symbol":"HIP1","href":"/targets/hip1/","tldr":"HIP1 (Huntingtin-interacting protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Lung cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"hla-b","symbol":"HLA-B","href":"/targets/hla-b/","tldr":"HLA-B (HLA class I histocompatibility antigen, B alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Oesophageal cancer, Head and neck squamous cell carcinoma and 3 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"hla-c","symbol":"HLA-C","href":"/targets/hla-c/","tldr":"HLA-C (HLA class I histocompatibility antigen, C alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Diffuse large B-cell lymphoma.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"hla-dqa1","symbol":"HLA-DQA1","href":"/targets/hla-dqa1/","tldr":"HLA-DQA1 (HLA class II histocompatibility antigen, DQ alpha 1 chain) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"hla-dra","symbol":"HLA-DRA","href":"/targets/hla-dra/","tldr":"HLA-DRA (HLA class II histocompatibility antigen, DR alpha chain) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"hlf","symbol":"HLF","href":"/targets/hlf/","tldr":"HLF (Transcription factor HLF) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"hmga1","symbol":"HMGA1","href":"/targets/hmga1/","tldr":"HMGA1 (High mobility group protein HMG-I/HMG-Y) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"hmga2","symbol":"HMGA2","href":"/targets/hmga2/","tldr":"HMGA2 (High mobility group protein HMGI-C) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer and Oral cavity cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"hmgcr","symbol":"HMGCR","href":"/targets/hmgcr/","tldr":"HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"hmox1","symbol":"HMOX1","href":"/targets/hmox1/","tldr":"HMOX1 (Heme oxygenase 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"hnf1a","symbol":"HNF1A","href":"/targets/hnf1a/","tldr":"HNF1A (Hepatocyte nuclear factor 1-alpha) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Renal cell carcinoma, Hepatocellular carcinoma, Skin cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"hnf1b","symbol":"HNF1B","href":"/targets/hnf1b/","tldr":"HNF1B (Hepatocyte nuclear factor 1-beta) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma and Ovarian cancer.","roles":[],"tier":"association-only"},{"id":"hnf4g","symbol":"HNF4G","href":"/targets/hnf4g/","tldr":"HNF4G (Hepatocyte nuclear factor 4-gamma) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"hnrnpa2b1","symbol":"HNRNPA2B1","href":"/targets/hnrnpa2b1/","tldr":"HNRNPA2B1 (Heterogeneous nuclear ribonucleoproteins A2/B1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Leukaemia and Non-Hodgkin lymphoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"hnrnph1","symbol":"HNRNPH1","href":"/targets/hnrnph1/","tldr":"HNRNPH1 (Heterogeneous nuclear ribonucleoprotein H) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mantle cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"hnrnpu","symbol":"HNRNPU","href":"/targets/hnrnpu/","tldr":"HNRNPU (Heterogeneous nuclear ribonucleoprotein U) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"hook3","symbol":"HOOK3","href":"/targets/hook3/","tldr":"HOOK3 (Protein Hook homolog 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"hoxa11","symbol":"HOXA11","href":"/targets/hoxa11/","tldr":"HOXA11 (Homeobox protein Hox-A11) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"hoxa13","symbol":"HOXA13","href":"/targets/hoxa13/","tldr":"HOXA13 (Homeobox protein Hox-A13) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"hoxb13","symbol":"HOXB13","href":"/targets/hoxb13/","tldr":"HOXB13 (Homeobox protein Hox-B13) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer and Gastric & gastro-oesophageal junction cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"hoxc10","symbol":"HOXC10","href":"/targets/hoxc10/","tldr":"HOXC10 (Homeobox protein Hox-C10) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"hoxc11","symbol":"HOXC11","href":"/targets/hoxc11/","tldr":"HOXC11 (Homeobox protein Hox-C11) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"hoxc13","symbol":"HOXC13","href":"/targets/hoxc13/","tldr":"HOXC13 (Homeobox protein Hox-C13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"hoxd11","symbol":"HOXD11","href":"/targets/hoxd11/","tldr":"HOXD11 (Homeobox protein Hox-D11) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"hoxd13","symbol":"HOXD13","href":"/targets/hoxd13/","tldr":"HOXD13 (Homeobox protein Hox-D13) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"hoxd8","symbol":"HOXD8","href":"/targets/hoxd8/","tldr":"HOXD8 (Homeobox protein Hox-D8) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"hras","symbol":"HRAS","href":"/targets/hras/","tldr":"HRAS (GTPase HRas) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Thyroid cancer, Sarcomas and 5 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"hsp90aa1","symbol":"HSP90AA1","href":"/targets/hsp90aa1/","tldr":"HSP90AA1 (Heat shock protein HSP 90-alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","tumour-suppressor"],"tier":"clinical-evidence"},{"id":"hsp90ab1","symbol":"HSP90AB1","href":"/targets/hsp90ab1/","tldr":"HSP90AB1 (Heat shock protein HSP 90-beta) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"hsp90b1","symbol":"HSP90B1","href":"/targets/hsp90b1/","tldr":"HSP90B1 (Endoplasmin) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"hspa5","symbol":"HSPA5","href":"/targets/hspa5/","tldr":"HSPA5 (Endoplasmic reticulum chaperone BiP) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"hspb1","symbol":"HSPB1","href":"/targets/hspb1/","tldr":"HSPB1 (Heat shock protein beta-1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"hspg2","symbol":"HSPG2","href":"/targets/hspg2/","tldr":"HSPG2 (Basement membrane-specific heparan sulfate proteoglycan core protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"hsph1","symbol":"HSPH1","href":"/targets/hsph1/","tldr":"HSPH1 (Heat shock protein 105 kDa) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer and Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"hvcn1","symbol":"HVCN1","href":"/targets/hvcn1/","tldr":"HVCN1 (Voltage-gated hydrogen channel 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"icos","symbol":"ICOS","href":"/targets/icos/","tldr":"ICOS (Inducible T-cell costimulator) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"id3","symbol":"ID3","href":"/targets/id3/","tldr":"ID3 (DNA-binding protein inhibitor ID-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Burkitt lymphoma and Diffuse large B-cell lymphoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ifna2","symbol":"IFNA2","href":"/targets/ifna2/","tldr":"IFNA2 (Interferon alpha-2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ifnar2","symbol":"IFNAR2","href":"/targets/ifnar2/","tldr":"IFNAR2 (Interferon alpha/beta receptor 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ifngr1","symbol":"IFNGR1","href":"/targets/ifngr1/","tldr":"IFNGR1 (Interferon gamma receptor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"igf2","symbol":"IGF2","href":"/targets/igf2/","tldr":"IGF2 (Insulin-like growth factor 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Ovarian cancer and Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"igf2r","symbol":"IGF2R","href":"/targets/igf2r/","tldr":"IGF2R (Cation-independent mannose-6-phosphate receptor) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ikbkb","symbol":"IKBKB","href":"/targets/ikbkb/","tldr":"IKBKB (Inhibitor of nuclear factor kappa-B kinase subunit beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer, Breast cancer and 2 more.","roles":["drug-target","oncogene-driver"],"tier":"clinical-evidence"},{"id":"il2rb","symbol":"IL2RB","href":"/targets/il2rb/","tldr":"IL2RB (Interleukin-2 receptor subunit beta) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Leukaemia, Renal cell carcinoma and 3 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"il2rg","symbol":"IL2RG","href":"/targets/il2rg/","tldr":"IL2RG (Cytokine receptor common subunit gamma) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Renal cell carcinoma, Leukaemia and 3 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"il33","symbol":"IL33","href":"/targets/il33/","tldr":"IL33 (Interleukin-33) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"il4r","symbol":"IL4R","href":"/targets/il4r/","tldr":"IL4R (Interleukin-4 receptor subunit alpha) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"il6st","symbol":"IL6ST","href":"/targets/il6st/","tldr":"IL6ST (Interleukin-6 receptor subunit beta) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Prostate cancer, Colorectal cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"il7r","symbol":"IL7R","href":"/targets/il7r/","tldr":"IL7R (Interleukin-7 receptor subunit alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"impdh1","symbol":"IMPDH1","href":"/targets/impdh1/","tldr":"IMPDH1 (Inosine-5'-monophosphate dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Myeloproliferative neoplasms and 2 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"incenp","symbol":"INCENP","href":"/targets/incenp/","tldr":"INCENP (Inner centromere protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ing1","symbol":"ING1","href":"/targets/ing1/","tldr":"ING1 (Inhibitor of growth protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Colorectal cancer and Endometrial cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"inhbb","symbol":"INHBB","href":"/targets/inhbb/","tldr":"INHBB (Inhibin beta B chain) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"inppl1","symbol":"INPPL1","href":"/targets/inppl1/","tldr":"INPPL1 (Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"iqgap1","symbol":"IQGAP1","href":"/targets/iqgap1/","tldr":"IQGAP1 (Ras GTPase-activating-like protein IQGAP1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"irak1","symbol":"IRAK1","href":"/targets/irak1/","tldr":"IRAK1 (Interleukin-1 receptor-associated kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Multiple myeloma.","roles":["drug-target","tumour-suppressor"],"tier":"approved-drug"},{"id":"irf1","symbol":"IRF1","href":"/targets/irf1/","tldr":"IRF1 (Interferon regulatory factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer and Multiple myeloma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"irf5","symbol":"IRF5","href":"/targets/irf5/","tldr":"IRF5 (Interferon regulatory factor 5) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"irf8","symbol":"IRF8","href":"/targets/irf8/","tldr":"IRF8 (Interferon regulatory factor 8) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"irs1","symbol":"IRS1","href":"/targets/irs1/","tldr":"IRS1 (Insulin receptor substrate 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"irs2","symbol":"IRS2","href":"/targets/irs2/","tldr":"IRS2 (Insulin receptor substrate 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"irs4","symbol":"IRS4","href":"/targets/irs4/","tldr":"IRS4 (Insulin receptor substrate 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"irx4","symbol":"IRX4","href":"/targets/irx4/","tldr":"IRX4 (Iroquois-class homeodomain protein IRX-4) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"itga2b","symbol":"ITGA2B","href":"/targets/itga2b/","tldr":"ITGA2B (Integrin alpha-IIb) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"itga6","symbol":"ITGA6","href":"/targets/itga6/","tldr":"ITGA6 (Integrin alpha-6) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"itgav","symbol":"ITGAV","href":"/targets/itgav/","tldr":"ITGAV (Integrin alpha-V) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"itgb3","symbol":"ITGB3","href":"/targets/itgb3/","tldr":"ITGB3 (Integrin beta-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"itk","symbol":"ITK","href":"/targets/itk/","tldr":"ITK (Tyrosine-protein kinase ITK/TSK) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Renal cell carcinoma and Sarcomas.","roles":["drug-target"],"tier":"approved-drug"},{"id":"itpkb","symbol":"ITPKB","href":"/targets/itpkb/","tldr":"ITPKB (Inositol-trisphosphate 3-kinase B) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"itpr1","symbol":"ITPR1","href":"/targets/itpr1/","tldr":"ITPR1 (Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"jag1","symbol":"JAG1","href":"/targets/jag1/","tldr":"JAG1 (jagged canonical Notch ligand 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"jag2","symbol":"JAG2","href":"/targets/jag2/","tldr":"JAG2 (jagged canonical Notch ligand 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"jak3","symbol":"JAK3","href":"/targets/jak3/","tldr":"JAK3 (Tyrosine-protein kinase JAK3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"approved-drug"},{"id":"jazf1","symbol":"JAZF1","href":"/targets/jazf1/","tldr":"JAZF1 (Juxtaposed with another zinc finger protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Skin cancer and Prostate cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"jun","symbol":"JUN","href":"/targets/jun/","tldr":"JUN (Transcription factor Jun) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Skin cancer and Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"kank1","symbol":"KANK1","href":"/targets/kank1/","tldr":"KANK1 (KN motif and ankyrin repeat domain-containing protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"kat2a","symbol":"KAT2A","href":"/targets/kat2a/","tldr":"KAT2A (Histone acetyltransferase KAT2A) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"kat2b","symbol":"KAT2B","href":"/targets/kat2b/","tldr":"KAT2B (Histone acetyltransferase KAT2B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"kat5","symbol":"KAT5","href":"/targets/kat5/","tldr":"KAT5 (Histone acetyltransferase KAT5) is a protein that switches other genes on and off. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"kat6a","symbol":"KAT6A","href":"/targets/kat6a/","tldr":"KAT6A (Histone acetyltransferase KAT6A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Skin cancer, Breast cancer and 5 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"kat6b","symbol":"KAT6B","href":"/targets/kat6b/","tldr":"KAT6B (Histone acetyltransferase KAT6B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Nasopharyngeal carcinoma, Prostate cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"kat7","symbol":"KAT7","href":"/targets/kat7/","tldr":"KAT7 (Histone acetyltransferase KAT7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer.","roles":["tumour-suppressor","dna-repair"],"tier":"cohort-driver"},{"id":"kcna3","symbol":"KCNA3","href":"/targets/kcna3/","tldr":"KCNA3 (Potassium voltage-gated channel subfamily A member 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcna4","symbol":"KCNA4","href":"/targets/kcna4/","tldr":"KCNA4 (Potassium voltage-gated channel subfamily A member 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnb2","symbol":"KCNB2","href":"/targets/kcnb2/","tldr":"KCNB2 (Potassium voltage-gated channel subfamily B member 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnc2","symbol":"KCNC2","href":"/targets/kcnc2/","tldr":"KCNC2 (Voltage-gated potassium channel KCNC2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnd2","symbol":"KCND2","href":"/targets/kcnd2/","tldr":"KCND2 (A-type voltage-gated potassium channel KCND2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnd3","symbol":"KCND3","href":"/targets/kcnd3/","tldr":"KCND3 (A-type voltage-gated potassium channel KCND3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnf1","symbol":"KCNF1","href":"/targets/kcnf1/","tldr":"KCNF1 (Voltage-gated potassium channel regulatory subunit KCNF1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnh1","symbol":"KCNH1","href":"/targets/kcnh1/","tldr":"KCNH1 (Voltage-gated delayed rectifier potassium channel KCNH1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnh7","symbol":"KCNH7","href":"/targets/kcnh7/","tldr":"KCNH7 (Voltage-gated inwardly rectifying potassium channel KCNH7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnh8","symbol":"KCNH8","href":"/targets/kcnh8/","tldr":"KCNH8 (Voltage-gated delayed rectifier potassium channel KCNH8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnq1","symbol":"KCNQ1","href":"/targets/kcnq1/","tldr":"KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnq3","symbol":"KCNQ3","href":"/targets/kcnq3/","tldr":"KCNQ3 (Potassium voltage-gated channel subfamily KQT member 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnq5","symbol":"KCNQ5","href":"/targets/kcnq5/","tldr":"KCNQ5 (Potassium voltage-gated channel subfamily KQT member 5) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kdm3b","symbol":"KDM3B","href":"/targets/kdm3b/","tldr":"KDM3B (Lysine-specific demethylase 3B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma and Paediatric low-grade glioma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"kdm5a","symbol":"KDM5A","href":"/targets/kdm5a/","tldr":"KDM5A (Lysine-specific demethylase 5A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Leukaemia, Lung cancer and 3 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"kdm5c","symbol":"KDM5C","href":"/targets/kdm5c/","tldr":"KDM5C (Lysine-specific demethylase 5C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"kdm5d","symbol":"KDM5D","href":"/targets/kdm5d/","tldr":"KDM5D (Lysine-specific demethylase 5D) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"kdm6a","symbol":"KDM6A","href":"/targets/kdm6a/","tldr":"KDM6A (Lysine-specific demethylase 6A) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Prostate cancer, Pancreatic ductal adenocarcinoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"kdm7a","symbol":"KDM7A","href":"/targets/kdm7a/","tldr":"KDM7A (Lysine-specific demethylase 7A) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"keap1","symbol":"KEAP1","href":"/targets/keap1/","tldr":"KEAP1 (Kelch-like ECH-associated protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Hepatocellular carcinoma, Nasopharyngeal carcinoma and 3 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"kiaa1549","symbol":"KIAA1549","href":"/targets/kiaa1549/","tldr":"KIAA1549 (UPF0606 protein KIAA1549) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"kif23","symbol":"KIF23","href":"/targets/kif23/","tldr":"KIF23 (Kinesin-like protein KIF23) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"kif5b","symbol":"KIF5B","href":"/targets/kif5b/","tldr":"KIF5B (Kinesin-1 heavy chain) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.","roles":["drug-target","oncogene-driver"],"tier":"approved-drug"},{"id":"kitlg","symbol":"KITLG","href":"/targets/kitlg/","tldr":"KITLG (Kit ligand) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Testicular germ cell tumours.","roles":[],"tier":"association-only"},{"id":"klc1","symbol":"KLC1","href":"/targets/klc1/","tldr":"KLC1 (Kinesin light chain 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"klf2","symbol":"KLF2","href":"/targets/klf2/","tldr":"KLF2 (Krueppel-like factor 2) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"klf4","symbol":"KLF4","href":"/targets/klf4/","tldr":"KLF4 (Krueppel-like factor 4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Hepatocellular carcinoma, Skin cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"klf5","symbol":"KLF5","href":"/targets/klf5/","tldr":"KLF5 (Krueppel-like factor 5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Cervical cancer, Colorectal cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"klf6","symbol":"KLF6","href":"/targets/klf6/","tldr":"KLF6 (Krueppel-like factor 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Skin cancer and Melanoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"klhdc8b","symbol":"KLHDC8B","href":"/targets/klhdc8b/","tldr":"KLHDC8B (Kelch domain-containing protein 8B) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Hodgkin lymphoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"klhl14","symbol":"KLHL14","href":"/targets/klhl14/","tldr":"KLHL14 (Kelch-like protein 14) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"klhl6","symbol":"KLHL6","href":"/targets/klhl6/","tldr":"KLHL6 (Kelch-like protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"klk3","symbol":"KLK3","href":"/targets/klk3/","tldr":"KLK3 (Prostate-specific antigen) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"klln","symbol":"KLLN","href":"/targets/klln/","tldr":"KLLN (Killin) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Renal cell carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"kmt2b","symbol":"KMT2B","href":"/targets/kmt2b/","tldr":"KMT2B (Histone-lysine N-methyltransferase 2B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Vulvar cancer, Melanoma and 1 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"kmt2c","symbol":"KMT2C","href":"/targets/kmt2c/","tldr":"KMT2C (Histone-lysine N-methyltransferase 2C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Bladder & urothelial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"kmt2d","symbol":"KMT2D","href":"/targets/kmt2d/","tldr":"KMT2D (Histone-lysine N-methyltransferase 2D) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Non-Hodgkin lymphoma, Bladder & urothelial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"kmt5a","symbol":"KMT5A","href":"/targets/kmt5a/","tldr":"KMT5A (N-lysine methyltransferase KMT5A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"knl1","symbol":"KNL1","href":"/targets/knl1/","tldr":"KNL1 (Outer kinetochore KNL1 complex subunit KNL1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Skin cancer, Colorectal cancer and 4 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"knstrn","symbol":"KNSTRN","href":"/targets/knstrn/","tldr":"KNSTRN (Small kinetochore-associated protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"krt18","symbol":"KRT18","href":"/targets/krt18/","tldr":"KRT18 (Keratin, type I cytoskeletal 18) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"krt5","symbol":"KRT5","href":"/targets/krt5/","tldr":"KRT5 (Keratin, type II cytoskeletal 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"ksr1","symbol":"KSR1","href":"/targets/ksr1/","tldr":"KSR1 (Kinase suppressor of Ras 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ksr2","symbol":"KSR2","href":"/targets/ksr2/","tldr":"KSR2 (Kinase suppressor of Ras 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ktn1","symbol":"KTN1","href":"/targets/ktn1/","tldr":"KTN1 (Kinectin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"l3mbtl3","symbol":"L3MBTL3","href":"/targets/l3mbtl3/","tldr":"L3MBTL3 (Lethal(3)malignant brain tumour-like protein 3) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"lama5","symbol":"LAMA5","href":"/targets/lama5/","tldr":"LAMA5 (Laminin subunit alpha-5) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lamc1","symbol":"LAMC1","href":"/targets/lamc1/","tldr":"LAMC1 (Laminin subunit gamma-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lats1","symbol":"LATS1","href":"/targets/lats1/","tldr":"LATS1 (Serine/threonine-protein kinase LATS1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Breast cancer, Ovarian cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"lats2","symbol":"LATS2","href":"/targets/lats2/","tldr":"LATS2 (Serine/threonine-protein kinase LATS2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Skin cancer, Colorectal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"lck","symbol":"LCK","href":"/targets/lck/","tldr":"LCK (Tyrosine-protein kinase Lck) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Renal cell carcinoma, Myeloproliferative neoplasms and 5 more.","roles":["drug-target","fusion-partner"],"tier":"approved-drug"},{"id":"ldb1","symbol":"LDB1","href":"/targets/ldb1/","tldr":"LDB1 (LIM domain-binding protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma and Paediatric low-grade glioma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"lef1","symbol":"LEF1","href":"/targets/lef1/","tldr":"LEF1 (Lymphoid enhancer-binding factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Hepatocellular carcinoma and 3 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"lepr","symbol":"LEPR","href":"/targets/lepr/","tldr":"LEPR (Leptin receptor) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Meningioma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"lgr5-gene","symbol":"LGR5","href":"/targets/lgr5-gene/","tldr":"LGR5 (Leucine-rich repeat-containing G protein-coupled receptor 5) is a protein on the cell surface. The public catalogues list it as a drug target, a biomarker and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Sarcomas.","roles":["drug-target","biomarker","antigen"],"tier":"clinical-evidence"},{"id":"lifr","symbol":"LIFR","href":"/targets/lifr/","tldr":"LIFR (Leukaemia inhibitory factor receptor) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma and Small-cell lung cancer.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"lig4","symbol":"LIG4","href":"/targets/lig4/","tldr":"LIG4 (DNA ligase 4) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"lmna","symbol":"LMNA","href":"/targets/lmna/","tldr":"LMNA (Prelamin-A/C) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lmo1","symbol":"LMO1","href":"/targets/lmo1/","tldr":"LMO1 (Rhombotin-1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"lmo2","symbol":"LMO2","href":"/targets/lmo2/","tldr":"LMO2 (Rhombotin-2) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"lmo7","symbol":"LMO7","href":"/targets/lmo7/","tldr":"LMO7 (LIM domain only protein 7) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lmx1b","symbol":"LMX1B","href":"/targets/lmx1b/","tldr":"LMX1B (LIM homeobox transcription factor 1-beta) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lpa","symbol":"LPA","href":"/targets/lpa/","tldr":"LPA (Apolipoprotein(a)) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"lpp","symbol":"LPP","href":"/targets/lpp/","tldr":"LPP (Lipoma-preferred partner) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Skin cancer, Breast cancer, Non-Hodgkin lymphoma and 4 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"lratd2","symbol":"LRATD2","href":"/targets/lratd2/","tldr":"LRATD2 (LRAT domain containing 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lrfn2","symbol":"LRFN2","href":"/targets/lrfn2/","tldr":"LRFN2 (Leucine-rich repeat and fibronectin type-III domain-containing protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lrig3","symbol":"LRIG3","href":"/targets/lrig3/","tldr":"LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Lung cancer and Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"lrp1b","symbol":"LRP1B","href":"/targets/lrp1b/","tldr":"LRP1B (Low-density lipoprotein receptor-related protein 1B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Prostate cancer, Pancreatic ductal adenocarcinoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"lrp5","symbol":"LRP5","href":"/targets/lrp5/","tldr":"LRP5 (Low-density lipoprotein receptor-related protein 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lrrfip1","symbol":"LRRFIP1","href":"/targets/lrrfip1/","tldr":"LRRFIP1 (Leucine-rich repeat flightless-interacting protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.","roles":[],"tier":"association-only"},{"id":"lsm14a","symbol":"LSM14A","href":"/targets/lsm14a/","tldr":"LSM14A (Protein LSM14 homolog A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"lsp1","symbol":"LSP1","href":"/targets/lsp1/","tldr":"LSP1 (Lymphocyte-specific protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"ltb","symbol":"LTB","href":"/targets/ltb/","tldr":"LTB (Lymphotoxin-beta) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"lyl1","symbol":"LYL1","href":"/targets/lyl1/","tldr":"LYL1 (LYL1 basic helix-loop-helix family member) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"lztr1","symbol":"LZTR1","href":"/targets/lztr1/","tldr":"LZTR1 (Leucine-zipper-like transcriptional regulator 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Prostate cancer, Endometrial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"macc1","symbol":"MACC1","href":"/targets/macc1/","tldr":"MACC1 (Metastasis-associated in colon cancer protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"maf","symbol":"MAF","href":"/targets/maf/","tldr":"MAF (Transcription factor Maf) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer and Multiple myeloma.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"mafb","symbol":"MAFB","href":"/targets/mafb/","tldr":"MAFB (Transcription factor MafB) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"mageh1","symbol":"MAGEH1","href":"/targets/mageh1/","tldr":"MAGEH1 (Melanoma-associated antigen H1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"malt1","symbol":"MALT1","href":"/targets/malt1/","tldr":"MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer and Diffuse large B-cell lymphoma.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"maml1","symbol":"MAML1","href":"/targets/maml1/","tldr":"MAML1 (Mastermind-like protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"maml2","symbol":"MAML2","href":"/targets/maml2/","tldr":"MAML2 (Mastermind-like protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Vulvar cancer, Breast cancer and 5 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"maml3","symbol":"MAML3","href":"/targets/maml3/","tldr":"MAML3 (Mastermind-like protein 3) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"mamld1","symbol":"MAMLD1","href":"/targets/mamld1/","tldr":"MAMLD1 (Mastermind-like domain-containing protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"map2k4","symbol":"MAP2K4","href":"/targets/map2k4/","tldr":"MAP2K4 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"map2k7","symbol":"MAP2K7","href":"/targets/map2k7/","tldr":"MAP2K7 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"map3k1","symbol":"MAP3K1","href":"/targets/map3k1/","tldr":"MAP3K1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"map3k13","symbol":"MAP3K13","href":"/targets/map3k13/","tldr":"MAP3K13 (Mitogen-activated protein kinase kinase kinase 13) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Breast cancer, Lung cancer and 1 more.","roles":[],"tier":"association-only"},{"id":"mapk1","symbol":"MAPK1","href":"/targets/mapk1/","tldr":"MAPK1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"mapk11","symbol":"MAPK11","href":"/targets/mapk11/","tldr":"MAPK11 (Mitogen-activated protein kinase 11) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"mapk3","symbol":"MAPK3","href":"/targets/mapk3/","tldr":"MAPK3 (Mitogen-activated protein kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"mapk8","symbol":"MAPK8","href":"/targets/mapk8/","tldr":"MAPK8 (Mitogen-activated protein kinase 8) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"mapk9","symbol":"MAPK9","href":"/targets/mapk9/","tldr":"MAPK9 (Mitogen-activated protein kinase 9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"mark2","symbol":"MARK2","href":"/targets/mark2/","tldr":"MARK2 (Serine/threonine-protein kinase MARK2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"mark3","symbol":"MARK3","href":"/targets/mark3/","tldr":"MARK3 (MAP/microtubule affinity-regulating kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"max","symbol":"MAX","href":"/targets/max/","tldr":"MAX (MYC associated transcriptional regulator X) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroendocrine tumours, Multiple myeloma, Endometrial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"mb21d2","symbol":"MB21D2","href":"/targets/mb21d2/","tldr":"MB21D2 (Nucleotidyltransferase MB21D2) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Sarcomas, Bladder & urothelial cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"mbd4","symbol":"MBD4","href":"/targets/mbd4/","tldr":"MBD4 (Methyl-CpG-binding domain protein 4) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Leukaemia, Myeloproliferative neoplasms and 3 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"mc1r","symbol":"MC1R","href":"/targets/mc1r/","tldr":"MC1R (Melanocyte-stimulating hormone receptor) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"mcl1","symbol":"MCL1","href":"/targets/mcl1/","tldr":"MCL1 (Induced myeloid leukaemia cell differentiation protein Mcl-1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"mcm7","symbol":"MCM7","href":"/targets/mcm7/","tldr":"MCM7 (DNA replication licensing factor MCM7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"mcm8","symbol":"MCM8","href":"/targets/mcm8/","tldr":"MCM8 (DNA helicase MCM8) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"mdga2","symbol":"MDGA2","href":"/targets/mdga2/","tldr":"MDGA2 (MAM domain-containing glycosylphosphatidylinositol anchor protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"mdm4","symbol":"MDM4","href":"/targets/mdm4/","tldr":"MDM4 (MDM4 regulator of p53) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 1 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mecom","symbol":"MECOM","href":"/targets/mecom/","tldr":"MECOM (Histone-lysine N-methyltransferase MECOM) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Endometrial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"med12","symbol":"MED12","href":"/targets/med12/","tldr":"MED12 (Mediator of RNA polymerase II transcription subunit 12) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Cervical cancer, Endometrial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"med23","symbol":"MED23","href":"/targets/med23/","tldr":"MED23 (Mediator of RNA polymerase II transcription subunit 23) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"mef2b","symbol":"MEF2B","href":"/targets/mef2b/","tldr":"MEF2B (Myocyte-specific enhancer factor 2B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Mantle cell lymphoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"mef2c","symbol":"MEF2C","href":"/targets/mef2c/","tldr":"MEF2C (Myocyte-specific enhancer factor 2C) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mef2d","symbol":"MEF2D","href":"/targets/mef2d/","tldr":"MEF2D (Myocyte-specific enhancer factor 2D) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mertk","symbol":"MERTK","href":"/targets/mertk/","tldr":"MERTK (Tyrosine-protein kinase Mer) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mga","symbol":"MGA","href":"/targets/mga/","tldr":"MGA (MAX gene-associated protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mesothelioma, Prostate cancer, Diffuse large B-cell lymphoma and 3 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"mgmt-protein","symbol":"MGMT","href":"/targets/mgmt-protein/","tldr":"MGMT is a DNA repair enzyme that removes the damage temozolomide causes; when the gene is switched off by methylation the tumour cannot repair itself and the drug works better.","roles":["drug-target","biomarker","dna-repair"],"tier":"approved-drug"},{"id":"mib2","symbol":"MIB2","href":"/targets/mib2/","tldr":"MIB2 (E3 ubiquitin-protein ligase MIB2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"minpp1","symbol":"MINPP1","href":"/targets/minpp1/","tldr":"MINPP1 (Multiple inositol polyphosphate phosphatase 1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"mir21","symbol":"MIR21","href":"/targets/mir21/","tldr":"MIR21 (microRNA 21) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mir218-1","symbol":"MIR218-1","href":"/targets/mir218-1/","tldr":"MIR218-1 (microRNA 218-1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Pancreatic ductal adenocarcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mitf","symbol":"MITF","href":"/targets/mitf/","tldr":"MITF (Microphthalmia-associated transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Ovarian cancer and 2 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mki67","symbol":"MKI67","href":"/targets/mki67/","tldr":"Ki-67 is a protein present only in cells that are dividing, so the share of tumour cells that stain for it is a direct read of how fast the cancer is growing.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mlf1","symbol":"MLF1","href":"/targets/mlf1/","tldr":"MLF1 (Myeloid leukaemia factor 1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Lung cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"mlh1","symbol":"MLH1","href":"/targets/mlh1/","tldr":"MLH1 (DNA mismatch repair protein Mlh1) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Ovarian cancer, Endometrial cancer and 4 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"mlh3","symbol":"MLH3","href":"/targets/mlh3/","tldr":"MLH3 (DNA mismatch repair protein Mlh3) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer and Endometrial cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"mllt1","symbol":"MLLT1","href":"/targets/mllt1/","tldr":"MLLT1 (MLLT1 super elongation complex subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Wilms tumour and 1 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"mllt10","symbol":"MLLT10","href":"/targets/mllt10/","tldr":"MLLT10 (MLLT10 histone lysine methyltransferase DOT1L cofactor) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer, Ovarian cancer, Leukaemia and 2 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"mllt3","symbol":"MLLT3","href":"/targets/mllt3/","tldr":"MLLT3 (MLLT3 super elongation complex subunit) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma and Melanoma.","roles":["fusion-partner"],"tier":"cohort-driver"},{"id":"mllt6","symbol":"MLLT6","href":"/targets/mllt6/","tldr":"MLLT6 (MLLT6, PHD finger containing) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pheochromocytoma and paraganglioma and Bladder & urothelial cancer.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"mlph","symbol":"MLPH","href":"/targets/mlph/","tldr":"MLPH (Melanophilin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"mmp1","symbol":"MMP1","href":"/targets/mmp1/","tldr":"MMP1 (Interstitial collagenase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to HR-positive / HER2-negative breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mmp2","symbol":"MMP2","href":"/targets/mmp2/","tldr":"MMP2 (72 kDa type IV collagenase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mmp7","symbol":"MMP7","href":"/targets/mmp7/","tldr":"MMP7 (Matrilysin) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"mmp9","symbol":"MMP9","href":"/targets/mmp9/","tldr":"MMP9 (Matrix metalloproteinase-9) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mn1","symbol":"MN1","href":"/targets/mn1/","tldr":"MN1 (Transcriptional activator MN1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Colorectal cancer, Skin cancer and 1 more.","roles":["biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"mov10","symbol":"MOV10","href":"/targets/mov10/","tldr":"MOV10 (RNA helicase MOV-10) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"mpeg1","symbol":"MPEG1","href":"/targets/mpeg1/","tldr":"MPEG1 (Macrophage-expressed gene 1 protein) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mprip","symbol":"MPRIP","href":"/targets/mprip/","tldr":"MPRIP (Myosin phosphatase Rho-interacting protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer and Renal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"mre11","symbol":"MRE11","href":"/targets/mre11/","tldr":"MRE11 (Double-strand break repair protein MRE11) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Endometrial cancer, Breast cancer and 1 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"mrtfa","symbol":"MRTFA","href":"/targets/mrtfa/","tldr":"MRTFA (Myocardin-related transcription factor A) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer, Skin cancer, Lung cancer and 1 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"msh2","symbol":"MSH2","href":"/targets/msh2/","tldr":"MSH2 (DNA mismatch repair protein Msh2) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"msh3","symbol":"MSH3","href":"/targets/msh3/","tldr":"MSH3 (DNA mismatch repair protein Msh3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer and Colorectal cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"msh6","symbol":"MSH6","href":"/targets/msh6/","tldr":"MSH6 (DNA mismatch repair protein Msh6) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"msi2","symbol":"MSI2","href":"/targets/msi2/","tldr":"MSI2 (RNA-binding protein Musashi homolog 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer and Neuroblastoma.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"msmb","symbol":"MSMB","href":"/targets/msmb/","tldr":"MSMB (Beta-microseminoprotein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"msn","symbol":"MSN","href":"/targets/msn/","tldr":"MSN (Moesin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Renal cell carcinoma, Basal cell carcinoma and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"msr1","symbol":"MSR1","href":"/targets/msr1/","tldr":"MSR1 (Macrophage scavenger receptor types I and II) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"mt-co1","symbol":"MT-CO1","href":"/targets/mt-co1/","tldr":"MT-CO1 (Cytochrome c oxidase subunit 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms and Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"mt-cyb","symbol":"MT-CYB","href":"/targets/mt-cyb/","tldr":"MT-CYB (Cytochrome b) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"mt-nd1","symbol":"MT-ND1","href":"/targets/mt-nd1/","tldr":"MT-ND1 (NADH-ubiquinone oxidoreductase chain 1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"mt-nd6","symbol":"MT-ND6","href":"/targets/mt-nd6/","tldr":"MT-ND6 (NADH-ubiquinone oxidoreductase chain 6) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"mtcp1","symbol":"MTCP1","href":"/targets/mtcp1/","tldr":"MTCP1 (Protein p13 MTCP-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"mthfr","symbol":"MTHFR","href":"/targets/mthfr/","tldr":"MTHFR (Methylenetetrahydrofolate reductase (NADPH)) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer and Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"muc6","symbol":"MUC6","href":"/targets/muc6/","tldr":"MUC6 (Mucin-6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Acute myeloid leukaemia and Non-small-cell lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"mus81","symbol":"MUS81","href":"/targets/mus81/","tldr":"MUS81 (Structure-specific endonuclease subunit MUS81) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"mutyh","symbol":"MUTYH","href":"/targets/mutyh/","tldr":"MUTYH (Adenine DNA glycosylase) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Breast cancer and 5 more.","roles":["dna-repair"],"tier":"association-only"},{"id":"mx2","symbol":"MX2","href":"/targets/mx2/","tldr":"MX2 (Interferon-induced GTP-binding protein Mx2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Melanoma.","roles":[],"tier":"association-only"},{"id":"mxi1","symbol":"MXI1","href":"/targets/mxi1/","tldr":"MXI1 (Max-interacting protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"myb","symbol":"MYB","href":"/targets/myb/","tldr":"MYB (Transcriptional activator Myb) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Colorectal cancer and 5 more.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mybl1","symbol":"MYBL1","href":"/targets/mybl1/","tldr":"MYBL1 (Myb-related protein A) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"myc-gene","symbol":"MYC","href":"/targets/myc-gene/","tldr":"MYC (Myc proto-oncogene protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Skin cancer, Multiple myeloma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"mycl","symbol":"MYCL","href":"/targets/mycl/","tldr":"MYCL (MYCL proto-oncogene, bHLH transcription factor) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer and Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mycn","symbol":"MYCN","href":"/targets/mycn/","tldr":"MYCN is a growth-driving gene that some neuroblastomas copy many times over; that amplification is one of the strongest signs the tumour is aggressive and sets the intensity of treatment.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"approved-drug"},{"id":"myd88","symbol":"MYD88","href":"/targets/myd88/","tldr":"MYD88 (Myeloid differentiation primary response protein MyD88) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"myeov","symbol":"MYEOV","href":"/targets/myeov/","tldr":"MYEOV (Myeloma-overexpressed gene protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"myh11","symbol":"MYH11","href":"/targets/myh11/","tldr":"MYH11 (Myosin-11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer, Head and neck squamous cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"myh9","symbol":"MYH9","href":"/targets/myh9/","tldr":"MYH9 (Myosin-9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Breast cancer, Colorectal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"myo18a","symbol":"MYO18A","href":"/targets/myo18a/","tldr":"MYO18A (Putative TGFB1-induced anti-apoptotic factor 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.","roles":[],"tier":"association-only"},{"id":"myo5a","symbol":"MYO5A","href":"/targets/myo5a/","tldr":"MYO5A (Unconventional myosin-Va) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Hepatocellular carcinoma, Lung cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"myod1","symbol":"MYOD1","href":"/targets/myod1/","tldr":"MYOD1 (Myoblast determination protein 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Colorectal cancer and Rhabdomyosarcoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mysm1","symbol":"MYSM1","href":"/targets/mysm1/","tldr":"MYSM1 (Deubiquitinase MYSM1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms.","roles":[],"tier":"association-only"},{"id":"n4bp2","symbol":"N4BP2","href":"/targets/n4bp2/","tldr":"N4BP2 (NEDD4-binding protein 2) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Bladder & urothelial cancer and Biliary tract cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"nab2","symbol":"NAB2","href":"/targets/nab2/","tldr":"NAB2 (NGFI-A-binding protein 2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"naca","symbol":"NACA","href":"/targets/naca/","tldr":"NACA (Nascent polypeptide-associated complex subunit alpha, muscle-specific form) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Melanoma and Basal cell carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"naf1","symbol":"NAF1","href":"/targets/naf1/","tldr":"NAF1 (H/ACA ribonucleoprotein complex non-core subunit NAF1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"naprt","symbol":"NAPRT","href":"/targets/naprt/","tldr":"NAPRT (Nicotinate phosphoribosyltransferase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"nbea","symbol":"NBEA","href":"/targets/nbea/","tldr":"NBEA (Neurobeachin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Breast cancer, Colorectal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"nbn","symbol":"NBN","href":"/targets/nbn/","tldr":"NBN (Nibrin) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"ncaph","symbol":"NCAPH","href":"/targets/ncaph/","tldr":"NCAPH (Condensin complex subunit 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"nckipsd","symbol":"NCKIPSD","href":"/targets/nckipsd/","tldr":"NCKIPSD (NCK-interacting protein with SH3 domain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"ncoa1","symbol":"NCOA1","href":"/targets/ncoa1/","tldr":"NCOA1 (Nuclear receptor coactivator 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["fusion-partner"],"tier":"cohort-driver"},{"id":"ncoa2","symbol":"NCOA2","href":"/targets/ncoa2/","tldr":"NCOA2 (Nuclear receptor coactivator 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Lung cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ncoa3","symbol":"NCOA3","href":"/targets/ncoa3/","tldr":"NCOA3 (Nuclear receptor coactivator 3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ncoa4","symbol":"NCOA4","href":"/targets/ncoa4/","tldr":"NCOA4 (Nuclear receptor coactivator 4) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"ncor1","symbol":"NCOR1","href":"/targets/ncor1/","tldr":"NCOR1 (Nuclear receptor corepressor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Prostate cancer, Lung cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ncor2","symbol":"NCOR2","href":"/targets/ncor2/","tldr":"NCOR2 (Nuclear receptor corepressor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Hepatocellular carcinoma, Prostate cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ncstn","symbol":"NCSTN","href":"/targets/ncstn/","tldr":"NCSTN (Nicastrin) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ndrg1","symbol":"NDRG1","href":"/targets/ndrg1/","tldr":"NDRG1 (N-myc downstream regulated 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer, Lung cancer, Colorectal cancer and 1 more.","roles":[],"tier":"association-only"},{"id":"ndufa13","symbol":"NDUFA13","href":"/targets/ndufa13/","tldr":"NDUFA13 (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"nedd9","symbol":"NEDD9","href":"/targets/nedd9/","tldr":"NEDD9 (Enhancer of filamentation 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"neil1","symbol":"NEIL1","href":"/targets/neil1/","tldr":"NEIL1 (Endonuclease 8-like 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"nek10","symbol":"NEK10","href":"/targets/nek10/","tldr":"NEK10 (Serine/threonine-protein kinase Nek10) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"nf2","symbol":"NF2","href":"/targets/nf2/","tldr":"NF2 (Merlin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mesothelioma, Renal cell carcinoma, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"nfatc2","symbol":"NFATC2","href":"/targets/nfatc2/","tldr":"NFATC2 (Nuclear factor of activated T-cells, cytoplasmic 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Breast cancer, Skin cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"nfe2l2","symbol":"NFE2L2","href":"/targets/nfe2l2/","tldr":"NFE2L2 (Nuclear factor erythroid 2-related factor 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"nfib","symbol":"NFIB","href":"/targets/nfib/","tldr":"NFIB (Nuclear factor 1 B-type) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer, Oral cavity cancer and Adenoid cystic carcinoma.","roles":[],"tier":"association-only"},{"id":"nfkb2","symbol":"NFKB2","href":"/targets/nfkb2/","tldr":"NFKB2 (Nuclear factor NF-kappa-B p100 subunit) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Colorectal cancer, Skin cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"nfkbia","symbol":"NFKBIA","href":"/targets/nfkbia/","tldr":"NFKBIA (NF-kappa-B inhibitor alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma and Diffuse large B-cell lymphoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"nfkbie","symbol":"NFKBIE","href":"/targets/nfkbie/","tldr":"NFKBIE (NF-kappa-B inhibitor epsilon) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"nfkbiz","symbol":"NFKBIZ","href":"/targets/nfkbiz/","tldr":"NFKBIZ (NF-kappa-B inhibitor zeta) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"nin","symbol":"NIN","href":"/targets/nin/","tldr":"NIN (Ninein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Mesothelioma, Gastric & gastro-oesophageal junction cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"nipbl","symbol":"NIPBL","href":"/targets/nipbl/","tldr":"NIPBL (Nipped-B-like protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"nktr","symbol":"NKTR","href":"/targets/nktr/","tldr":"NKTR (NK-tumour recognition protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"nkx2-1","symbol":"NKX2-1","href":"/targets/nkx2-1/","tldr":"NKX2-1 (Homeobox protein Nkx-2.1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer, Lung cancer, Skin cancer and 1 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"nkx3-1","symbol":"NKX3-1","href":"/targets/nkx3-1/","tldr":"NKX3-1 (Homeobox protein Nkx-3.1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"nol9","symbol":"NOL9","href":"/targets/nol9/","tldr":"NOL9 (Polynucleotide 5'-hydroxyl-kinase NOL9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"notch1","symbol":"NOTCH1","href":"/targets/notch1/","tldr":"NOTCH1 (Neurogenic locus notch homolog protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Head and neck squamous cell carcinoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"notch2","symbol":"NOTCH2","href":"/targets/notch2/","tldr":"NOTCH2 (Neurogenic locus notch homolog protein 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Breast cancer, Lung cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"notch3","symbol":"NOTCH3","href":"/targets/notch3/","tldr":"NOTCH3 (Neurogenic locus notch homolog protein 3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"nox4","symbol":"NOX4","href":"/targets/nox4/","tldr":"NOX4 (NADPH oxidase 4) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"nprl2","symbol":"NPRL2","href":"/targets/nprl2/","tldr":"NPRL2 (GATOR1 complex protein NPRL2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"nptxr","symbol":"NPTXR","href":"/targets/nptxr/","tldr":"NPTXR (Neuronal pentraxin receptor) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"nqo1","symbol":"NQO1","href":"/targets/nqo1/","tldr":"NQO1 (NAD(P)H dehydrogenase [quinone] 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"nr2f2","symbol":"NR2F2","href":"/targets/nr2f2/","tldr":"NR2F2 (COUP transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"nr4a2","symbol":"NR4A2","href":"/targets/nr4a2/","tldr":"NR4A2 (Nuclear receptor subfamily 4 group A member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"nr4a3","symbol":"NR4A3","href":"/targets/nr4a3/","tldr":"NR4A3 (Nuclear receptor subfamily 4 group A member 3) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Colorectal cancer, Lung cancer and 1 more.","roles":["biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"nr5a2","symbol":"NR5A2","href":"/targets/nr5a2/","tldr":"NR5A2 (Nuclear receptor subfamily 5 group A member 2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"nrg1","symbol":"NRG1","href":"/targets/nrg1/","tldr":"NRG1 (Pro-neuregulin-1, membrane-bound isoform) is a protein on the cell surface. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker, a fusion partner and an antigen, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner","antigen"],"tier":"approved-drug"},{"id":"nrg2","symbol":"NRG2","href":"/targets/nrg2/","tldr":"NRG2 (Pro-neuregulin-2, membrane-bound isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"nrg3","symbol":"NRG3","href":"/targets/nrg3/","tldr":"NRG3 (Pro-neuregulin-3, membrane-bound isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"nrg4","symbol":"NRG4","href":"/targets/nrg4/","tldr":"NRG4 (Pro-neuregulin-4, membrane-bound isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"nrip1","symbol":"NRIP1","href":"/targets/nrip1/","tldr":"NRIP1 (Nuclear receptor-interacting protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"nrk","symbol":"NRK","href":"/targets/nrk/","tldr":"NRK (Nik-related protein kinase) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"nsd1","symbol":"NSD1","href":"/targets/nsd1/","tldr":"NSD1 (Histone-lysine N-methyltransferase, H3 lysine-36 specific) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Myeloproliferative neoplasms, Head and neck squamous cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"nsd2","symbol":"NSD2","href":"/targets/nsd2/","tldr":"NSD2 (Histone-lysine N-methyltransferase NSD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Bladder & urothelial cancer, Lung cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"nsd3","symbol":"NSD3","href":"/targets/nsd3/","tldr":"NSD3 (Histone-lysine N-methyltransferase NSD3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 1 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"nt5c2","symbol":"NT5C2","href":"/targets/nt5c2/","tldr":"NT5C2 (Cytosolic purine 5'-nucleotidase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 1 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"nt5c3a","symbol":"NT5C3A","href":"/targets/nt5c3a/","tldr":"NT5C3A (Cytosolic 5'-nucleotidase 3A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"nthl1","symbol":"NTHL1","href":"/targets/nthl1/","tldr":"NTHL1 (Endonuclease III-like protein 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"nudt15","symbol":"NUDT15","href":"/targets/nudt15/","tldr":"NUDT15 (Nucleotide triphosphate diphosphatase NUDT15) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"numa1","symbol":"NUMA1","href":"/targets/numa1/","tldr":"NUMA1 (Nuclear mitotic apparatus protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Oesophageal cancer and Oesophageal and junctional adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"nup214","symbol":"NUP214","href":"/targets/nup214/","tldr":"NUP214 (Nuclear pore complex protein Nup214) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Renal cell carcinoma and 4 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"nup98","symbol":"NUP98","href":"/targets/nup98/","tldr":"NUP98 (Nuclear pore complex protein Nup98-Nup96) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Lung cancer, Leukaemia and 3 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"nutm1","symbol":"NUTM1","href":"/targets/nutm1/","tldr":"NUTM1 (NUT family member 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Oesophageal cancer, Ovarian cancer and 4 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"nutm2b","symbol":"NUTM2B","href":"/targets/nutm2b/","tldr":"NUTM2B (NUT family member 2B) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas.","roles":[],"tier":"association-only"},{"id":"nutm2d","symbol":"NUTM2D","href":"/targets/nutm2d/","tldr":"NUTM2D (NUT family member 2D) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"nvl","symbol":"NVL","href":"/targets/nvl/","tldr":"NVL (Nuclear valosin-containing protein-like) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"nxf1","symbol":"NXF1","href":"/targets/nxf1/","tldr":"NXF1 (Nuclear RNA export factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Chronic lymphocytic leukaemia.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"oca2","symbol":"OCA2","href":"/targets/oca2/","tldr":"OCA2 (P protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"ogg1","symbol":"OGG1","href":"/targets/ogg1/","tldr":"OGG1 (N-glycosylase/DNA lyase) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"olig2","symbol":"OLIG2","href":"/targets/olig2/","tldr":"OLIG2 (Oligodendrocyte transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"orc1","symbol":"ORC1","href":"/targets/orc1/","tldr":"ORC1 (Origin recognition complex subunit 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"osbpl10","symbol":"OSBPL10","href":"/targets/osbpl10/","tldr":"OSBPL10 (Oxysterol-binding protein-related protein 10) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"otx1","symbol":"OTX1","href":"/targets/otx1/","tldr":"OTX1 (Homeobox protein OTX1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"ovol2","symbol":"OVOL2","href":"/targets/ovol2/","tldr":"OVOL2 (Transcription factor Ovo-like 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"p2ry8","symbol":"P2RY8","href":"/targets/p2ry8/","tldr":"P2RY8 (S-geranylgeranyl-glutathione receptor P2RY8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Diffuse large B-cell lymphoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"pabpc1","symbol":"PABPC1","href":"/targets/pabpc1/","tldr":"PABPC1 (Polyadenylate-binding protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Multiple myeloma, Bladder & urothelial cancer and 5 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"palb2","symbol":"PALB2","href":"/targets/palb2/","tldr":"PALB2 (Partner and localizer of BRCA2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer, Colorectal cancer and 5 more.","roles":["drug-target","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"pald1","symbol":"PALD1","href":"/targets/pald1/","tldr":"PALD1 (Paladin) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma.","roles":[],"tier":"association-only"},{"id":"pappa2","symbol":"PAPPA2","href":"/targets/pappa2/","tldr":"PAPPA2 (Pappalysin-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"papss1","symbol":"PAPSS1","href":"/targets/papss1/","tldr":"PAPSS1 (Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"parp2","symbol":"PARP2","href":"/targets/parp2/","tldr":"PARP2 (Poly [ADP-ribose] polymerase 2) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Breast cancer and Prostate cancer.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"parp3","symbol":"PARP3","href":"/targets/parp3/","tldr":"PARP3 (Protein mono-ADP-ribosyltransferase PARP3) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer and Prostate cancer.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"parp4","symbol":"PARP4","href":"/targets/parp4/","tldr":"PARP4 (Protein mono-ADP-ribosyltransferase PARP4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Multiple myeloma and Non-small-cell lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"patz1","symbol":"PATZ1","href":"/targets/patz1/","tldr":"PATZ1 (POZ-, AT hook-, and zinc finger-containing protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Skin cancer and Colorectal cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"pax3","symbol":"PAX3","href":"/targets/pax3/","tldr":"PAX3 (Paired box protein Pax-3) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Rhabdomyosarcoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"pax5","symbol":"PAX5","href":"/targets/pax5/","tldr":"PAX5 (Paired box protein Pax-5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"pax6","symbol":"PAX6","href":"/targets/pax6/","tldr":"PAX6 (Paired box protein Pax-6) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"pax7","symbol":"PAX7","href":"/targets/pax7/","tldr":"PAX7 (Paired box protein Pax-7) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Rhabdomyosarcoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"pax8","symbol":"PAX8","href":"/targets/pax8/","tldr":"PAX8 (Paired box protein Pax-8) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"pax9","symbol":"PAX9","href":"/targets/pax9/","tldr":"PAX9 (Paired box protein Pax-9) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"pbk","symbol":"PBK","href":"/targets/pbk/","tldr":"PBK (Lymphokine-activated killer T-cell-originated protein kinase) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"pbld","symbol":"PBLD","href":"/targets/pbld/","tldr":"PBLD (Phenazine biosynthesis-like domain-containing protein) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"pbrm1","symbol":"PBRM1","href":"/targets/pbrm1/","tldr":"PBRM1 (polybromo 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Skin cancer, Biliary tract cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"pbx1","symbol":"PBX1","href":"/targets/pbx1/","tldr":"PBX1 (Pre-B-cell leukaemia transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma, Leukaemia, Lung cancer and 3 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"pcbp1","symbol":"PCBP1","href":"/targets/pcbp1/","tldr":"PCBP1 (Poly(rC)-binding protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 2 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"pcm1","symbol":"PCM1","href":"/targets/pcm1/","tldr":"PCM1 (Pericentriolar material 1 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"pcmtd1","symbol":"PCMTD1","href":"/targets/pcmtd1/","tldr":"PCMTD1 (Protein-L-isoaspartate O-methyltransferase domain-containing protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"pcna","symbol":"PCNA","href":"/targets/pcna/","tldr":"PCNA (DNA sliding clamp PCNA) is a gene. The public catalogues list it as a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroblastoma.","roles":["biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"pcnx2","symbol":"PCNX2","href":"/targets/pcnx2/","tldr":"PCNX2 (Pecanex-like protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"pdcd1lg2","symbol":"PDCD1LG2","href":"/targets/pdcd1lg2/","tldr":"PDCD1LG2 (Programmed cell death 1 ligand 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and an antigen, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma, Thyroid cancer, Breast cancer and 2 more.","roles":["drug-target","oncogene-driver","biomarker","antigen"],"tier":"approved-drug"},{"id":"pdcd4","symbol":"PDCD4","href":"/targets/pdcd4/","tldr":"PDCD4 (Programmed cell death protein 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"pde3a","symbol":"PDE3A","href":"/targets/pde3a/","tldr":"PDE3A (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.","roles":["drug-target"],"tier":"approved-drug"},{"id":"pde3b","symbol":"PDE3B","href":"/targets/pde3b/","tldr":"PDE3B (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.","roles":["drug-target"],"tier":"approved-drug"},{"id":"pdgfb","symbol":"PDGFB","href":"/targets/pdgfb/","tldr":"PDGFB (Platelet-derived growth factor subunit B) is a gene. The public catalogues list it as a drug target, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas and Dermatofibrosarcoma protuberans.","roles":["drug-target","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"pdgfrl","symbol":"PDGFRL","href":"/targets/pdgfrl/","tldr":"PDGFRL (Platelet-derived growth factor receptor-like protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"pdlim5","symbol":"PDLIM5","href":"/targets/pdlim5/","tldr":"PDLIM5 (PDZ and LIM domain protein 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"pdpk1","symbol":"PDPK1","href":"/targets/pdpk1/","tldr":"PDPK1 (3-phosphoinositide-dependent protein kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"pdzd2","symbol":"PDZD2","href":"/targets/pdzd2/","tldr":"PDZD2 (PDZ domain-containing protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"peg3","symbol":"PEG3","href":"/targets/peg3/","tldr":"PEG3 (Paternally-expressed gene 3 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"per1","symbol":"PER1","href":"/targets/per1/","tldr":"PER1 (Period circadian protein homolog 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Lung cancer, Gastric & gastro-oesophageal junction cancer and 2 more.","roles":[],"tier":"association-only"},{"id":"per3","symbol":"PER3","href":"/targets/per3/","tldr":"PER3 (Period circadian protein homolog 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"phf6","symbol":"PHF6","href":"/targets/phf6/","tldr":"PHF6 (PHD finger protein 6) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Myeloproliferative neoplasms and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"phox2b","symbol":"PHOX2B","href":"/targets/phox2b/","tldr":"PHOX2B (Paired mesoderm homeobox protein 2B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Colorectal cancer, Lung cancer and 2 more.","roles":[],"tier":"association-only"},{"id":"pi4ka","symbol":"PI4KA","href":"/targets/pi4ka/","tldr":"PI4KA (Phosphatidylinositol 4-kinase alpha) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"picalm","symbol":"PICALM","href":"/targets/picalm/","tldr":"PICALM (Phosphatidylinositol-binding clathrin assembly protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer and Papillary thyroid cancer.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"pik3cb","symbol":"PIK3CB","href":"/targets/pik3cb/","tldr":"PIK3CB is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"pik3cg","symbol":"PIK3CG","href":"/targets/pik3cg/","tldr":"PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Acute lymphoblastic leukaemia and 2 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"pik3r1","symbol":"PIK3R1","href":"/targets/pik3r1/","tldr":"PIK3R1 (Phosphatidylinositol 3-kinase regulatory subunit alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Colorectal cancer, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"pik3r2","symbol":"PIK3R2","href":"/targets/pik3r2/","tldr":"PIK3R2 (Phosphatidylinositol 3-kinase regulatory subunit beta) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"pik3r3","symbol":"PIK3R3","href":"/targets/pik3r3/","tldr":"PIK3R3 (Phosphatidylinositol 3-kinase regulatory subunit gamma) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"pik3r5","symbol":"PIK3R5","href":"/targets/pik3r5/","tldr":"PIK3R5 (Phosphoinositide 3-kinase regulatory subunit 5) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"pim1","symbol":"PIM1","href":"/targets/pim1/","tldr":"PIM1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"pim2","symbol":"PIM2","href":"/targets/pim2/","tldr":"PIM2 (Serine/threonine-protein kinase pim-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"plag1","symbol":"PLAG1","href":"/targets/plag1/","tldr":"PLAG1 (Zinc finger protein PLAG1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Melanoma and Oral cavity cancer.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"plcg1","symbol":"PLCG1","href":"/targets/plcg1/","tldr":"PLCG1 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Renal cell carcinoma, Non-Hodgkin lymphoma and 5 more.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"plcg2","symbol":"PLCG2","href":"/targets/plcg2/","tldr":"PLCG2 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chronic lymphocytic leukaemia.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"plk1","symbol":"PLK1","href":"/targets/plk1/","tldr":"PLK1 (Serine/threonine-protein kinase PLK1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"plxnb2","symbol":"PLXNB2","href":"/targets/plxnb2/","tldr":"PLXNB2 (Plexin-B2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"plxnc1","symbol":"PLXNC1","href":"/targets/plxnc1/","tldr":"PLXNC1 (Plexin-C1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"pml","symbol":"PML","href":"/targets/pml/","tldr":"PML (PML nuclear body scaffold) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Thyroid cancer, Lung cancer and 3 more.","roles":["drug-target","tumour-suppressor","biomarker","fusion-partner"],"tier":"approved-drug"},{"id":"pms1","symbol":"PMS1","href":"/targets/pms1/","tldr":"PMS1 (PMS1 protein homolog 1) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"pms2","symbol":"PMS2","href":"/targets/pms2/","tldr":"PMS2 (Mismatch repair endonuclease PMS2) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"pnpla3","symbol":"PNPLA3","href":"/targets/pnpla3/","tldr":"PNPLA3 (1-acylglycerol-3-phosphate O-acyltransferase PNPLA3) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Hepatocellular carcinoma.","roles":[],"tier":"association-only"},{"id":"poglut3","symbol":"POGLUT3","href":"/targets/poglut3/","tldr":"POGLUT3 (Protein O-glucosyltransferase 3) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"pola2","symbol":"POLA2","href":"/targets/pola2/","tldr":"POLA2 (DNA polymerase alpha subunit B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"pold1","symbol":"POLD1","href":"/targets/pold1/","tldr":"POLD1 (DNA polymerase delta catalytic subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Lung cancer, Breast cancer and 5 more.","roles":["drug-target","tumour-suppressor","biomarker","dna-repair"],"tier":"approved-drug"},{"id":"pold2","symbol":"POLD2","href":"/targets/pold2/","tldr":"POLD2 (DNA polymerase delta subunit 2) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"pold3","symbol":"POLD3","href":"/targets/pold3/","tldr":"POLD3 (DNA polymerase delta subunit 3) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"pold4","symbol":"POLD4","href":"/targets/pold4/","tldr":"POLD4 (DNA polymerase delta subunit 4) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"pole","symbol":"POLE","href":"/targets/pole/","tldr":"POLE (DNA polymerase epsilon catalytic subunit A) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Ovarian cancer, Lung cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker","dna-repair"],"tier":"approved-drug"},{"id":"pole2","symbol":"POLE2","href":"/targets/pole2/","tldr":"POLE2 (DNA polymerase epsilon subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Lung cancer and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"pole3","symbol":"POLE3","href":"/targets/pole3/","tldr":"POLE3 (DNA polymerase epsilon subunit 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"pole4","symbol":"POLE4","href":"/targets/pole4/","tldr":"POLE4 (DNA polymerase epsilon subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"polk","symbol":"POLK","href":"/targets/polk/","tldr":"POLK (DNA polymerase kappa) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"polq","symbol":"POLQ","href":"/targets/polq/","tldr":"POLQ (DNA polymerase theta) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Endometrial cancer, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","dna-repair"],"tier":"cohort-driver"},{"id":"pot1","symbol":"POT1","href":"/targets/pot1/","tldr":"POT1 (Protection of telomeres protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"pou2af1","symbol":"POU2AF1","href":"/targets/pou2af1/","tldr":"POU2AF1 (POU domain class 2-associating factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.","roles":["biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"pou2f2","symbol":"POU2F2","href":"/targets/pou2f2/","tldr":"POU2F2 (POU domain, class 2, transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"pou5f1","symbol":"POU5F1","href":"/targets/pou5f1/","tldr":"POU5F1 (POU domain, class 5, transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"pou5f1b","symbol":"POU5F1B","href":"/targets/pou5f1b/","tldr":"POU5F1B (POU domain, class 5, transcription factor 1B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer and Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"pparg","symbol":"PPARG","href":"/targets/pparg/","tldr":"PPARG (Peroxisome proliferator-activated receptor gamma) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Thyroid cancer and Endometrial cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"ppat","symbol":"PPAT","href":"/targets/ppat/","tldr":"PPAT (Amidophosphoribosyltransferase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ppfibp1","symbol":"PPFIBP1","href":"/targets/ppfibp1/","tldr":"PPFIBP1 (Liprin-beta-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppm1b","symbol":"PPM1B","href":"/targets/ppm1b/","tldr":"PPM1B (Protein phosphatase 1B) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppm1d","symbol":"PPM1D","href":"/targets/ppm1d/","tldr":"PPM1D (Protein phosphatase 1D) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Ovarian cancer, Myeloproliferative neoplasms and 5 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"ppp1r14a","symbol":"PPP1R14A","href":"/targets/ppp1r14a/","tldr":"PPP1R14A (Protein phosphatase 1 regulatory subunit 14A) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"ppp1r15a","symbol":"PPP1R15A","href":"/targets/ppp1r15a/","tldr":"PPP1R15A (Protein phosphatase 1 regulatory subunit 15A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ppp2ca","symbol":"PPP2CA","href":"/targets/ppp2ca/","tldr":"PPP2CA (Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"ppp2cb","symbol":"PPP2CB","href":"/targets/ppp2cb/","tldr":"PPP2CB (Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"ppp2r1a","symbol":"PPP2R1A","href":"/targets/ppp2r1a/","tldr":"PPP2R1A is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ppp2r1b","symbol":"PPP2R1B","href":"/targets/ppp2r1b/","tldr":"PPP2R1B (Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppp2r2a","symbol":"PPP2R2A","href":"/targets/ppp2r2a/","tldr":"PPP2R2A (Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ppp2r5a","symbol":"PPP2R5A","href":"/targets/ppp2r5a/","tldr":"PPP2R5A (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppp2r5b","symbol":"PPP2R5B","href":"/targets/ppp2r5b/","tldr":"PPP2R5B (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppp2r5c","symbol":"PPP2R5C","href":"/targets/ppp2r5c/","tldr":"PPP2R5C (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppp2r5d","symbol":"PPP2R5D","href":"/targets/ppp2r5d/","tldr":"PPP2R5D (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppp2r5e","symbol":"PPP2R5E","href":"/targets/ppp2r5e/","tldr":"PPP2R5E (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppp3ca","symbol":"PPP3CA","href":"/targets/ppp3ca/","tldr":"PPP3CA (Protein phosphatase 3 catalytic subunit alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"ppp6c","symbol":"PPP6C","href":"/targets/ppp6c/","tldr":"PPP6C (Serine/threonine-protein phosphatase 6 catalytic subunit) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Melanoma and Basal cell carcinoma.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"prc1","symbol":"PRC1","href":"/targets/prc1/","tldr":"PRC1 (Protein regulator of cytokinesis 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"prcc","symbol":"PRCC","href":"/targets/prcc/","tldr":"PRCC (Proline-rich protein PRCC) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"prdm1","symbol":"PRDM1","href":"/targets/prdm1/","tldr":"PRDM1 (PR domain zinc finger protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Prostate cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"prdm16","symbol":"PRDM16","href":"/targets/prdm16/","tldr":"PRDM16 (Histone-lysine N-methyltransferase PRDM16) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma, Breast cancer, Neuroendocrine tumours and 4 more.","roles":["fusion-partner"],"tier":"cohort-driver"},{"id":"prdm2","symbol":"PRDM2","href":"/targets/prdm2/","tldr":"PRDM2 (PR domain zinc finger protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Renal cell carcinoma, Neuroblastoma and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"prex2","symbol":"PREX2","href":"/targets/prex2/","tldr":"PREX2 is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"prf1","symbol":"PRF1","href":"/targets/prf1/","tldr":"PRF1 (Perforin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 2 more.","roles":[],"tier":"association-only"},{"id":"prim1","symbol":"PRIM1","href":"/targets/prim1/","tldr":"PRIM1 (DNA primase small subunit) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prim2","symbol":"PRIM2","href":"/targets/prim2/","tldr":"PRIM2 (DNA primase large subunit) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prkaa2","symbol":"PRKAA2","href":"/targets/prkaa2/","tldr":"PRKAA2 (5'-AMP-activated protein kinase catalytic subunit alpha-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"prkaca","symbol":"PRKACA","href":"/targets/prkaca/","tldr":"PRKACA (cAMP-dependent protein kinase catalytic subunit alpha) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Hepatocellular carcinoma.","roles":[],"tier":"association-only"},{"id":"prkar1a","symbol":"PRKAR1A","href":"/targets/prkar1a/","tldr":"PRKAR1A (cAMP-dependent protein kinase type I-alpha regulatory subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Adrenocortical carcinoma, Thyroid cancer, Renal cell carcinoma and 2 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"prkcb","symbol":"PRKCB","href":"/targets/prkcb/","tldr":"PRKCB (Protein kinase C beta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Head and neck squamous cell carcinoma and 5 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"approved-drug"},{"id":"prkcd","symbol":"PRKCD","href":"/targets/prkcd/","tldr":"PRKCD (Protein kinase C delta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.","roles":["drug-target","tumour-suppressor"],"tier":"approved-drug"},{"id":"prkce","symbol":"PRKCE","href":"/targets/prkce/","tldr":"PRKCE (Protein kinase C epsilon type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prkcg","symbol":"PRKCG","href":"/targets/prkcg/","tldr":"PRKCG (Protein kinase C gamma type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prkch","symbol":"PRKCH","href":"/targets/prkch/","tldr":"PRKCH (PRKCH upstream open reading frame 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prkci","symbol":"PRKCI","href":"/targets/prkci/","tldr":"PRKCI (Protein kinase C iota type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prkcq","symbol":"PRKCQ","href":"/targets/prkcq/","tldr":"PRKCQ (Protein kinase C theta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prkcz","symbol":"PRKCZ","href":"/targets/prkcz/","tldr":"PRKCZ (Protein kinase C zeta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prkd1","symbol":"PRKD1","href":"/targets/prkd1/","tldr":"PRKD1 (Serine/threonine-protein kinase D1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Colorectal cancer and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor"],"tier":"approved-drug"},{"id":"prkd2","symbol":"PRKD2","href":"/targets/prkd2/","tldr":"PRKD2 (Serine/threonine-protein kinase D2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"prkd3","symbol":"PRKD3","href":"/targets/prkd3/","tldr":"PRKD3 (Serine/threonine-protein kinase D3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prkdc","symbol":"PRKDC","href":"/targets/prkdc/","tldr":"PRKDC (DNA-dependent protein kinase catalytic subunit) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma, Non-small-cell lung cancer and Diffuse large B-cell lymphoma.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"prkn","symbol":"PRKN","href":"/targets/prkn/","tldr":"PRKN (E3 ubiquitin-protein ligase parkin) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"prncr1","symbol":"PRNCR1","href":"/targets/prncr1/","tldr":"PRNCR1 (prostate cancer associated non-coding RNA 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"prom1","symbol":"PROM1","href":"/targets/prom1/","tldr":"PROM1 (Prominin-1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"prps1","symbol":"PRPS1","href":"/targets/prps1/","tldr":"PRPS1 (Ribose-phosphate pyrophosphokinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute lymphoblastic leukaemia.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"prune2","symbol":"PRUNE2","href":"/targets/prune2/","tldr":"PRUNE2 (Protein prune homolog 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroblastoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"psca","symbol":"PSCA","href":"/targets/psca/","tldr":"PSCA (Prostate stem cell antigen) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"psen2","symbol":"PSEN2","href":"/targets/psen2/","tldr":"PSEN2 (Presenilin-2) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psenen","symbol":"PSENEN","href":"/targets/psenen/","tldr":"PSENEN (Gamma-secretase subunit PEN-2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psip1","symbol":"PSIP1","href":"/targets/psip1/","tldr":"PSIP1 (PC4 and SFRS1-interacting protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Colorectal cancer and Gallbladder cancer.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"psma1","symbol":"PSMA1","href":"/targets/psma1/","tldr":"PSMA1 (Proteasome subunit alpha type-1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psma2","symbol":"PSMA2","href":"/targets/psma2/","tldr":"PSMA2 (Proteasome subunit alpha type-2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psma3","symbol":"PSMA3","href":"/targets/psma3/","tldr":"PSMA3 (Proteasome subunit alpha type-3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psma4","symbol":"PSMA4","href":"/targets/psma4/","tldr":"PSMA4 (Proteasome subunit alpha type-4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psma5","symbol":"PSMA5","href":"/targets/psma5/","tldr":"PSMA5 (Proteasome subunit alpha type-5) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psma6","symbol":"PSMA6","href":"/targets/psma6/","tldr":"PSMA6 (Proteasome subunit alpha type-6) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psma7","symbol":"PSMA7","href":"/targets/psma7/","tldr":"PSMA7 (Proteasome subunit alpha type-7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psma8","symbol":"PSMA8","href":"/targets/psma8/","tldr":"PSMA8 (Proteasome subunit alpha-type 8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmb1","symbol":"PSMB1","href":"/targets/psmb1/","tldr":"PSMB1 (Proteasome subunit beta type-1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmb10","symbol":"PSMB10","href":"/targets/psmb10/","tldr":"PSMB10 (Proteasome subunit beta type-10) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmb11","symbol":"PSMB11","href":"/targets/psmb11/","tldr":"PSMB11 (Proteasome subunit beta type-11) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmb2","symbol":"PSMB2","href":"/targets/psmb2/","tldr":"PSMB2 (Proteasome subunit beta type-2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmb3","symbol":"PSMB3","href":"/targets/psmb3/","tldr":"PSMB3 (Proteasome subunit beta type-3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmb4","symbol":"PSMB4","href":"/targets/psmb4/","tldr":"PSMB4 (Proteasome subunit beta type-4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmb6","symbol":"PSMB6","href":"/targets/psmb6/","tldr":"PSMB6 (Proteasome subunit beta type-6) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmb7","symbol":"PSMB7","href":"/targets/psmb7/","tldr":"PSMB7 (Proteasome subunit beta type-7) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmb8","symbol":"PSMB8","href":"/targets/psmb8/","tldr":"PSMB8 (Proteasome subunit beta type-8) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Gastric & gastro-oesophageal junction cancer, Non-Hodgkin lymphoma and 1 more.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"psmb9","symbol":"PSMB9","href":"/targets/psmb9/","tldr":"PSMB9 (Proteasome subunit beta type-9) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmc1","symbol":"PSMC1","href":"/targets/psmc1/","tldr":"PSMC1 (26S proteasome regulatory subunit 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmc2","symbol":"PSMC2","href":"/targets/psmc2/","tldr":"PSMC2 (26S proteasome regulatory subunit 7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmc3","symbol":"PSMC3","href":"/targets/psmc3/","tldr":"PSMC3 (26S proteasome regulatory subunit 6A) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmc4","symbol":"PSMC4","href":"/targets/psmc4/","tldr":"PSMC4 (26S proteasome regulatory subunit 6B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmc5","symbol":"PSMC5","href":"/targets/psmc5/","tldr":"PSMC5 (26S proteasome regulatory subunit 8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmc6","symbol":"PSMC6","href":"/targets/psmc6/","tldr":"PSMC6 (26S proteasome regulatory subunit 10B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmd1","symbol":"PSMD1","href":"/targets/psmd1/","tldr":"PSMD1 (26S proteasome non-ATPase regulatory subunit 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmd11","symbol":"PSMD11","href":"/targets/psmd11/","tldr":"PSMD11 (26S proteasome non-ATPase regulatory subunit 11) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmd12","symbol":"PSMD12","href":"/targets/psmd12/","tldr":"PSMD12 (26S proteasome non-ATPase regulatory subunit 12) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmd13","symbol":"PSMD13","href":"/targets/psmd13/","tldr":"PSMD13 (26S proteasome non-ATPase regulatory subunit 13) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmd14","symbol":"PSMD14","href":"/targets/psmd14/","tldr":"PSMD14 (Ubiquitin C-terminal hydrolase PSMD14) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"psmd2","symbol":"PSMD2","href":"/targets/psmd2/","tldr":"PSMD2 (26S proteasome non-ATPase regulatory subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmd3","symbol":"PSMD3","href":"/targets/psmd3/","tldr":"PSMD3 (26S proteasome non-ATPase regulatory subunit 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmd4","symbol":"PSMD4","href":"/targets/psmd4/","tldr":"PSMD4 (26S proteasome non-ATPase regulatory subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Colorectal cancer, Breast cancer and 2 more.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"psmd6","symbol":"PSMD6","href":"/targets/psmd6/","tldr":"PSMD6 (26S proteasome non-ATPase regulatory subunit 6) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmd7","symbol":"PSMD7","href":"/targets/psmd7/","tldr":"PSMD7 (26S proteasome non-ATPase regulatory subunit 7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmd8","symbol":"PSMD8","href":"/targets/psmd8/","tldr":"PSMD8 (26S proteasome non-ATPase regulatory subunit 8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"pspc1","symbol":"PSPC1","href":"/targets/pspc1/","tldr":"PSPC1 (Paraspeckle component 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"pten","symbol":"PTEN","href":"/targets/pten/","tldr":"PTEN is the brake on the PI3K growth pathway; when a tumour loses it the pathway runs unchecked, which is why PTEN loss now selects patients for the AKT inhibitor capivasertib.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ptgs1","symbol":"PTGS1","href":"/targets/ptgs1/","tldr":"PTGS1 (Prostaglandin G/H synthase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ptma","symbol":"PTMA","href":"/targets/ptma/","tldr":"PTMA (Prothymosin alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Testicular germ cell tumours.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"ptp4a3","symbol":"PTP4A3","href":"/targets/ptp4a3/","tldr":"PTP4A3 (Protein tyrosine phosphatase type IVA 3) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ptpn12","symbol":"PTPN12","href":"/targets/ptpn12/","tldr":"PTPN12 (Tyrosine-protein phosphatase non-receptor type 12) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ptpn13","symbol":"PTPN13","href":"/targets/ptpn13/","tldr":"PTPN13 (Tyrosine-protein phosphatase non-receptor type 13) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma, Endometrial cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ptpn14","symbol":"PTPN14","href":"/targets/ptpn14/","tldr":"PTPN14 (Tyrosine-protein phosphatase non-receptor type 14) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Basal cell carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"ptpn22","symbol":"PTPN22","href":"/targets/ptpn22/","tldr":"PTPN22 (Tyrosine-protein phosphatase non-receptor type 22) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ptpn3","symbol":"PTPN3","href":"/targets/ptpn3/","tldr":"PTPN3 (Tyrosine-protein phosphatase non-receptor type 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"ptpn6","symbol":"PTPN6","href":"/targets/ptpn6/","tldr":"PTPN6 (Tyrosine-protein phosphatase non-receptor type 6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Diffuse large B-cell lymphoma and Melanoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ptprb","symbol":"PTPRB","href":"/targets/ptprb/","tldr":"PTPRB (Receptor-type tyrosine-protein phosphatase beta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Mesothelioma, Skin cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ptprc","symbol":"PTPRC","href":"/targets/ptprc/","tldr":"PTPRC (Receptor-type tyrosine-protein phosphatase C) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Anal cancer, Hepatocellular carcinoma, Skin cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ptprd","symbol":"PTPRD","href":"/targets/ptprd/","tldr":"PTPRD (Receptor-type tyrosine-protein phosphatase delta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"ptprf","symbol":"PTPRF","href":"/targets/ptprf/","tldr":"PTPRF (Receptor-type tyrosine-protein phosphatase F) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ptprk","symbol":"PTPRK","href":"/targets/ptprk/","tldr":"PTPRK (Receptor-type tyrosine-protein phosphatase kappa) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Bladder & urothelial cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ptprt","symbol":"PTPRT","href":"/targets/ptprt/","tldr":"PTPRT (Receptor-type tyrosine-protein phosphatase T) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"pttg1","symbol":"PTTG1","href":"/targets/pttg1/","tldr":"PTTG1 (Securin) is a gene. The public catalogues list it as a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Meningioma.","roles":["biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"pwwp2a","symbol":"PWWP2A","href":"/targets/pwwp2a/","tldr":"PWWP2A (PWWP domain-containing protein 2A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"pxdnl","symbol":"PXDNL","href":"/targets/pxdnl/","tldr":"PXDNL (Probable oxidoreductase PXDNL) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"qki","symbol":"QKI","href":"/targets/qki/","tldr":"QKI (KH domain-containing RNA-binding protein QKI) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"rabl3","symbol":"RABL3","href":"/targets/rabl3/","tldr":"RABL3 (Rab-like protein 3) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"rac1","symbol":"RAC1","href":"/targets/rac1/","tldr":"RAC1 (Ras-related C3 botulinum toxin substrate 1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Head and neck squamous cell carcinoma and Melanoma.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"rad21","symbol":"RAD21","href":"/targets/rad21/","tldr":"RAD21 (Double-strand-break repair protein rad21 homolog) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Myeloproliferative neoplasms, Lung cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor","dna-repair"],"tier":"cohort-driver"},{"id":"rad23b","symbol":"RAD23B","href":"/targets/rad23b/","tldr":"RAD23B (Lysine-specific demethylase RAD23B) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"rad50","symbol":"RAD50","href":"/targets/rad50/","tldr":"RAD50 (DNA repair protein RAD50) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Colorectal cancer and 2 more.","roles":["drug-target","oncogene-driver","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"rad51","symbol":"RAD51","href":"/targets/rad51/","tldr":"RAD51 (DNA repair protein RAD51 homolog 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"rad51b","symbol":"RAD51B","href":"/targets/rad51b/","tldr":"RAD51B (DNA repair protein RAD51 homolog 2) is a gene. The public catalogues list it as a drug target, a biomarker, a fusion partner and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Ovarian cancer and 2 more.","roles":["drug-target","biomarker","fusion-partner","dna-repair"],"tier":"clinical-evidence"},{"id":"rad51c","symbol":"RAD51C","href":"/targets/rad51c/","tldr":"RAD51C (DNA repair protein RAD51 homolog 3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 2 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"rad51d","symbol":"RAD51D","href":"/targets/rad51d/","tldr":"RAD51D (DNA repair protein RAD51 homolog 4) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 3 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"rad54l","symbol":"RAD54L","href":"/targets/rad54l/","tldr":"RAD54L (DNA repair and recombination protein RAD54-like) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"ranbp2","symbol":"RANBP2","href":"/targets/ranbp2/","tldr":"RANBP2 (E3 SUMO-protein ligase RanBP2) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Hepatocellular carcinoma, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"rap1a","symbol":"RAP1A","href":"/targets/rap1a/","tldr":"RAP1A (Ras-related protein Rap-1A) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"rap1b","symbol":"RAP1B","href":"/targets/rap1b/","tldr":"RAP1B (Ras-related protein Rap-1b) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rap1gds1","symbol":"RAP1GDS1","href":"/targets/rap1gds1/","tldr":"RAP1GDS1 (Rap1 GTPase-GDP dissociation stimulator 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Renal cell carcinoma, Oesophageal cancer, Breast cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"rarb","symbol":"RARB","href":"/targets/rarb/","tldr":"RARB (Retinoic acid receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"rarg","symbol":"RARG","href":"/targets/rarg/","tldr":"RARG (Retinoic acid receptor gamma) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"rasa1","symbol":"RASA1","href":"/targets/rasa1/","tldr":"RASA1 (Ras GTPase-activating protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Colorectal cancer, Lung cancer and 4 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"rasa2","symbol":"RASA2","href":"/targets/rasa2/","tldr":"RASA2 (Ras GTPase-activating protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Diffuse large B-cell lymphoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rassf6","symbol":"RASSF6","href":"/targets/rassf6/","tldr":"RASSF6 (Ras association domain-containing protein 6) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"rb1","symbol":"RB1","href":"/targets/rb1/","tldr":"RB1 (Retinoblastoma-associated protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Lung cancer, Neuroendocrine tumours and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"rbbp7","symbol":"RBBP7","href":"/targets/rbbp7/","tldr":"RBBP7 (Histone-binding protein RBBP7) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"rbbp8","symbol":"RBBP8","href":"/targets/rbbp8/","tldr":"RBBP8 (DNA endonuclease RBBP8) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"rbfox1","symbol":"RBFOX1","href":"/targets/rbfox1/","tldr":"RBFOX1 (RNA binding protein fox-1 homolog 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rbm10","symbol":"RBM10","href":"/targets/rbm10/","tldr":"RBM10 (Ribosome biogenesis inhibitor MINAS-60) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"rbm15","symbol":"RBM15","href":"/targets/rbm15/","tldr":"RBM15 (RNA-binding protein 15) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"rbm38","symbol":"RBM38","href":"/targets/rbm38/","tldr":"RBM38 (RNA-binding protein 38) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Diffuse large B-cell lymphoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rbm39","symbol":"RBM39","href":"/targets/rbm39/","tldr":"RBM39 (RNA-binding protein 39) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"rbpj","symbol":"RBPJ","href":"/targets/rbpj/","tldr":"RBPJ (Recombining binding protein suppressor of hairless) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"rbx1","symbol":"RBX1","href":"/targets/rbx1/","tldr":"RBX1 (E3 ubiquitin-protein ligase RBX1) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"rcc2","symbol":"RCC2","href":"/targets/rcc2/","tldr":"RCC2 (regulator of chromosome condensation 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"recql4","symbol":"RECQL4","href":"/targets/recql4/","tldr":"RECQL4 (ATP-dependent DNA helicase Q4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Gastric & gastro-oesophageal junction cancer, Breast cancer and 5 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rel","symbol":"REL","href":"/targets/rel/","tldr":"REL (Proto-oncogene c-Rel) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"rela","symbol":"RELA","href":"/targets/rela/","tldr":"RELA (Transcription factor p65) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"rest","symbol":"REST","href":"/targets/rest/","tldr":"REST (RE1-silencing transcription factor) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Wilms tumour.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rfwd3","symbol":"RFWD3","href":"/targets/rfwd3/","tldr":"RFWD3 (E3 ubiquitin-protein ligase RFWD3) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"rfx7","symbol":"RFX7","href":"/targets/rfx7/","tldr":"RFX7 (DNA-binding protein RFX7) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer and Burkitt lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"rgpd3","symbol":"RGPD3","href":"/targets/rgpd3/","tldr":"RGPD3 (RanBP2-like and GRIP domain-containing protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Non-small-cell lung cancer and Melanoma.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"rgs17","symbol":"RGS17","href":"/targets/rgs17/","tldr":"RGS17 (Regulator of G protein signalling 17) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"rgs7","symbol":"RGS7","href":"/targets/rgs7/","tldr":"RGS7 (Regulator of G protein signalling 7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Non-small-cell lung cancer and Melanoma.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"rheb","symbol":"RHEB","href":"/targets/rheb/","tldr":"RHEB (GTP-binding protein Rheb) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"rhoa","symbol":"RHOA","href":"/targets/rhoa/","tldr":"RHOA (Transforming protein RhoA) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Gastric & gastro-oesophageal junction cancer, Bladder & urothelial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"rhobtb2","symbol":"RHOBTB2","href":"/targets/rhobtb2/","tldr":"RHOBTB2 (Rho-related BTB domain-containing protein 2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"rhoh","symbol":"RHOH","href":"/targets/rhoh/","tldr":"RHOH (Rho-related GTP-binding protein RhoH) is an enzyme. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"rhpn2","symbol":"RHPN2","href":"/targets/rhpn2/","tldr":"RHPN2 (Rhophilin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer and Non-small-cell lung cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"rictor","symbol":"RICTOR","href":"/targets/rictor/","tldr":"RICTOR (Rapamycin-insensitive companion of mTOR) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Lung cancer, Breast cancer and 5 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ripk1","symbol":"RIPK1","href":"/targets/ripk1/","tldr":"RIPK1 (Receptor-interacting serine/threonine-protein kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Chronic lymphocytic leukaemia.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rit1","symbol":"RIT1","href":"/targets/rit1/","tldr":"RIT1 (GTP-binding protein Rit1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"rmi1","symbol":"RMI1","href":"/targets/rmi1/","tldr":"RMI1 (RecQ-mediated genome instability protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"rmi2","symbol":"RMI2","href":"/targets/rmi2/","tldr":"RMI2 (RecQ-mediated genome instability protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma, Breast cancer, Lung cancer and 1 more.","roles":[],"tier":"association-only"},{"id":"rnasel","symbol":"RNASEL","href":"/targets/rnasel/","tldr":"RNASEL (2-5A-dependent ribonuclease) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"rnaset2","symbol":"RNASET2","href":"/targets/rnaset2/","tldr":"RNASET2 (Ribonuclease T2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"rnf213","symbol":"RNF213","href":"/targets/rnf213/","tldr":"RNF213 (E3 ubiquitin-protein ligase RNF213) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Bladder & urothelial cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"rnf43","symbol":"RNF43","href":"/targets/rnf43/","tldr":"RNF43 (E3 ubiquitin-protein ligase RNF43) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Colorectal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"rnf6","symbol":"RNF6","href":"/targets/rnf6/","tldr":"RNF6 (E3 ubiquitin-protein ligase RNF6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer and Oesophageal cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"robo2","symbol":"ROBO2","href":"/targets/robo2/","tldr":"ROBO2 (Roundabout homolog 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Prostate cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"robo4","symbol":"ROBO4","href":"/targets/robo4/","tldr":"ROBO4 (Roundabout homolog 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"rpl10","symbol":"RPL10","href":"/targets/rpl10/","tldr":"RPL10 (Large ribosomal subunit protein uL16) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 1 more.","roles":["drug-target","oncogene-driver"],"tier":"clinical-evidence"},{"id":"rpl22","symbol":"RPL22","href":"/targets/rpl22/","tldr":"RPL22 (Large ribosomal subunit protein eL22) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Colorectal cancer and Gastric & gastro-oesophageal junction cancer.","roles":["drug-target","tumour-suppressor"],"tier":"clinical-evidence"},{"id":"rpl5","symbol":"RPL5","href":"/targets/rpl5/","tldr":"RPL5 (Large ribosomal subunit protein uL18) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Skin cancer and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor"],"tier":"clinical-evidence"},{"id":"rps19","symbol":"RPS19","href":"/targets/rps19/","tldr":"RPS19 (Small ribosomal subunit protein eS19) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"rps24","symbol":"RPS24","href":"/targets/rps24/","tldr":"RPS24 (Small ribosomal subunit protein eS24) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"rps26","symbol":"RPS26","href":"/targets/rps26/","tldr":"RPS26 (Small ribosomal subunit protein eS26) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"rps27","symbol":"RPS27","href":"/targets/rps27/","tldr":"RPS27 (Small ribosomal subunit protein eS27) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"rps27a","symbol":"RPS27A","href":"/targets/rps27a/","tldr":"RPS27A (Ubiquitin-ribosomal protein eS31 fusion protein) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"rps29","symbol":"RPS29","href":"/targets/rps29/","tldr":"RPS29 (Small ribosomal subunit protein uS14) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia and Myeloproliferative neoplasms.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"rps3a","symbol":"RPS3A","href":"/targets/rps3a/","tldr":"RPS3A (Small ribosomal subunit protein eS1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"rps6","symbol":"RPS6","href":"/targets/rps6/","tldr":"RPS6 (Small ribosomal subunit protein eS6) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"rps6ka3","symbol":"RPS6KA3","href":"/targets/rps6ka3/","tldr":"RPS6KA3 (Ribosomal protein S6 kinase alpha-3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rps7","symbol":"RPS7","href":"/targets/rps7/","tldr":"RPS7 (Small ribosomal subunit protein eS7) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"rragc","symbol":"RRAGC","href":"/targets/rragc/","tldr":"RRAGC (Ras-related GTP-binding protein C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-Hodgkin lymphoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"rras2","symbol":"RRAS2","href":"/targets/rras2/","tldr":"RRAS2 (Ras-related protein R-Ras2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Ovarian cancer and Breast cancer.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"rrm2","symbol":"RRM2","href":"/targets/rrm2/","tldr":"RRM2 (Ribonucleoside-diphosphate reductase subunit M2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Breast cancer and 5 more.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"rrm2b","symbol":"RRM2B","href":"/targets/rrm2b/","tldr":"RRM2B (Ribonucleoside-diphosphate reductase subunit M2 B) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 5 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"rrn3","symbol":"RRN3","href":"/targets/rrn3/","tldr":"RRN3 (RNA polymerase I-specific transcription initiation factor RRN3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"rsf1","symbol":"RSF1","href":"/targets/rsf1/","tldr":"RSF1 (Remodeling and spacing factor 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"rspo2","symbol":"RSPO2","href":"/targets/rspo2/","tldr":"RSPO2 (R-spondin-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer and Colorectal cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"rspo3","symbol":"RSPO3","href":"/targets/rspo3/","tldr":"RSPO3 (R-spondin-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Breast cancer and Lung cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"rtel1","symbol":"RTEL1","href":"/targets/rtel1/","tldr":"RTEL1 (Regulator of telomere elongation helicase 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.","roles":["dna-repair"],"tier":"association-only"},{"id":"runx1","symbol":"RUNX1","href":"/targets/runx1/","tldr":"RUNX1 (Runt-related transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"runx1t1","symbol":"RUNX1T1","href":"/targets/runx1t1/","tldr":"RUNX1T1 (RUNX1 partner transcriptional co-repressor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Leukaemia, Hepatocellular carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"s100b","symbol":"S100B","href":"/targets/s100b/","tldr":"S100B (S100 calcium binding protein B) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"s1pr1","symbol":"S1PR1","href":"/targets/s1pr1/","tldr":"S1PR1 (Sphingosine 1-phosphate receptor 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mantle cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"s1pr2","symbol":"S1PR2","href":"/targets/s1pr2/","tldr":"S1PR2 (Sphingosine 1-phosphate receptor 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"sall4","symbol":"SALL4","href":"/targets/sall4/","tldr":"SALL4 (Sal-like protein 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Colorectal cancer, Gastric & gastro-oesophageal junction cancer and 2 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"samd9","symbol":"SAMD9","href":"/targets/samd9/","tldr":"SAMD9 (Sterile alpha motif domain-containing protein 9) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms.","roles":[],"tier":"association-only"},{"id":"samd9l","symbol":"SAMD9L","href":"/targets/samd9l/","tldr":"SAMD9L (Sterile alpha motif domain-containing protein 9-like) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms.","roles":[],"tier":"association-only"},{"id":"samhd1","symbol":"SAMHD1","href":"/targets/samhd1/","tldr":"SAMHD1 (Deoxynucleoside triphosphate triphosphohydrolase SAMHD1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["tumour-suppressor","dna-repair"],"tier":"cohort-driver"},{"id":"sbds","symbol":"SBDS","href":"/targets/sbds/","tldr":"SBDS (Ribosome maturation protein SBDS) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.","roles":[],"tier":"association-only"},{"id":"scn10a","symbol":"SCN10A","href":"/targets/scn10a/","tldr":"SCN10A (Sodium channel protein type 10 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn11a","symbol":"SCN11A","href":"/targets/scn11a/","tldr":"SCN11A (Sodium channel protein type 11 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn1a","symbol":"SCN1A","href":"/targets/scn1a/","tldr":"SCN1A (Sodium channel protein type 1 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn2a","symbol":"SCN2A","href":"/targets/scn2a/","tldr":"SCN2A (Sodium channel protein type 2 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn3a","symbol":"SCN3A","href":"/targets/scn3a/","tldr":"SCN3A (Sodium channel protein type 3 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn4a","symbol":"SCN4A","href":"/targets/scn4a/","tldr":"SCN4A (Sodium channel protein type 4 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn5a","symbol":"SCN5A","href":"/targets/scn5a/","tldr":"SCN5A (Sodium channel protein type 5 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn7a","symbol":"SCN7A","href":"/targets/scn7a/","tldr":"SCN7A (Sodium channel protein type 7 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn8a","symbol":"SCN8A","href":"/targets/scn8a/","tldr":"SCN8A (Sodium channel protein type 8 subunit alpha) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"scn9a","symbol":"SCN9A","href":"/targets/scn9a/","tldr":"SCN9A (Sodium channel protein type 9 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"sdc4","symbol":"SDC4","href":"/targets/sdc4/","tldr":"SDC4 (Syndecan-4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer and Non-small-cell lung cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"sdcbp","symbol":"SDCBP","href":"/targets/sdcbp/","tldr":"SDCBP (Syntenin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"sdccag8","symbol":"SDCCAG8","href":"/targets/sdccag8/","tldr":"SDCCAG8 (Serologically defined colon cancer antigen 8) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"sdha","symbol":"SDHA","href":"/targets/sdha/","tldr":"SDHA (Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"sdhaf2","symbol":"SDHAF2","href":"/targets/sdhaf2/","tldr":"SDHAF2 (Succinate dehydrogenase assembly factor 2, mitochondrial) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours and Ovarian cancer.","roles":[],"tier":"association-only"},{"id":"sdhb","symbol":"SDHB","href":"/targets/sdhb/","tldr":"SDHB (Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Breast cancer and Gastrointestinal stromal tumour.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"sdhc","symbol":"SDHC","href":"/targets/sdhc/","tldr":"SDHC (Succinate dehydrogenase cytochrome b560 subunit, mitochondrial) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours, Breast cancer, Colorectal cancer and 1 more.","roles":[],"tier":"association-only"},{"id":"sdhd","symbol":"SDHD","href":"/targets/sdhd/","tldr":"SDHD (Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours.","roles":[],"tier":"association-only"},{"id":"sem1","symbol":"SEM1","href":"/targets/sem1/","tldr":"SEM1 (26S proteasome complex subunit SEM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"set","symbol":"SET","href":"/targets/set/","tldr":"SET (SET nuclear proto-oncogene) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.","roles":["fusion-partner"],"tier":"association-only"},{"id":"setbp1","symbol":"SETBP1","href":"/targets/setbp1/","tldr":"SETBP1 (SET-binding protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Breast cancer and 5 more.","roles":["oncogene-driver","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"setd1b","symbol":"SETD1B","href":"/targets/setd1b/","tldr":"SETD1B (Histone-lysine N-methyltransferase SETD1B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"setd2","symbol":"SETD2","href":"/targets/setd2/","tldr":"SETD2 (Histone-lysine N-methyltransferase SETD2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Renal cell carcinoma, Leukaemia, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","dna-repair"],"tier":"approved-drug"},{"id":"setdb1","symbol":"SETDB1","href":"/targets/setdb1/","tldr":"SETDB1 (Histone-lysine N-methyltransferase SETDB1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Colorectal cancer, Hepatocellular carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"sf3b1","symbol":"SF3B1","href":"/targets/sf3b1/","tldr":"SF3B1 (Splicing factor 3B subunit 1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"sfpq","symbol":"SFPQ","href":"/targets/sfpq/","tldr":"SFPQ (Splicing factor, proline- and glutamine-rich) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner and a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["fusion-partner","dna-repair"],"tier":"association-only"},{"id":"sfrp4","symbol":"SFRP4","href":"/targets/sfrp4/","tldr":"SFRP4 (Secreted frizzled-related protein 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer and Skin cancer.","roles":[],"tier":"association-only"},{"id":"sgk1","symbol":"SGK1","href":"/targets/sgk1/","tldr":"SGK1 (Serine/threonine-protein kinase Sgk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 2 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"sh2b3","symbol":"SH2B3","href":"/targets/sh2b3/","tldr":"SH2B3 (SH2B adapter protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Myeloproliferative neoplasms, Endometrial cancer and 4 more.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"sh3gl1","symbol":"SH3GL1","href":"/targets/sh3gl1/","tldr":"SH3GL1 (Endophilin-A2) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"shc1","symbol":"SHC1","href":"/targets/shc1/","tldr":"SHC1 (SHC-transforming protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"shtn1","symbol":"SHTN1","href":"/targets/shtn1/","tldr":"SHTN1 (Shootin-1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"sidt1","symbol":"SIDT1","href":"/targets/sidt1/","tldr":"SIDT1 (SID1 transmembrane family member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"sim2","symbol":"SIM2","href":"/targets/sim2/","tldr":"SIM2 (Single-minded homolog 2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"sin3a","symbol":"SIN3A","href":"/targets/sin3a/","tldr":"SIN3A (Paired amphipathic helix protein Sin3a) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Burkitt lymphoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"sirpa","symbol":"SIRPA","href":"/targets/sirpa/","tldr":"SIRPA (Tyrosine-protein phosphatase non-receptor type substrate 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Colorectal cancer, Non-Hodgkin lymphoma and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"sirt1","symbol":"SIRT1","href":"/targets/sirt1/","tldr":"SIRT1 (NAD-dependent protein deacetylase sirtuin-1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"six1","symbol":"SIX1","href":"/targets/six1/","tldr":"SIX1 (Homeobox protein SIX1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer and Wilms tumour.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"skil","symbol":"SKIL","href":"/targets/skil/","tldr":"SKIL (Ski-like protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"skp1","symbol":"SKP1","href":"/targets/skp1/","tldr":"SKP1 (S-phase kinase-associated protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"slc12a2","symbol":"SLC12A2","href":"/targets/slc12a2/","tldr":"SLC12A2 (Solute carrier family 12 member 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"slc14a1","symbol":"SLC14A1","href":"/targets/slc14a1/","tldr":"SLC14A1 (Urea transporter 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"slc22a3","symbol":"SLC22A3","href":"/targets/slc22a3/","tldr":"SLC22A3 (Solute carrier family 22 member 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"slc24a5","symbol":"SLC24A5","href":"/targets/slc24a5/","tldr":"SLC24A5 (Sodium/potassium/calcium exchanger 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.","roles":[],"tier":"association-only"},{"id":"slc25a11","symbol":"SLC25A11","href":"/targets/slc25a11/","tldr":"SLC25A11 (Mitochondrial 2-oxoglutarate/malate carrier protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours.","roles":[],"tier":"association-only"},{"id":"slc29a1","symbol":"SLC29A1","href":"/targets/slc29a1/","tldr":"SLC29A1 (Equilibrative nucleoside transporter 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"slc34a2","symbol":"SLC34A2","href":"/targets/slc34a2/","tldr":"SLC34A2 (Sodium-dependent phosphate transport protein 2B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Colorectal cancer, Non-small-cell lung cancer and 1 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"clinical-evidence"},{"id":"slc45a2","symbol":"SLC45A2","href":"/targets/slc45a2/","tldr":"SLC45A2 (Membrane-associated transporter protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"slc67a1","symbol":"SLC67A1","href":"/targets/slc67a1/","tldr":"SLC67A1 (Solute carrier family 67 member A1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"slc6a2","symbol":"SLC6A2","href":"/targets/slc6a2/","tldr":"SLC6A2 (Sodium-dependent noradrenaline transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"slc6a3","symbol":"SLC6A3","href":"/targets/slc6a3/","tldr":"SLC6A3 (Sodium-dependent dopamine transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"slc6a4","symbol":"SLC6A4","href":"/targets/slc6a4/","tldr":"SLC6A4 (Sodium-dependent serotonin transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"slco1b1","symbol":"SLCO1B1","href":"/targets/slco1b1/","tldr":"SLCO1B1 (Solute carrier organic anion transporter family member 1B1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"slfn11","symbol":"SLFN11","href":"/targets/slfn11/","tldr":"SLFN11 (Schlafen family member 11) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Ewing sarcoma and Small-cell lung cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"slx4","symbol":"SLX4","href":"/targets/slx4/","tldr":"SLX4 (Structure-specific endonuclease subunit SLX4) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms, Leukaemia, Myeloproliferative neoplasms and 1 more.","roles":["dna-repair"],"tier":"association-only"},{"id":"smad2","symbol":"SMAD2","href":"/targets/smad2/","tldr":"SMAD2 (SMAD family member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 1 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"approved-drug"},{"id":"smad3","symbol":"SMAD3","href":"/targets/smad3/","tldr":"SMAD3 (SMAD family member 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Pancreatic ductal adenocarcinoma, Skin cancer and 4 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"smad4","symbol":"SMAD4","href":"/targets/smad4/","tldr":"SMAD4 (SMAD family member 4) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Oesophageal cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"smad7","symbol":"SMAD7","href":"/targets/smad7/","tldr":"SMAD7 (SMAD family member 7) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"smarca2","symbol":"SMARCA2","href":"/targets/smarca2/","tldr":"SMARCA2 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Salivary gland cancers.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"smarca4","symbol":"SMARCA4","href":"/targets/smarca4/","tldr":"SMARCA4 is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"smarcb1","symbol":"SMARCB1","href":"/targets/smarcb1/","tldr":"SMARCB1 is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"smarcd1","symbol":"SMARCD1","href":"/targets/smarcd1/","tldr":"SMARCD1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"smarce1","symbol":"SMARCE1","href":"/targets/smarce1/","tldr":"SMARCE1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Meningioma.","roles":[],"tier":"association-only"},{"id":"smc1a","symbol":"SMC1A","href":"/targets/smc1a/","tldr":"SMC1A (Structural maintenance of chromosomes protein 1A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver","dna-repair"],"tier":"cohort-driver"},{"id":"snap25","symbol":"SNAP25","href":"/targets/snap25/","tldr":"SNAP25 (Synaptosomal-associated protein 25) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"sncaip","symbol":"SNCAIP","href":"/targets/sncaip/","tldr":"SNCAIP (Synphilin-1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"snd1","symbol":"SND1","href":"/targets/snd1/","tldr":"SND1 (Staphylococcal nuclease domain-containing protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Breast cancer, Lung cancer and 3 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"sntb1","symbol":"SNTB1","href":"/targets/sntb1/","tldr":"SNTB1 (Beta-1-syntrophin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"snw1","symbol":"SNW1","href":"/targets/snw1/","tldr":"SNW1 (SNW domain-containing protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"snx29","symbol":"SNX29","href":"/targets/snx29/","tldr":"SNX29 (Sorting nexin-29) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer and Small intestine cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"socs1","symbol":"SOCS1","href":"/targets/socs1/","tldr":"SOCS1 (Suppressor of cytokine signalling 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Rectal cancer.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"sorcs3","symbol":"SORCS3","href":"/targets/sorcs3/","tldr":"SORCS3 (VPS10 domain-containing receptor SorCS3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"sos1","symbol":"SOS1","href":"/targets/sos1/","tldr":"SOS1 (Son of sevenless homolog 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Skin cancer, Breast cancer and 1 more.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"sox10","symbol":"SOX10","href":"/targets/sox10/","tldr":"SOX10 (Transcription factor SOX-10) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"sox17","symbol":"SOX17","href":"/targets/sox17/","tldr":"SOX17 (Transcription factor SOX-17) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"sox2","symbol":"SOX2","href":"/targets/sox2/","tldr":"SOX2 (Transcription factor SOX-2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Skin cancer and Lung cancer.","roles":[],"tier":"association-only"},{"id":"sox21","symbol":"SOX21","href":"/targets/sox21/","tldr":"SOX21 (Transcription factor SOX-21) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"sox9","symbol":"SOX9","href":"/targets/sox9/","tldr":"SOX9 (Transcription factor SOX-9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"sp140","symbol":"SP140","href":"/targets/sp140/","tldr":"SP140 (Nuclear body protein SP140) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Mantle cell lymphoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"spdl1","symbol":"SPDL1","href":"/targets/spdl1/","tldr":"SPDL1 (spindle apparatus coiled-coil protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"spen","symbol":"SPEN","href":"/targets/spen/","tldr":"SPEN (Msx2-interacting protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"sphk1","symbol":"SPHK1","href":"/targets/sphk1/","tldr":"SPHK1 (Sphingosine kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"spop","symbol":"SPOP","href":"/targets/spop/","tldr":"SPOP (Speckle-type POZ protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Endometrial cancer, Non-Hodgkin lymphoma and 4 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"spry2","symbol":"SPRY2","href":"/targets/spry2/","tldr":"SPRY2 (Protein sprouty homolog 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"sptbn1","symbol":"SPTBN1","href":"/targets/sptbn1/","tldr":"SPTBN1 (Spectrin beta chain, non-erythrocytic 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"sqstm1","symbol":"SQSTM1","href":"/targets/sqstm1/","tldr":"SQSTM1 (Sequestosome-1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Osteosarcoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"srd5a1","symbol":"SRD5A1","href":"/targets/srd5a1/","tldr":"SRD5A1 (3-oxo-5-alpha-steroid 4-dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"srd5a3","symbol":"SRD5A3","href":"/targets/srd5a3/","tldr":"SRD5A3 (Polyprenal reductase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"srgap1","symbol":"SRGAP1","href":"/targets/srgap1/","tldr":"SRGAP1 (SLIT-ROBO Rho GTPase-activating protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"srgap3","symbol":"SRGAP3","href":"/targets/srgap3/","tldr":"SRGAP3 (SLIT-ROBO Rho GTPase-activating protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"srms","symbol":"SRMS","href":"/targets/srms/","tldr":"SRMS (Tyrosine-protein kinase Srms) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"srsf2","symbol":"SRSF2","href":"/targets/srsf2/","tldr":"SRSF2 (Serine/arginine-rich splicing factor 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Myelodysplastic syndromes / neoplasms and 3 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"srsf3","symbol":"SRSF3","href":"/targets/srsf3/","tldr":"SRSF3 (Serine/arginine-rich splicing factor 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ss18","symbol":"SS18","href":"/targets/ss18/","tldr":"SS18 (SS18 subunit of BAF chromatin remodeling complex) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Synovial sarcoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"sstr1","symbol":"SSTR1","href":"/targets/sstr1/","tldr":"SSTR1 (Somatostatin receptor type 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"sstr3","symbol":"SSTR3","href":"/targets/sstr3/","tldr":"SSTR3 (Somatostatin receptor type 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"sstr4","symbol":"SSTR4","href":"/targets/sstr4/","tldr":"SSTR4 (Somatostatin receptor type 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"sstr5","symbol":"SSTR5","href":"/targets/sstr5/","tldr":"SSTR5 (Somatostatin receptor type 5) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"ssx1","symbol":"SSX1","href":"/targets/ssx1/","tldr":"SSX1 (SSX family member 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Synovial sarcoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"ssx2","symbol":"SSX2","href":"/targets/ssx2/","tldr":"SSX2 (SSX family member 2) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Synovial sarcoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"stag2","symbol":"STAG2","href":"/targets/stag2/","tldr":"STAG2 (Cohesin subunit SA-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Sarcomas, Renal cell carcinoma and 5 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"stag2-as1","symbol":"STAG2-AS1","href":"/targets/stag2-as1/","tldr":"STAG2-AS1 (STAG2 antisense RNA 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"stag3","symbol":"STAG3","href":"/targets/stag3/","tldr":"STAG3 (Cohesin subunit SA-3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"stat1","symbol":"STAT1","href":"/targets/stat1/","tldr":"STAT1 (Signal transducer and activator of transcription 1-alpha/beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"stat3","symbol":"STAT3","href":"/targets/stat3/","tldr":"STAT3 (Signal transducer and activator of transcription 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"stat6","symbol":"STAT6","href":"/targets/stat6/","tldr":"STAT6 (Signal transducer and activator of transcription 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"stil","symbol":"STIL","href":"/targets/stil/","tldr":"STIL (SCL-interrupting locus protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma, Skin cancer and Leukaemia.","roles":[],"tier":"association-only"},{"id":"stk11","symbol":"STK11","href":"/targets/stk11/","tldr":"STK11 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"stmn1","symbol":"STMN1","href":"/targets/stmn1/","tldr":"STMN1 (Stathmin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"stn1","symbol":"STN1","href":"/targets/stn1/","tldr":"STN1 (CST complex subunit STN1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Melanoma.","roles":[],"tier":"association-only"},{"id":"strn","symbol":"STRN","href":"/targets/strn/","tldr":"STRN (Striatin) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer and Lung cancer.","roles":[],"tier":"association-only"},{"id":"sufu","symbol":"SUFU","href":"/targets/sufu/","tldr":"SUFU (Suppressor of fused homolog) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Medulloblastoma and 3 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"susd2","symbol":"SUSD2","href":"/targets/susd2/","tldr":"SUSD2 (Sushi domain-containing protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"suz12","symbol":"SUZ12","href":"/targets/suz12/","tldr":"SUZ12 (Polycomb protein SUZ12) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Breast cancer, Prostate cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"syk","symbol":"SYK","href":"/targets/syk/","tldr":"SYK (Tyrosine-protein kinase SYK) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Skin cancer, Lung cancer and 4 more.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"taf15","symbol":"TAF15","href":"/targets/taf15/","tldr":"TAF15 (TATA-binding protein-associated factor 2N) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Mesothelioma and Pleural mesothelioma.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"taf1l","symbol":"TAF1L","href":"/targets/taf1l/","tldr":"TAF1L (Transcription initiation factor TFIID subunit 1-like) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"tal1","symbol":"TAL1","href":"/targets/tal1/","tldr":"TAL1 (T-cell acute lymphocytic leukaemia protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Non-Hodgkin lymphoma, Skin cancer and 2 more.","roles":["fusion-partner"],"tier":"cohort-driver"},{"id":"tal2","symbol":"TAL2","href":"/targets/tal2/","tldr":"TAL2 (T-cell acute lymphocytic leukaemia protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"tbk1","symbol":"TBK1","href":"/targets/tbk1/","tldr":"TBK1 (Serine/threonine-protein kinase TBK1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"tbl1xr1","symbol":"TBL1XR1","href":"/targets/tbl1xr1/","tldr":"TBL1XR1 (F-box-like/WD repeat-containing protein TBL1XR1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"tbpl1","symbol":"TBPL1","href":"/targets/tbpl1/","tldr":"TBPL1 (TATA box-binding protein-like 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tbx1","symbol":"TBX1","href":"/targets/tbx1/","tldr":"TBX1 (T-box transcription factor TBX1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tbx3","symbol":"TBX3","href":"/targets/tbx3/","tldr":"TBX3 (T-box transcription factor TBX3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Colorectal cancer, Skin cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"tbxt","symbol":"TBXT","href":"/targets/tbxt/","tldr":"TBXT (T-box transcription factor T) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chordoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"tcea1","symbol":"TCEA1","href":"/targets/tcea1/","tldr":"TCEA1 (Transcription elongation factor A protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Oral cavity cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"tcf12","symbol":"TCF12","href":"/targets/tcf12/","tldr":"TCF12 (Transcription factor 12) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"tcf19","symbol":"TCF19","href":"/targets/tcf19/","tldr":"TCF19 (Transcription factor 19) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"tcf3","symbol":"TCF3","href":"/targets/tcf3/","tldr":"TCF3 (Transcription factor E2-alpha) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 3 more.","roles":["biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"tcf4","symbol":"TCF4","href":"/targets/tcf4/","tldr":"TCF4 (Transcription factor 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma and Paediatric low-grade glioma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"tcf7l2","symbol":"TCF7L2","href":"/targets/tcf7l2/","tldr":"TCF7L2 (Transcription factor 7-like 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Breast cancer, Prostate cancer and 3 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"tcl1a","symbol":"TCL1A","href":"/targets/tcl1a/","tldr":"TCL1A (T-cell leukaemia/lymphoma protein 1A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-Hodgkin lymphoma, Skin cancer, Diffuse large B-cell lymphoma and 1 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"tec","symbol":"TEC","href":"/targets/tec/","tldr":"TEC (Tyrosine-protein kinase Tec) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Oesophageal cancer and Oesophageal squamous cell carcinoma.","roles":["drug-target","oncogene-driver"],"tier":"approved-drug"},{"id":"tent4a","symbol":"TENT4A","href":"/targets/tent4a/","tldr":"TENT4A (Terminal nucleotidyltransferase 4A) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tent5c","symbol":"TENT5C","href":"/targets/tent5c/","tldr":"TENT5C (Terminal nucleotidyltransferase 5C) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma, Skin cancer, Colorectal cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"tert","symbol":"TERT","href":"/targets/tert/","tldr":"TERT (Telomerase reverse transcriptase) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Lung cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"approved-drug"},{"id":"tet1","symbol":"TET1","href":"/targets/tet1/","tldr":"TET1 (Methylcytosine dioxygenase TET1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Hepatocellular carcinoma, Testicular germ cell tumours and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"tf","symbol":"TF","href":"/targets/tf/","tldr":"TF (Serotransferrin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"tfap4","symbol":"TFAP4","href":"/targets/tfap4/","tldr":"TFAP4 (Transcription factor AP-4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Burkitt lymphoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"tfe3","symbol":"TFE3","href":"/targets/tfe3/","tldr":"TFE3 (Transcription factor E3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma, Sarcomas, Colorectal cancer and 1 more.","roles":["drug-target","fusion-partner"],"tier":"association-only"},{"id":"tfeb","symbol":"TFEB","href":"/targets/tfeb/","tldr":"TFEB (Transcription factor EB) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer and Melanoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"tff3","symbol":"TFF3","href":"/targets/tff3/","tldr":"TFF3 (Trefoil factor 3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"tfg","symbol":"TFG","href":"/targets/tfg/","tldr":"TFG (trafficking from ER to golgi regulator) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma and Lung cancer.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"tfrc","symbol":"TFRC","href":"/targets/tfrc/","tldr":"TFRC (Transferrin receptor protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer and Non-small-cell lung cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"tg","symbol":"TG","href":"/targets/tg/","tldr":"TG (Thyroglobulin) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"tgfa","symbol":"TGFA","href":"/targets/tgfa/","tldr":"TGFA (Protransforming growth factor alpha) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"tgfb1","symbol":"TGFB1","href":"/targets/tgfb1/","tldr":"TGFB1 (Transforming growth factor beta-1 proprotein) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tgfb2","symbol":"TGFB2","href":"/targets/tgfb2/","tldr":"TGFB2 (Transforming growth factor beta-2 proprotein) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.","roles":["drug-target","fusion-partner"],"tier":"approved-drug"},{"id":"tgfb3","symbol":"TGFB3","href":"/targets/tgfb3/","tldr":"TGFB3 (Transforming growth factor beta-3 proprotein) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tgfbr1","symbol":"TGFBR1","href":"/targets/tgfbr1/","tldr":"TGFBR1 (TGF-beta receptor type-1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer and Oesophageal and junctional adenocarcinoma.","roles":["drug-target","tumour-suppressor"],"tier":"clinical-evidence"},{"id":"tgfbr2","symbol":"TGFBR2","href":"/targets/tgfbr2/","tldr":"TGFBR2 (TGF-beta receptor type-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Oesophageal cancer, Pancreatic ductal adenocarcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"tgfbr3","symbol":"TGFBR3","href":"/targets/tgfbr3/","tldr":"TGFBR3 (Transforming growth factor beta receptor type 3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"tgif1","symbol":"TGIF1","href":"/targets/tgif1/","tldr":"TGIF1 (Homeobox protein TGIF1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"tgm3","symbol":"TGM3","href":"/targets/tgm3/","tldr":"TGM3 (Protein-glutamine gamma-glutamyltransferase E) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"thbs2","symbol":"THBS2","href":"/targets/thbs2/","tldr":"THBS2 (Thrombospondin-2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"thra","symbol":"THRA","href":"/targets/thra/","tldr":"THRA (Thyroid hormone receptor alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"thrap3","symbol":"THRAP3","href":"/targets/thrap3/","tldr":"THRAP3 (Thyroid hormone receptor-associated protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"thrb","symbol":"THRB","href":"/targets/thrb/","tldr":"THRB (Thyroid hormone receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"timp1","symbol":"TIMP1","href":"/targets/timp1/","tldr":"TIMP1 (Metalloproteinase inhibitor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"tlk2","symbol":"TLK2","href":"/targets/tlk2/","tldr":"TLK2 (Serine/threonine-protein kinase tousled-like 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"tln1","symbol":"TLN1","href":"/targets/tln1/","tldr":"TLN1 (Talin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tlx1","symbol":"TLX1","href":"/targets/tlx1/","tldr":"TLX1 (T-cell leukaemia homeobox protein 1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"tlx3","symbol":"TLX3","href":"/targets/tlx3/","tldr":"TLX3 (T-cell leukaemia homeobox protein 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tmem127","symbol":"TMEM127","href":"/targets/tmem127/","tldr":"TMEM127 (Transmembrane protein 127) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours and Melanoma.","roles":[],"tier":"association-only"},{"id":"tmem17","symbol":"TMEM17","href":"/targets/tmem17/","tldr":"TMEM17 (Transmembrane protein 17) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"tmem238l","symbol":"TMEM238L","href":"/targets/tmem238l/","tldr":"TMEM238L (Transmembrane protein 238-like) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"tmprss2","symbol":"TMPRSS2","href":"/targets/tmprss2/","tldr":"TMPRSS2 (Transmembrane protease serine 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"tmsb4x","symbol":"TMSB4X","href":"/targets/tmsb4x/","tldr":"TMSB4X (Thymosin beta-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"tnc","symbol":"TNC","href":"/targets/tnc/","tldr":"TNC (Tenascin) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Adrenocortical carcinoma, Bladder & urothelial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"tnfaip3","symbol":"TNFAIP3","href":"/targets/tnfaip3/","tldr":"TNFAIP3 (Tumour necrosis factor alpha-induced protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 2 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"tnfrsf10b","symbol":"TNFRSF10B","href":"/targets/tnfrsf10b/","tldr":"TNFRSF10B (Tumour necrosis factor receptor superfamily member 10B) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"tnfrsf13b","symbol":"TNFRSF13B","href":"/targets/tnfrsf13b/","tldr":"TNFRSF13B (Tumour necrosis factor receptor superfamily member 13B) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Multiple myeloma.","roles":[],"tier":"association-only"},{"id":"tnfrsf14","symbol":"TNFRSF14","href":"/targets/tnfrsf14/","tldr":"TNFRSF14 (Tumour necrosis factor receptor superfamily member 14) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"tnfsf10","symbol":"TNFSF10","href":"/targets/tnfsf10/","tldr":"TNFSF10 (Tumour necrosis factor ligand superfamily member 10) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tns1","symbol":"TNS1","href":"/targets/tns1/","tldr":"TNS1 (Tensin-1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tns3","symbol":"TNS3","href":"/targets/tns3/","tldr":"TNS3 (Tensin-3) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"toe1","symbol":"TOE1","href":"/targets/toe1/","tldr":"TOE1 (Target of EGR1 protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"top2b","symbol":"TOP2B","href":"/targets/top2b/","tldr":"TOP2B (DNA topoisomerase 2-beta) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Neuroendocrine tumours, Breast cancer and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"top3a","symbol":"TOP3A","href":"/targets/top3a/","tldr":"TOP3A (DNA topoisomerase 3-alpha) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tox","symbol":"TOX","href":"/targets/tox/","tldr":"TOX (Thymocyte selection-associated high mobility group box protein TOX) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"tox3","symbol":"TOX3","href":"/targets/tox3/","tldr":"TOX3 (TOX high mobility group box family member 3) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"tp53bp1","symbol":"TP53BP1","href":"/targets/tp53bp1/","tldr":"TP53BP1 (TP53-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, a fusion partner and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.","roles":["biomarker","fusion-partner","dna-repair"],"tier":"clinical-evidence"},{"id":"tp63","symbol":"TP63","href":"/targets/tp63/","tldr":"TP63 (Tumour protein 63) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Skin cancer, Non-Hodgkin lymphoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"tpcn2","symbol":"TPCN2","href":"/targets/tpcn2/","tldr":"TPCN2 (Two pore channel protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.","roles":[],"tier":"association-only"},{"id":"tph2","symbol":"TPH2","href":"/targets/tph2/","tldr":"TPH2 (Tryptophan 5-hydroxylase 2) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tpm3","symbol":"TPM3","href":"/targets/tpm3/","tldr":"TPM3 (Tropomyosin alpha-3 chain) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Lung cancer, Colorectal cancer and Non-small-cell lung cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"tpm4","symbol":"TPM4","href":"/targets/tpm4/","tldr":"TPM4 (Tropomyosin alpha-4 chain) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tpr","symbol":"TPR","href":"/targets/tpr/","tldr":"TPR (Nucleoprotein TPR) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma and Medulloblastoma.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"tpt1","symbol":"TPT1","href":"/targets/tpt1/","tldr":"TPT1 (Translationally-controlled tumour protein) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"traf3","symbol":"TRAF3","href":"/targets/traf3/","tldr":"TRAF3 (TNF receptor-associated factor 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"traf7","symbol":"TRAF7","href":"/targets/traf7/","tldr":"TRAF7 (E3 ubiquitin-protein ligase TRAF7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Skin cancer, Pleural mesothelioma and 1 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"trak1","symbol":"TRAK1","href":"/targets/trak1/","tldr":"TRAK1 (Trafficking kinesin-binding protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"trim24","symbol":"TRIM24","href":"/targets/trim24/","tldr":"TRIM24 (Transcription intermediary factor 1-alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Prostate cancer, Lung cancer and 3 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"trim27","symbol":"TRIM27","href":"/targets/trim27/","tldr":"TRIM27 (Zinc finger protein RFP) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"trim28","symbol":"TRIM28","href":"/targets/trim28/","tldr":"TRIM28 (Transcription intermediary factor 1-beta) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Wilms tumour.","roles":[],"tier":"association-only"},{"id":"trim33","symbol":"TRIM33","href":"/targets/trim33/","tldr":"TRIM33 (E3 ubiquitin-protein ligase TRIM33) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Breast cancer, Colorectal cancer and 1 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"trim49c","symbol":"TRIM49C","href":"/targets/trim49c/","tldr":"TRIM49C (Tripartite motif-containing protein 49C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"trip11","symbol":"TRIP11","href":"/targets/trip11/","tldr":"TRIP11 (Thyroid receptor-interacting protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"trps1","symbol":"TRPS1","href":"/targets/trps1/","tldr":"TRPS1 (Zinc finger transcription factor Trps1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"trrap","symbol":"TRRAP","href":"/targets/trrap/","tldr":"TRRAP (Transformation/transcription domain-associated protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Renal cell carcinoma, Lung cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"tsc1","symbol":"TSC1","href":"/targets/tsc1/","tldr":"TSC1 (Hamartin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Bladder & urothelial cancer, Hepatocellular carcinoma, Renal cell carcinoma and 5 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"approved-drug"},{"id":"tsc2","symbol":"TSC2","href":"/targets/tsc2/","tldr":"TSC2 (Tuberin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Hepatocellular carcinoma, Renal cell carcinoma, Thyroid cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"approved-drug"},{"id":"tspyl1","symbol":"TSPYL1","href":"/targets/tspyl1/","tldr":"TSPYL1 (Testis-specific Y-encoded-like protein 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ttf1","symbol":"TTF1","href":"/targets/ttf1/","tldr":"TTF1 (Transcription termination factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"tuba1a","symbol":"TUBA1A","href":"/targets/tuba1a/","tldr":"TUBA1A (Tubulin alpha-1A chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tuba1b","symbol":"TUBA1B","href":"/targets/tuba1b/","tldr":"TUBA1B (Tubulin alpha-1B chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Prostate cancer and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tuba1c","symbol":"TUBA1C","href":"/targets/tuba1c/","tldr":"TUBA1C (Tubulin alpha-1C chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Breast cancer, Lung cancer and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tuba3c","symbol":"TUBA3C","href":"/targets/tuba3c/","tldr":"TUBA3C (Tubulin alpha-3C chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tuba3e","symbol":"TUBA3E","href":"/targets/tuba3e/","tldr":"TUBA3E (Tubulin alpha-3E chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tuba4a","symbol":"TUBA4A","href":"/targets/tuba4a/","tldr":"TUBA4A (Tubulin alpha-4A chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tubb1","symbol":"TUBB1","href":"/targets/tubb1/","tldr":"TUBB1 (Tubulin beta-1 chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tubb2a","symbol":"TUBB2A","href":"/targets/tubb2a/","tldr":"TUBB2A (Tubulin beta-2A chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tubb2b","symbol":"TUBB2B","href":"/targets/tubb2b/","tldr":"TUBB2B (Tubulin beta-2B chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Sarcomas and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tubb3","symbol":"TUBB3","href":"/targets/tubb3/","tldr":"TUBB3 (Tubulin beta-3 chain) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Prostate cancer and 5 more.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"tubb4a","symbol":"TUBB4A","href":"/targets/tubb4a/","tldr":"TUBB4A (Tubulin beta-4A chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Breast cancer, Lung cancer and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tubb4b","symbol":"TUBB4B","href":"/targets/tubb4b/","tldr":"TUBB4B (Tubulin beta-4B chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Breast cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tubb6","symbol":"TUBB6","href":"/targets/tubb6/","tldr":"TUBB6 (Tubulin beta-6 chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Breast cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tubb8","symbol":"TUBB8","href":"/targets/tubb8/","tldr":"TUBB8 (Tubulin beta-8 chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tyk2","symbol":"TYK2","href":"/targets/tyk2/","tldr":"TYK2 (Non-receptor tyrosine-protein kinase TYK2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Malignant peripheral nerve sheath tumour and Polycythaemia vera.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"tymp","symbol":"TYMP","href":"/targets/tymp/","tldr":"TYMP (Thymidine phosphorylase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tyr","symbol":"TYR","href":"/targets/tyr/","tldr":"TYR (Tyrosinase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"tyrp1","symbol":"TYRP1","href":"/targets/tyrp1/","tldr":"TYRP1 (5,6-dihydroxyindole-2-carboxylic acid oxidase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.","roles":[],"tier":"association-only"},{"id":"tyw2","symbol":"TYW2","href":"/targets/tyw2/","tldr":"TYW2 (tRNA wybutosine-synthesising protein 2 homolog) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"u2af1","symbol":"U2AF1","href":"/targets/u2af1/","tldr":"U2AF1 (Splicing factor U2AF 35 kDa subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Lung cancer and 5 more.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence"},{"id":"u2af2","symbol":"U2AF2","href":"/targets/u2af2/","tldr":"U2AF2 (Splicing factor U2AF 65 kDa subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"uba52","symbol":"UBA52","href":"/targets/uba52/","tldr":"UBA52 (Ubiquitin-ribosomal protein eL40 fusion protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ubb","symbol":"UBB","href":"/targets/ubb/","tldr":"UBB (Polyubiquitin-B) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ubc","symbol":"UBC","href":"/targets/ubc/","tldr":"UBC (Polyubiquitin-C) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ube2a","symbol":"UBE2A","href":"/targets/ube2a/","tldr":"UBE2A (Ubiquitin-conjugating enzyme E2 A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"ubr5","symbol":"UBR5","href":"/targets/ubr5/","tldr":"UBR5 (E3 ubiquitin-protein ligase UBR5) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"ubtf","symbol":"UBTF","href":"/targets/ubtf/","tldr":"UBTF (Nucleolar transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"ubxn11","symbol":"UBXN11","href":"/targets/ubxn11/","tldr":"UBXN11 (UBX domain-containing protein 11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"ugt1a","symbol":"UGT1A","href":"/targets/ugt1a/","tldr":"UGT1A (UDP glucuronosyltransferase family 1 member A complex locus) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ugt1a1","symbol":"UGT1A1","href":"/targets/ugt1a1/","tldr":"UGT1A1 (UDP-glucuronosyltransferase 1A1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"usp28","symbol":"USP28","href":"/targets/usp28/","tldr":"USP28 (Ubiquitin carboxyl-terminal hydrolase 28) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"usp6","symbol":"USP6","href":"/targets/usp6/","tldr":"USP6 (Ubiquitin carboxyl-terminal hydrolase 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Breast cancer, Hepatocellular carcinoma and 5 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"usp7","symbol":"USP7","href":"/targets/usp7/","tldr":"USP7 (Ubiquitin C-terminal hydrolase 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Burkitt lymphoma.","roles":["tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"usp8","symbol":"USP8","href":"/targets/usp8/","tldr":"USP8 (Ubiquitin carboxyl-terminal hydrolase 8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Multiple myeloma, Breast cancer and 1 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"usp9x","symbol":"USP9X","href":"/targets/usp9x/","tldr":"USP9X (Ubiquitin carboxyl-terminal hydrolase 9X) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer, Hepatocellular carcinoma, Sarcomas and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"vav1","symbol":"VAV1","href":"/targets/vav1/","tldr":"VAV1 (Proto-oncogene vav) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"vcl","symbol":"VCL","href":"/targets/vcl/","tldr":"VCL (Vinculin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"vdr","symbol":"VDR","href":"/targets/vdr/","tldr":"VDR (Vitamin D3 receptor) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"vegfc","symbol":"VEGFC","href":"/targets/vegfc/","tldr":"VEGFC (Vascular endothelial growth factor C) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"vhl","symbol":"VHL","href":"/targets/vhl/","tldr":"VHL (von Hippel-Lindau disease tumour suppressor) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Neuroendocrine tumours, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"vps37a","symbol":"VPS37A","href":"/targets/vps37a/","tldr":"VPS37A (Vacuolar protein sorting-associated protein 37A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"vps53","symbol":"VPS53","href":"/targets/vps53/","tldr":"VPS53 (Vacuolar protein sorting-associated protein 53 homolog) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"vti1a","symbol":"VTI1A","href":"/targets/vti1a/","tldr":"VTI1A (Vesicle transport through interaction with t-SNAREs homolog 1A) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"vwf","symbol":"VWF","href":"/targets/vwf/","tldr":"VWF (von Willebrand factor) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"was","symbol":"WAS","href":"/targets/was/","tldr":"WAS (Actin nucleation-promoting factor WAS) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Medulloblastoma and Melanoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"wdcp","symbol":"WDCP","href":"/targets/wdcp/","tldr":"WDCP (WD repeat and coiled-coil-containing protein) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"wdr12","symbol":"WDR12","href":"/targets/wdr12/","tldr":"WDR12 (Ribosome biogenesis protein WDR12) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"wif1","symbol":"WIF1","href":"/targets/wif1/","tldr":"WIF1 (Wnt inhibitory factor 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer and Oral cavity cancer.","roles":[],"tier":"association-only"},{"id":"wnk1","symbol":"WNK1","href":"/targets/wnk1/","tldr":"WNK1 (Serine/threonine-protein kinase WNK1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"wnk2","symbol":"WNK2","href":"/targets/wnk2/","tldr":"WNK2 (Serine/threonine-protein kinase WNK2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Hepatocellular carcinoma, Mesothelioma and 2 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"wnt1","symbol":"WNT1","href":"/targets/wnt1/","tldr":"WNT1 (Proto-oncogene Wnt-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Uterine carcinosarcoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"wnt11","symbol":"WNT11","href":"/targets/wnt11/","tldr":"WNT11 (Wnt family member 11) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"wnt6","symbol":"WNT6","href":"/targets/wnt6/","tldr":"WNT6 (Wnt family member 6) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"wrap53","symbol":"WRAP53","href":"/targets/wrap53/","tldr":"WRAP53 (Telomerase Cajal body protein 1) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"wt1","symbol":"WT1","href":"/targets/wt1/","tldr":"WT1 (Wilms tumour protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Mesothelioma, Myeloproliferative neoplasms and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence"},{"id":"wwox","symbol":"WWOX","href":"/targets/wwox/","tldr":"WWOX (WW domain-containing oxidoreductase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Oesophageal cancer.","roles":[],"tier":"association-only"},{"id":"wwtr1","symbol":"WWTR1","href":"/targets/wwtr1/","tldr":"WWTR1 (WW domain-containing transcription regulator protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer, Breast cancer and Skin cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"xpa","symbol":"XPA","href":"/targets/xpa/","tldr":"XPA (DNA repair protein complementing XP-A cells) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Skin cancer, Colorectal cancer and Basal cell carcinoma.","roles":["dna-repair"],"tier":"association-only"},{"id":"xpc","symbol":"XPC","href":"/targets/xpc/","tldr":"XPC (DNA repair protein complementing XP-C cells) is a protein that switches other genes on and off. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Lung cancer and Prostate cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"xrcc1","symbol":"XRCC1","href":"/targets/xrcc1/","tldr":"XRCC1 (DNA repair protein XRCC1) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"xrcc2","symbol":"XRCC2","href":"/targets/xrcc2/","tldr":"XRCC2 (DNA repair protein XRCC2) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"xrcc3","symbol":"XRCC3","href":"/targets/xrcc3/","tldr":"XRCC3 (DNA repair protein XRCC3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"yap1","symbol":"YAP1","href":"/targets/yap1/","tldr":"YAP1 (Transcriptional coactivator YAP1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer and Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"yes1","symbol":"YES1","href":"/targets/yes1/","tldr":"YES1 (Tyrosine-protein kinase Yes) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Leukaemia and 5 more.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"ywhab","symbol":"YWHAB","href":"/targets/ywhab/","tldr":"YWHAB (14-3-3 protein beta/alpha) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ywhae","symbol":"YWHAE","href":"/targets/ywhae/","tldr":"YWHAE (14-3-3 protein epsilon) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas.","roles":[],"tier":"association-only"},{"id":"zbtb10","symbol":"ZBTB10","href":"/targets/zbtb10/","tldr":"ZBTB10 (Zinc finger and BTB domain-containing protein 10) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"zbtb16","symbol":"ZBTB16","href":"/targets/zbtb16/","tldr":"ZBTB16 (Zinc finger and BTB domain-containing protein 16) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Oesophageal cancer, Skin cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"zbtb20","symbol":"ZBTB20","href":"/targets/zbtb20/","tldr":"ZBTB20 (Zinc finger and BTB domain-containing protein 20) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"zbtb48","symbol":"ZBTB48","href":"/targets/zbtb48/","tldr":"ZBTB48 (Zinc finger and BTB domain-containing protein 48) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Angiosarcoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"zbtb7b","symbol":"ZBTB7B","href":"/targets/zbtb7b/","tldr":"ZBTB7B (Zinc finger and BTB domain-containing protein 7B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Uterine carcinosarcoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"zc3hav1","symbol":"ZC3HAV1","href":"/targets/zc3hav1/","tldr":"ZC3HAV1 (Zinc finger CCCH-type antiviral protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"zcchc8","symbol":"ZCCHC8","href":"/targets/zcchc8/","tldr":"ZCCHC8 (Zinc finger CCHC domain-containing protein 8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"zcrb1","symbol":"ZCRB1","href":"/targets/zcrb1/","tldr":"ZCRB1 (Zinc finger CCHC-type and RNA-binding motif-containing protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"zeb1","symbol":"ZEB1","href":"/targets/zeb1/","tldr":"ZEB1 (Zinc finger E-box-binding homeobox 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Nasopharyngeal carcinoma, Multiple myeloma and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"zfhx3","symbol":"ZFHX3","href":"/targets/zfhx3/","tldr":"ZFHX3 (Zinc finger homeobox protein 3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Endometrial cancer, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"zfhx4","symbol":"ZFHX4","href":"/targets/zfhx4/","tldr":"ZFHX4 (Zinc finger homeobox protein 4) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"zfp36l1","symbol":"ZFP36L1","href":"/targets/zfp36l1/","tldr":"ZFP36L1 (mRNA decay activator protein ZFP36L1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"zfpm2","symbol":"ZFPM2","href":"/targets/zfpm2/","tldr":"ZFPM2 (Zinc finger protein ZFPM2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"zhx2","symbol":"ZHX2","href":"/targets/zhx2/","tldr":"ZHX2 (Zinc fingers and homeoboxes protein 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Papillary renal cell carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"zmiz1","symbol":"ZMIZ1","href":"/targets/zmiz1/","tldr":"ZMIZ1 (Zinc finger MIZ domain-containing protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer, Prostate cancer and Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"zmym2","symbol":"ZMYM2","href":"/targets/zmym2/","tldr":"ZMYM2 (Zinc finger MYM-type protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Prostate cancer, Non-Hodgkin lymphoma and 1 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"zmym3","symbol":"ZMYM3","href":"/targets/zmym3/","tldr":"ZMYM3 (Zinc finger MYM-type protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer, Head and neck squamous cell carcinoma and 4 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"znf208","symbol":"ZNF208","href":"/targets/znf208/","tldr":"ZNF208 (Zinc finger protein 208) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer and Oesophageal and junctional adenocarcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf217","symbol":"ZNF217","href":"/targets/znf217/","tldr":"ZNF217 (Zinc finger protein 217) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer and Osteosarcoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"znf274","symbol":"ZNF274","href":"/targets/znf274/","tldr":"ZNF274 (Neurotrophin receptor-interacting factor homolog) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf292","symbol":"ZNF292","href":"/targets/znf292/","tldr":"ZNF292 (Zinc finger protein 292) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"znf331","symbol":"ZNF331","href":"/targets/znf331/","tldr":"ZNF331 (Zinc finger protein 331) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma, Skin cancer and Melanoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf395","symbol":"ZNF395","href":"/targets/znf395/","tldr":"ZNF395 (Zinc finger protein 395) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf429","symbol":"ZNF429","href":"/targets/znf429/","tldr":"ZNF429 (Zinc finger protein 429) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Hepatocellular carcinoma, Prostate cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"znf462","symbol":"ZNF462","href":"/targets/znf462/","tldr":"ZNF462 (Zinc finger protein 462) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"znf521","symbol":"ZNF521","href":"/targets/znf521/","tldr":"ZNF521 (Zinc finger protein 521) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Oesophageal cancer, Cervical cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"znf626","symbol":"ZNF626","href":"/targets/znf626/","tldr":"ZNF626 (Zinc finger protein 626) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf680","symbol":"ZNF680","href":"/targets/znf680/","tldr":"ZNF680 (Zinc finger protein 680) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf703","symbol":"ZNF703","href":"/targets/znf703/","tldr":"ZNF703 (Zinc finger protein 703) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"znf721","symbol":"ZNF721","href":"/targets/znf721/","tldr":"ZNF721 (Zinc finger protein 721) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf750","symbol":"ZNF750","href":"/targets/znf750/","tldr":"ZNF750 (Zinc finger protein 750) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Oesophageal and junctional adenocarcinoma and Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"znf780a","symbol":"ZNF780A","href":"/targets/znf780a/","tldr":"ZNF780A (Zinc finger protein 780A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf814","symbol":"ZNF814","href":"/targets/znf814/","tldr":"ZNF814 (Zinc finger protein 814) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf90","symbol":"ZNF90","href":"/targets/znf90/","tldr":"ZNF90 (Zinc finger protein 90) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf93","symbol":"ZNF93","href":"/targets/znf93/","tldr":"ZNF93 (Zinc finger protein 93) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znrf3","symbol":"ZNRF3","href":"/targets/znrf3/","tldr":"ZNRF3 (E3 ubiquitin-protein ligase ZNRF3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Adrenocortical carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"zrsr2","symbol":"ZRSR2","href":"/targets/zrsr2/","tldr":"ZRSR2 (U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 2 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence"},{"id":"zxdb","symbol":"ZXDB","href":"/targets/zxdb/","tldr":"ZXDB (Zinc finger X-linked protein ZXDB) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"}]